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The mutation of transcription factor genes is a main cause for acute myeloid leukaemia. 
RUNX1/ETO, the product of the t(8;21) chromosomal translocation, subverts normal 
blood cell development by impairing myeloid differentiation. RUNX1/ETO knockdown 
alleviates this block, with a global reprogramming of transcription factor binding and 
initiation of myeloid differentiation. Co-depletion of the myeloid transcription factor 
C/EBPα with RUNX1/ETO suppressed this differentiation response. Furthermore, C/EBPα 
overexpression largely phenocopied the effect of RUNX1/ETO knockdown. Our data show 
that low levels of C/EBPα are critical to the maintenance of t(8;21) AML and that C/EBPα 
drives the response to RUNX1/ETO depletion.  
To examine how changes in transcription factor binding impact on the activity of cis-
regulatory elements we mapped genome wide promoter-distal-element interactions in a 
t(8;21) AML cell line, via Capture HiC, and found that hundreds of interactions were 
altered by RUNX1/ETO knockdown. Differentially interacting elements exhibited changes 
in C/EBPα binding and were enriched for the CTCF motif. Our results demonstrate that 
the presence or absence of RUNX1/ETO has a profound impact on the intra-nuclear 
organisation of t(8;21) AML cells, and indicate which transcription factors are driving 
these changes. This work provides a novel mechanism for the RUNX1/ETO mediated 
differentiation block in t(8;21) AML. 
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Chapter 1. INTRODUCTION 
1.1 Chromatin structure 
Chromosomes were visualised for the first time in the 19th century, but it was not until 
much later it was discovered that they contain the genetic material of the cell, the 
genome. The genome is made up of billions of DNA bases, which carry the information to 
create complex organisms, made up of hundreds of different cell types. All of this 
information is compressed into the nucleus of a single cell. This is no easy feat; roughly 
two metres of linear DNA must be packaged into the nucleus, which is a mere six 
thousandths of a millimetre in diameter.  
The way in which it is organised must also be highly dynamic, to facilitate the complex 
processes which take place during the cell cycle. For example, during mitosis, the 
chromosomes are very condensed to ensure transmission of genetic material to daughter 
cells. The requirements are more complex during interphase; the genome must be 
organised in such a way that gene transcription, DNA replication and DNA repair can be 
tightly regulated. The following section will outline how this is achieved.  
 The nucleosome  1.1.1
The first step of DNA packaging is nucleosome assembly. The DNA double helix is spooled 
around a protein complex, 147 base pairs (bp) at a time, to form the smallest component 
of chromatin - the nucleosome.  The protein core of the nucleosome consists of 8 histone 
molecules; two molecules of histone H2A, H2B, H3 and H4. H2A and H2B form dimers and 
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H3 and H4 form dimers, which combine to form a compact complex.  Each of the histones 
has a long, protruding amino acid ‘tail’ that extends clear of the central core (figure 1-1). 
These tails can be covalently modified, which enables regulation of various aspects of 
chromatin structure (1). This is discussed in section 1.1.4.  
Multiple nucleosomes are linked with an approximately 20 bp to 80 bp linker region to 
form a chromatin thread, commonly described as having a ‘beads on a string’ appearance. 
This first level of packaging already reduces the length of the genome by approximately 
one third (1). 
 
 
Figure 1-1: Nucleosome structure 
This schematic illustrates the assembly of the core histone octamer. Two H3/H4 dimers are 
incorporated, followed by two H2A/H2B dimers  (image modified from (1)).  
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The ‘beads on a string’ structure is condensed further by packing nucleosomes on top of 
each other, in a highly ordered fashion, to form an approximately 30 nm chromatin fibre 
(2, 3) (figure 1-2). The way in which nucleosomes are packed together resembles a ‘zig-
zag’ pattern (4). An additional histone, histone H1, binds to the nucleosome, contacting 
both protein and DNA. It protects linker DNA from nuclease digestion and promotes the 
packing of nucleosomal DNA into this structure (5, 6). The way in which it assists in 
packaging is still unclear. One theory is that histone H1 can bend DNA, thus increasing 




Figure 1-2: The chromatin fibre  
A) 10 nm fibre B) Horizontal view of a 30 nm fibre C) Vertical view of the 30 nm fibre D) Zig-zag 
model of the 30 nm fibre organisation (figure adapted from (8)). 
 
 
 A                               B                              C                                D  
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 Histone variants 1.1.2
 
Each of the canonical histones found in the nucleosome has a repertoire of variants that 
differ in their amino acid sequence, primarily at the N-terminus. The canonical histones 
are mostly made during DNA replication in the S-phase of the cell cycle, so are 
incorporated into chromatin in a DNA replication-dependent fashion. In contrast, the 
histone variants can be incorporated independently to DNA replication and are expressed 
during all stages of the cell-cycle (9).  
The histone variants are brought to the nucleosome by histone chaperones where they 
can then recruit chromatin modifiers (9-13).  The replacement of a canonical histone with 
its variant introduces structural changes. This can alter the interaction strength between 
histone proteins within the nucleosome, which therefore affects nucleosome stability and 
level of chromatin compaction. For example, the deposition of histone variants H2A.Z and 
H3.3 are associated with open and active chromatin (14). Whereas incorporation of  
macroH2A leads to stabilisation of the nucleosome and is usually associated with a 
repressive chromatin state (15). The availability of histone variants is therefore 
considered to add another level of complexity to the genome and plays an important role 
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Table 1: Eukaryotic histone variants and their functions. (table adapted from (16))  
 
 Chromatin remodelers 1.1.3
 
The positioning of nucleosomes must be highly dynamic and there are times when the 
DNA needs to be temporarily less compacted. This is achieved by an active process 
termed ‘nucleosome remodeling’. This is usually implemented to enable access of 
proteins to the DNA to drive important biological processes, such as gene transcription 
and DNA replication. The rearrangement is orchestrated by ‘chromatin remodeling 
complexes’, which use ATP to temporarily alter the nucleosome structure to reduce how 
tightly bound the DNA is to the histone core (17). There are several different remodelling 
complexes, but most are very large complexes made up of many protein subunits. The 
best known are the ISWI, SWI/SNF, and SWR1 complex families. The exact way in which 
they remodel varies depending on the type of complex. Briefly, the ISWI family is thought 
to ‘slide’ nucleosomes along the DNA, SWI/SNF proteins displace nucleosomes and the 
SWR1 family replace core histones with a histone variant (H2A/H2B dimers are replaced 
with H2AZ/H2B dimers) (18-20).  
Histone variant Function Conserved? 
CENP-A/CID/cse4 Epigenetic marker of the centromere Yes 
H3.3 Transcription Yes 
H2A.Z/H2AV Transcription/double strand break repair Yes 
H2A.X 
Double strand break repair/meiotic remodelling of sex 
chromosomes Yes 
macroH2A Gene silencing/X chromosome inactivation Yes 
H2A.Bbd Epigenetic mark of active chromatin Yes 
H3.Z Regulation of cellular response to outside stimuli No 
H3.Y Regulation of cellular response to outside stimuli No 
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 Chromatin modifications 1.1.4
 
Core histone protein tails are subject to a multitude of covalent modifications, at several 
different amino acid residues (see table 1 for key examples), by specific nuclear enzymes. 
Thus far, 60 residues have been detected, but it is likely that there are many more. The 
modifications include lysine acetylation, lysine methylation and serine phosphorylation. 
Further complexity is added by the fact these residues come in different forms – mono, di 
or tri and mono or di for methylation and acetylation respectively.  Their effect on the 
stability of the chromatin and therefore accessibility of the DNA to other proteins is 
tremendously influential to gene expression and therefore the regulation of cellular 
processes. 
There is an increasing body of literature which highlights both the variety and biological 
specificity linked to particular patterns of modifications (21-24). This has sparked the 
analogy that histone modifications are a ‘language’ which is ‘read’ by other proteins to 
trigger downstream events. This language has been termed ‘the histone code’ (25). The 
different combinations of histone modifications (the histone code) allow the cell to 
carefully regulate contacts with the underlying DNA. The enzymes which transduce the 
information can be very specific to the modification, and its amino acid positions, thus 
adding an extra level of information to the genetic (DNA) code.  
Acetylation of histone H3 and histone H4, and di/tri methylation of H3K4 are associated 
with active transcription, and are commonly termed ‘euchromatin modifications’. The 
modifications associated with transcriptional repression, ‘heterochromatin 
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modifications’, include methylation of H3K9 and H3K27. It is not only the particular 
modification and the residue which is important for regulation, the localisation on the 
linear genomic sequence also plays a role – for example, whether a modification is at the 
promoter, the 3’ end or the 5’ end of an open reading frame will alter its effect on 
transcription (26, 27).  
Histone modifying enzymes are responsible for carefully controlling this dynamic 
arrangement of modifications on chromatin.  In general, acetylation is laid down by 
histone acetyltransferase complexes (HATs), of which there are many. Key examples of 
HATs include HAT1, p300 and GCN5 (28). Acetylation can then be removed by histone 
deacetylases (HDACs). There are approximately 18 mammalian HDACs which can be 
divided into two main classes. Class I are ubiquitously expressed in human cells and have 
a nuclear localisation. Class I includes HDACs 1,2,3 and 8. Class II can be found in the 
cytoplasm as well as the nucleus, suggesting that they may deacetylate non-histone 
proteins. Class II are expressed in a tissue specific fashion and include HDACs 4,6,7,9 and 
10 (29). Similarly, methyl groups are added by histone methyl transferases, and removed 
by histone demethylases. 
A long standing model is that histone modifications alter the net charge of nucleosomes, 
and thus weaken inter or intra-nucleosomal interactions. The strongest support for this 
comes from studies with acetylated histones.  Several groups have found that acetylated 
histones are easier to separate from DNA both in vivo and in vitro (30, 31) (32, 33).  
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Histone modification can also serve as binding sites for effector proteins. The earliest 
example is the recognition and selective interaction of protein bromodomains with 
acetylated histones (34). Once bound to the chromatin via the acetylated histones, 
bromodomain containing proteins can then recruit other proteins to form a complex (34). 
Bromodomains therefore allow the regulation of protein-protein interaction via lysine 
acetylation. Recent research has highlighted the importance of this mechanism to the 
regulation of gene transcription and chromatin organisation (reviewed in (35)). 
The histone code is also ‘read’ by components of the polycomb pathway, which silences 
gene expression.  Polycomb proteins recognise methylated histones which then triggers 
downstream processes. Polycomb repressive complex 2 (PRC2) is targeted to polycomb 
response elements (PRE) where it methylates local histones. This leads to the 
accumulation of H3K27Me3, which in turn attracts polycomb repressive complex 1 (PRC1) 
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Table 2: Overview of histone modifications, their site and role in transcription  
(adapted from (37)) 
 
1.2 Eukaryotic transcription and its regulation 
Every eukaryotic organism has a vast diversity of cell phenotypes, despite each cell 
carrying an identical genome. These differences are largely driven by difference in gene 
expression, which leads to the controlled production of a specified set of proteins in the 
cell, via the processes of transcription and translation. This complement of proteins 
defines the cell type, and further variations to the protein levels and timing of expression 
can alter the cells behaviour during different biological processes. The following section 
will outline how gene expression is regulated. 
Modification Role in transcription Modification site 
Acetylation Activation H3 (K9,K14,K18,K56)  
H4 (K5,K8,K12,K16) 
H2B (K6,K7,K16,K17) 
Methylation Activation H3(K4me2,K4me3, 
K36me3,K79me2) 
Methylation Repression H3(K9me3,K27me3) 
H4 (K20me3) 
Phosphorylatoin Activation H3(S10) 
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 The Eukaryotic transcriptional machinery 1.2.1
 
RNA polymerase II (Pol II), along with several other proteins, is responsible for the 
transcription of protein coding genes in eukaryotes. The other proteins include general 
transcription factors, activator proteins and co-activators. General transcription factors 
assemble on the core promoter to form the pre-initiation complex (PIC). The assembly of 
the pre-initiation complex usually begins with the binding of TFIID, a complex made up of 
TATA-box-binding protein (TBP) and several other TBP-associated factors (TAFs) (figure 1-
3). The PIC then recruits Pol II to the transcription start site; recruitment of Pol II is a rate 
limiting step for transcription (38). The recruitment of Pol II to the DNA is often termed 
‘initiation’.  
Once recruited, Pol II can begin the process of elongation, which can be divided into two 
main parts. It begins with the incorporation of nucleotides to the 3’ end of Pol II, so it can 
transcribe the first 20 to 50 nucleotides of RNA (39). At almost 50% of active genes, Pol II 
then pauses after this initial early transcription. Three models have been proposed to 
explain how and why this promoter proximal pausing occurs. The first model, the ‘Kinetic 
model’ states that the pause is due to the fact that elongation is energetically 
unfavourable, due to the recruitment of pausing factors to the DNA (40). The ‘barrier 
model’ proposes that Pol II pauses due to nucleosomes acting as a physical barrier which 
hinders elongation (41). The ‘interaction model’ involves factors which bind to DNA and 
Pol II at the same time, ‘tethering’ them and pausing elongation (42). Progression beyond 
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this ‘promoter proximal’ pausing is often tightly controlled so is therefore recognized as 
an important step in gene regulation (43). 
The escape of Pol II from pausing is dependent on two processes taking place during its 
residence at the promoter; the 5’ capping of the nascent RNA (39) and the 
phosphorylation of the paused complex (44). Phosphorylation is mediated by P-TEFb , a 
heterodimer complex of Cyclin-dependent kinase 9 (Cdk9) and Cyclin T (CycT) (44). P-TEFb 
phosphorylates serine 2 of Pol II (45), as well as pausing factors DSIF and NELF, leading to 
their release (46). P-TEFb can be recruited via the coactivator Brd4 (47, 48). 
Once Pol II is released from its paused state it can begin productive elongation, where it 
progresses along the gene body. The elongating Pol II inevitably encounters nucleosome 
barriers, which it can overcome with the help of elongation factors, for example FACT and 
Spt6 (49). FACT does not displace nucleosomes. Instead, it removes H2A-H2B dimers from 
the octamer, which allows Pol II to transcribe through the remaining components (50). 
Spt6 is thought to directly interact with histones, displacing the nucleosome in front of 
Pol II then reassembling it behind (51). Spt6 has also been shown to increase the 
elongation rate of Pol II, even when no nucleosomes are present (52, 53). 
Pol II continues elongation through the gene body until it eventually reaches the end of 
the gene. To mark the end of the transcript, the nascent RNA is then cleaved and 
polyadenylated, usually approximately 8 kb downstream from the 3’ end of the gene (54).   
After Pol II has escaped the core promoter and began the process of elongation, the PIC 
does not completely dissemble. TFIID, TFIIE, TFIIH and Mediator remain as a ‘scaffold’ for 
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efficient subsequent reinitiation of transcription via recruitment of Pol II (55). 
Furthermore, RNA polymerase can be maintained at the same gene through several 
cycles of transcription, via a facilitated recycling pathway (56). There is also evidence that 
DNA looping could bring the same polymerase molecule from the end to the beginning of 
the gene, to reinitiate transcription (57).  
 
 
Figure 1-3: The basal eukaryotic transcriptional machinery 
The PIC, consisting of general transcription factors (including RNA polymerase II, TFIIA, TFIIB, 
TFIID, TFIIE, TFIIF and TFIIH), assembles at the core promoter in a stepwise fashion. This targets 
RNA polymerase II to the transcription start site (TSS). The transcriptional activity can be 
increased by activators (green), which bind to distal elements. Activators usually contain a distinct 
DNA-binding domain (DBD) and an activation domain (AD). Question marked arrows represent 
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  Role of transcription factors 1.2.2
 
The rate of transcription can be dramatically increased or decreased by other 
transcription factors. Transcription factors are modular proteins that increase (activators) 
or decrease (repressors) the rate of gene transcription. Transcription factors are often 
members of multiprotein families, for example, CCAAT-enhancer-binding proteins and Sp 
family proteins.  The members of the family usually have very similar DNA binding 
properties but varied effects on transcription. In general, they repress transcription by 
blocking the general transcriptional machinery, and activate by the following main 
mechanisms: 
1. Promoting the assembly of the PIC at the core promoter (12). 
2.  Stimulating the activity of the general transcriptional machinery by, for example, 
post-translation modification, subsequent conformational change and the 
recruitment of co activators (59-61).  
3.  Interacting with chromatin remodelers to open chromatin, thus allowing access of 
other general transcription factors to cis elements (62). 
4. Bringing together enhancers and promoters by physically ‘looping’ out intervening 
DNA. RUNX1 and GATA2 are examples of transcription factors that mediate DNA 
looping (63) (64) 
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Transcription factors usually consist of a DNA binding domain, transactivation domain and 
interaction domain. The three dimensional shape, and amino acid composition, of the 
DNA binding domains determines the affinity to specific bases of DNA, thereby providing 
sequence specific DNA binding. There are several main categories of DNA binding domain 
or ‘motifs’. These include; helix-turn-helix, zinc finger, basic leucine zipper and the basic-
loop-helix  (65).  
Coactivators are proteins which can modulate the activity of activator proteins. In 
contrast to activators, they generally do not have sequence-specific DNA binding activity, 
so are recruited by protein-protein interaction with DNA bound activators. They function 
via two main mechanisms. The first class of activators stimulate PIC assembly. The second 
class are chromatin remodeling or modifying enzymes. Coactivators and activators 
cooperate to act synergistically, presumably via post binding interactions (66).   
A key example of the first class of activators is TBP associating factors (TAFs). They are 
proposed to act as a link between the sequence specific DNA binding activators and the 
basal transcriptional machinery, to stimulate activator dependant transcription. This 
model is based on experiments which detected a direct interaction of TAFs with various 
activation domains (67). Furthermore, mutation of the TAF binding sites leads to the 
failure to activate transcription (68). Interestingly, select TAF mutations can lead to 
defects in specific subsets of genes, suggesting that TAFs help to regulate genes in a 
gene/activator specific manner (69-71). 
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The second class of activators are associated with histone modification. An early 
experiment in yeast, in which the Tetrahymena histone acetyltransferase A was found to 
be homologous to the coactivator Gcn5, was one of the first to link coactivator function 
with histone acetylation (72). Several mammalian coactivators have since been identified 
as having HAT activity. One of the most well studied is the CREB-binding protein (CBP) and  
the E1A-interacting protein p300 (reviewed in (73)). The TBP associating factor TAF250 
has also been shown to have intrinsic HAT activity (74) .  
 Transcriptional regulatory elements 1.2.3
Only approximately 1.5% of the eukaryotic genome is protein-coding. However, the 
remaining DNA is not redundant. The typical protein-coding gene is associated with 
several transcriptional regulatory elements that  can be located immediately before the 
transcription start site (promoter elements) or distributed over many kilobases  (long-
range elements). These regulatory elements are specific DNA sequences that are 
recognised by transcription factors. Many cells in an organism will express the same 
transcription factors. However, the unique combinations of accessible elements, and the 
particular combination of transcription factors, can lead to great complexity and diversity 
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Promoters 
The core promoter element defines the transcription start site. It is the binding site for 
PIC and the basic transcription machinery. The core promoter can contain several distinct 
elements. The first to be described was the TATA box – the binding site for TBP, a subunit 
of TFIID. Other core promoter elements include the downstream core element (DCE), the 
downstream promoter element (DPE) and the motif ten element (MTE). Like the TATA 
box, all of these serve as docking sites for TFIIID. The different combinations and 
organisation of these elements is diverse, which is believed to serve a regulatory role. The 
region immediately upstream of the core promoter is called the ‘proximal promoter’(75). 
It usually contains several elements which have binding sites for activator proteins.  
Enhancers 
Gene promoter activity can be amplified by elements called ‘enhancers’ (76). Enhancer 
activity is often tissue and/or developmental stage specific so they play a very important 
role in differentiation and many biological processes. They are typically approximately 
500 bp in length and contain several clusters of transcription factor binding sites (TFBS), 
which work together to increase transcription. In contrast to promoter elements, they 
can be located upstream, downstream, and within introns, sometimes over a megabase 
away from the promoter (77). This long range regulation is mediated by the physical 
interaction between the two elements, with the intervening DNA looping out. These 
interactions are specific, highlighted by the fact genes are often not regulated by the 
nearest element (78). Multiple enhancers will often act on the same promoter to co-
ordinate expression in different cell types (79) 
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Silencers 
In contrast to enhancers, silencers repress transcription of their target genes. However, 
like enhancer elements, they can act over long distances and often work in concert. They 
contain binding sites for repressive cofactors, sometimes called corepressors (80).  
Key examples of transcriptional corepressors are SMRT (Silencing Mediator of Retinoic 
acid and Thyroid hormone receptors) and N-CoR (Nuclear hormone receptor Co-
Repressors). As their names suggest, they mediate repression via nuclear hormone 
receptors (81, 82). However, they also repress via several different transcription factors, 
for example PLZF, BCL-6 and ETO (83-85).  
There are numerous possible mechanisms for repressor function. One proposed model is 
that repressors block and/or compete with coactivator binding (86). Repressors may also 
promote a repressive chromatin structure via the recruitment of histone modifying 
enzymes, thereby blocking activator binding (87). For example, ETO recruits N-Cor and 
SMRT, which in turn recruit histone deactylases (HDACs) (see section 1.1.4 for more on 
HDACs).  
Experiments in yeast have shown that repressors can hinder PIC assembly, thus 
supressing transcription (88).  This mechanism has since been shown in human B cells. 
The transcription factor PAX5 was found to inhibit transcription of the c-fms gene by 
binding to the major transcriptional start site thus blocking the assembly of the basal 
transcriptional machinery (89) 
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Insulators 
Insulators are also known as ‘boundary elements’ as they function by hindering 
interactions between neighbouring loci by sectioning the genome into discrete domains 
of transcriptional regulation. They function in two main ways; by blocking promoter - 
enhancer physical interaction and by limiting the spread of repressive chromatin (90). 
They are commonly bound by CCCTC-binding factor (CTCF), which maintains DNA 
interaction and genome partitioning, however their precise mechanism of blockade is not 
yet known (91).  
1.3 Higher-order chromatin structure 
So far in this chapter, chromatin organisation has been described up to the level of the 
chromatin fibre. However, much further compaction is required to fit the entire genome 
into the nucleus. This section will outline higher order chromatin structure.  
 Topologically associating domains 1.3.1
The chromatin fibre is folded into a hierarchy of domains. The most robust pattern is the 
presence of well defined, sub-megabased sized regions termed ‘topologically associating 
domains’ (TADs). TADs are characterized by a high frequency of chromosomal contacts 
within the domain, but infrequent contacts between TADs (92).The boundaries sectioning 
off these regions of interaction are largely conserved between cell types of the same 
species and even during transcriptional activity. Genes within the same block are 
generally in close physical proximity, have many epigenetic features in common, and tend 
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to be up and down regulated in concert (92). It is due to these characteristics that the 
TAD is viewed as a unit of transcriptional regulation, enabling the coordination of the 
epigenetic status of several genes simultaneously. 
TAD boundaries are defined by specific DNA interactions; either DNA to DNA loops or 
DNA to the nuclear laminar (93). These contacts are mediated and stabilised by several 
different structural proteins. For example CTCF is a major player in genome architecture 
by bringing together DNA and acting as an insulator between TADs (94). These DNA-CTCF 
interactions are commonly stabilised by cohesin (95). The transcriptional co-activator 
mediator can join the complex to stabilise DNA to DNA loops at active promoter regions, 
partitioning off ‘sub-TADs’ to enable cell type specific promoter-enhancer interactions. 
This CTCF-cohesin-mediator complex has the ability to hold together several different 
loops, enabling coordinated transcriptional activity (96) (figure 1-4). 
 
 
Figure 1-4: Chromatin is folded at different length scales by combinations of structural proteins 
TADs are demarcated by CTCF and cohesin binding. Others factors can act in combination with 
these proteins to divide the Mb-sized TADs into smaller sub-TADS, facilitating shorter range DNA 
looping between promoters and enhancers (figure adapted from (96). 
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In addition to these ubiquitous structural proteins, more cell type specific proteins have 
been shown to play an important role in genome architecture. For example, the 
Yamanaka reprogramming transcription factors mediate embryonic stem cell (ESC) 
specific DNA interactions, driving reprogramming into ‘induced pluripotent stem 
cells’ (iPSCs) (97). Another example comes from work on the CD34 locus. It was shown 
that the transcription factor RUNX1 is required for the interaction between the CD34 
promoter and enhancer, and this interaction was needed for CD34 gene expression (63). 
Furthermore, studies in Drosophila melanogaster have identified a role for the polycomb 
complex proteins in mediating DNA interactions, to bring genes into so called ‘polycomb 
bodies’ (98). 
 Chromosome compartments 1.3.2
With the development of genome wide DNA interaction mapping (HiC), Lieberman-Aiden, 
E. et al. demonstrated that the genome is divided into two compartments –A and B. At 
approximately 5 Mb in size, these compartments are significantly larger than TADs. They 
alternate along chromosomes represent regions of active (A) and inactive (B) chromatin. 
A-compartments of chromosomes preferentially interact with other A compartments and 
vice-versa for B compartments (99) (figure 1-5). 
Lieberman-Aiden, E. et al. demonstrated that, in contrast to TADs, these compartments 
are cell type specific (99).  However, the genome wide differences between cell types 
were not comprehensively described. A more recent study from Dixon, JR et al. 
highlighted that over a third of the genome changes compartment during stem cell 
differentiation. These reorganisations were associated with changes in gene expression 
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(100). As a result of these findings they state “that the A and B compartments have a 
contributory but not deterministic role in determining cell-type-specific patterns of gene 
expression” (100).  
In short, TADs are regarded as the very robust features of chromosomes, which can then 
be arranged into either an A or B compartments. Hence, differences in expression 
between cell types are more likely to be mediated via re-arrangement of TADS into 




Figure 1-5: Topologically associating domains are organised into two separate compartments. 
Chromatin is packed into TADs (grey circles) which are in turn positioned into either compartment 
A or B, depending on their transcriptional activity. The arrangement of TADs can change in order 
to alter expression level of genes within a TAD. Note that TAD organisation does not change upon 
change of expression status (figure adapted from (101)). 
 
  22 
 
 Chromosome territories 1.3.3
During cell division, all chromosomes are replicated and equally distributed between the 
two daughter cells. After division, the nuclear membrane reforms around the 
chromosomes and the chromosomes are distributed within sub-volumes of the nucleus – 
chromosome territories (CTs). The way in which the chromosomes are distributed within 
these CTs is not random (102-104). To a certain extent, chromosome size affects the 
radial position of chromosomes due to size-dependent mitotic forces acting on the 
chromosomes (102, 103, 105). Radial positions are also related to gene density (102).  For 
example, gene – poor chromosome 18 is usually located closer to the outside of the 
nucleus than gene-dense chromosome 19 (102). 
The activity states of distinct loci within a CT effects their positions in nuclear space and 
position in relation to each other (106-109). Genes which are active can migrate outside 
of their defined CT and undergo transcriptional ‘bursts’ when they join so called 
‘transcription factories’ (regions with highly concentrated, active RNA polymerase II) (106, 
110). Inactive genes, on the other hand, are usually located at the nuclear periphery, 
close to the nuclear laminar (111, 112).  They can, however, migrate away from the 
lamina and become active, for example during differentiation (112). 
 Transcription factories 1.3.4
The term ‘transcription factory’ was coined in 1993 (113). They are regions of the nucleus 
that have a micro-environment which favours transcription. In these hubs, RNA 
polymerase II (pol II) is active and at high levels. It is thought that pol II may be stabilised 
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at these discrete sites, and during transcription genes are passed through the 
polymerases (114, 115). Genes at a particular transcription factory are often co-regulated 
and are bound by the same transcription factors. Dynamic transcription regulation can be 
achieved by moving genes in or out of these factories (116). It is due to these properties 
that transcription factories are believed to improve the efficiency of transcription and its 
regulation.  
 The beta-globin locus and the HOX gene cluster 1.3.5
 
The beta-globin locus is an excellent example of the principles described previously in this 
chapter. Beta and alpha globin chains combine to make haemoglobin and their regulation 
is very carefully controlled, as free globin chains are toxic. The beta globin locus contains 
a number of genes encoding beta subunits which are used at different stages of 
development. A far upstream locus control region (LCR) consisting of several regulatory 
elements, helps orchestrate the tightly controlled expression of those genes (117). When 
silent during the progenitor stage of erythroid development, the locus is positioned at the 
nuclear periphery. However, as the cells differentiate into mature blood cells, one of the 
beta globin genes is expressed and the locus moves away from the periphery and 
associates with a transcription factory, where expression levels can significantly increase. 
During this process, an enhancer within the LCR is brought into physical contact with the 
beta globin promoter via DNA looping (118-120).  
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The HOX gene locus is another excellent example of a link between 3D genomic 
arrangement and the temporal and spatial expression of genes. Work over the past few 
years has identified several long-range enhancers within the two gene deserts either side 
of the HoxD gene cluster which, during limb development, control the expression of the 
HoxD genes (reviewed in (121)). These flanking regulatory regions overlap with the TAD 
boundaries established by Dixon et al. (92). They are referred to as the T-DOM (telomeric 
TAD) and the C-DOM (centromeric TAD). Interestingly, chromosome conformation 
capture and gene expression analysis revealed that the T-DOM and C-DOM control the 
early and late phases of development respectively (122, 123). Thus, a switch between 
which TAD regulates HoxD expression is required for normal limb development. A very 
recent study from the Denis Deboule group showed that HOX13 is critically involved in 
mediating this switch between TAD activities (124).  
 
1.4 Interrogating nuclear organisation and chromosome conformation 
It is now very clear that genome organisation is fundamental to many crucial biological 
processes, such as transcriptional regulation and DNA replication. Hence the 
development of techniques to interrogate chromosome conformation has been, and still 
is, a highly active area of research. The above findings regarding 3D genome structure 
were made possible with the relatively recent advent of chromosome conformation 
capture technologies.  
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 Assays based on microscopy 1.4.1
At the turn of the 20th century, it was from observations with early microscopes that 
Theodor Boveri introduced the term ‘chromosomal territory’ as a result of his work with 
the blastomere stages of the horse round worm (125). It wasn’t until the late 1970s that 
more concrete evidence came from laser-UV-micro irradiation experiments (126, 127). A 
laser micro-beam was directed at a small part of the nucleus to induce DNA damage .The 
cells were allowed to enter metaphase and then, once re-condensed, the chromosomes 
were assessed for signs of damage. Different results were predicted to transpire, 
depending on the way chromosomes were arranged. If chromosomes were randomly 
arranged and inter-mingled together, multiple inter-chromosomal arrangements are 
likely to occur. In contrast, if chromosomes resided in distinct sub-compartments with 
minimal inter-chromosomal contact, directed damage would result in predominantly 
intra-chromosomal rearrangements and damage on one particular chromosome.  The 
latter was found to be true (126, 128, 129). 
With the advent of florescence in situ hybridisation (FISH) technology, these 
chromosomal territories could be directly observed, using fluorescently labelled probes 
complimentary to entire chromosomes (130, 131) (figure 1-6). Promoter-enhancer 
interactions can also be directly visualised with the same technology, using probes 
complimentary to specific loci (132, 133) (figure 1-7).  
 
 




Figure 1-6: Fluorescence in situ hybridization imaging of chromosome territories 
A) Chicken diploid metaphase spread of chromosomes. Nuclei were stained with DAPI. B) The 
metaphase spread was subject to multicolour fluorescence in situ hybridization. The probes were 
labelled by a combinatorial scheme with Estradiol (1, 4, 5, 6), Digoxigenin (2, 4, 6, Z) and Biotin (3, 
5, 6, Z). C) These probes were detected using secondary antibodies labelled with the indicated 
fluorophore. D) Fluorescence microscopy was used to visualise the chromosomes in an optical 
section of the nucleus. You can clearly see that homologous chromosomes are positioned in 




Figure 1-7: Fluorescence in situ hybridization imaging of specific promoter-enhancer 
interactions.  
Sonic hedgehog (Shh) in mouse limb buds is regulated by a long-range enhancer 1 Mb upstream 
of the Shh promoter. B) A nucleus in which the Shh the promoter and enhancer are colocalised, 
presumably via DNA looping. C) A nucleus in which the two loci are separate. TOPRO-3 (blue) was 
used to stain nuclei and the white bar represent 1 μm (132). 
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 Chromosome conformation capture 1.4.2
 
Experiments using imaging techniques have resulted in landmark discoveries. However, 
these techniques are limited. They have low resolution, they require cell fixation so only 
display ‘snapshot’ data and they are very low throughput. To circumvent some of these 
issues, molecular techniques have been developed. Rather than directly measuring 
interactions in a single cell via microscopy, these molecular methods deduce interactions 
in a population of cells, in vivo. The original assay is called ‘Chromosome Conformation 
Capture’ or 3C (see figure 1-8). This assay assesses the frequency that two particular loci 
are in close physical proximity, at a single time point, in a population of nuclei. This is 
achieved by formaldehyde crosslinking to fix the conformation of the genome. The DNA is 
then digested with a restriction enzyme and then any restriction fragment ends of the 
crosslinked fragments are ligated together. The result is a collection of chimeric DNA 
molecules consisting of two restriction fragments that were in close physical proximity. 
This is effectively a one dimensional demonstration of the 3D nuclear structure.  In the 
traditional 3C experiments, to determine interaction frequency, the collection of 
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Figure 1-8: Simplistic overview of 3C based chromosome conformation capture techniques 
A) All of the 3C based techniques follow the same fundament steps to convert chromatin 
interaction into ligation products. B) The different methods vary in the way ligation products 
(which represent interactions) are detected and quantified (see methods section for a detailed 
description and depiction of the 4C and Hi-C methods)(134). 
 
The development of this method by Dekker et al. in 2002 was ground breaking (107). 
However, this original 3C method is low throughput and requires prior prediction of 
which two loci are interacting; it does not allow unbiased screening. It is perhaps due to 
these limitations that significant efforts have been made to modify this protocol, and as a 
result, it is now possible to analyse several interactions in a single experiment.  
One such modified protocol is called ‘4C’, a ‘one-vs-all’ strategy (see figure 1-8). This 
refers to the fact that the technique allows the analysis of all interactions which are 
taking place with one selected region of the genome, the ‘view-point’. This protocol 
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follows the sample fundamental principles of the original 3C experiment; however 
following 3C library generation the DNA is subject to a second restriction digestion to 
enable the formation of small circles upon ligation. Primers specific to the view-point are 
then used to amplify, via inverse PCR, all fragments which are ligated to the viewpoint i.e. 
all fragments which were in contact with the viewpoint. This 4C library can then be 
analysed via either micro array or next generation sequencing (135, 136). The use of next 
generation sequencing allows genome wide analysis of interactions made by the loci of 
interest.  
One limitation of 4C is that it is only possible to determine all the interactions made by 
one select region of the genome at a time. Therefore, with this protocol, one cannot 
obtain conformation information for an entire domain of a chromosome. It is for this that 
5C was developed, which is referred to as a ‘many vs many’ approach. Although it is not a 
genome-wide analysis, it allows the experimenter to detect many interactions made by 
several restriction fragments, simultaneously. In this method, a set of oligos are designed 
adjacent to the restriction site of all restriction fragments in the genomic region to be 
interrogated. The primers are then used to amplify a 3C library. If, due to a ligation 
junction, two primers are next to each other, they are ligated together by taq ligase. This 
generates new DNA molecules; a combination of the two primers. This 5C library is then 
amplified using primers specific to a shared sequence on all 5C oligos. The resultant 
library is then subject to high throughput sequencing. The end result is a quantitation of 
interactions made by all regions covered by the original 5C oligos. The scale of 5C data 
can vary, depending on the number of regions covered by 5C primers.  
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5C has been used to interrogate large, even chromosome sized, regions of the genome 
(137-139). However, it wasn’t until the development of HiC that scientists could obtain a 
true genome wide analysis of chromosome conformation. The HiC technique involves 
direct quantitation of all ligation junctions. Again, the protocol follows the same initial 
steps – a population of nuclei are fixed and digested with a restriction enzyme. In this 
case, the resultant sticky over hang is filled in with a deoxynucleoside triphosphates 
(dNTPs) mix that includes a biotinylated nucleotide. The now blunt-ended restriction 
fragments, within the same DNA-protein complex, are then ligated to each other. The 
biotinylated nucleotide enables the subsequent enrichment of the library for ligation 
junctions via streptavidin pull down. Illumina’s paired end next generation sequencing is 
then used to identify the ligation junctions (140). 
Since a HiC library is extremely complex, in order to obtain an informative level of signal 
at any given point in the genome, a huge depth of sequencing is required. Furthermore, 
data from bioinformatic ‘windows’ of the genome must be pooled together in order to 
obtain sufficient signal. Therefore the assay is of relatively low resolution. It is for this 
reason that this technique is more suitable for mapping larger, domain structures of the 
genome, rather than specific promoter-enhancer interactions.  
To circumvent these issues; Capture HiC was developed. In this method the complexity of 
the library is reduced, thus improving resolution, whilst maintaining the valuable 
promoter-enhancer interaction data. This is achieved by enriching the HiC library so that 
it only contains DNA fragments with at least one gene promoter. Biotinylated oligos 
complimentary to gene promoters are hybridized to the library, and the complexes are 
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captured with streptavidin beads. The technique was initially used to capture a few 
hundred promoters and more recently almost all promoters in the genome (22,000 
promoters) (see methods sections 2.10 and 2.11 for a detailed description and depiction 
of the 4C and Hi-C experimental procedures) (141) (77).  
 
1.5 Haematopoiesis 
Haematopoiesis is the process during which blood cells are generated within the bone 
marrow. The process begins with a type of cell that has the potential to give rise to each 
of the mature blood cell types. These cells were first purified from mouse bone marrow in 
1986 (142). Subsequent experimentation demonstrated that the cell population was 
unique in its ability to completely reconstitute the hematopoietic system in lethally 
irradiated mice (143). These pluripotent cells, now termed hematopoietic stem cells 
(HSCs), also have the ability to self-renew, thus ensuring that the relatively short-lived 
mature blood cells are replenished. During haematopoiesis, the HSCs first differentiate 
into more restricted progenitor cells, which gradually become progressively more 
restricted to a specific cell fate. This is accompanied by a loss of self-renewal capacity. The 
whole process requires tight regulation of gene expression by various transcription 
factors. If not appropriately regulated, haematological disorders, such as leukaemia, can 
occur (144, 145).  
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 Origin of haematopoietic stem cells 1.5.1
 
In vertebrates, the HSCs emerge in the embryo at various sites. The initial site is the extra-
embryonic yolk sack, where ‘primitive haematopoiesis’ takes place. This process 
generates nucleated primitive erythrocytes (EryP) which ensure the embryo is sufficiently 
oxygenated, enabling its rapid growth (145, 146). Primitive haematopoiesis is followed by 
definitive haematopoiesis, which takes place in the in the aorta-gonad mesonephros 
region (AGM), foetal liver, thymus, spleen and finally the bone marrow. In contrast to 
primitive haematopoiesis, definitive haematopoiesis gives rise to pluripotent cells which 
have the potential to differentiate into cells of all haematopoietic lineages; 
haematopoietic stem cells (HSCs). These cells arise from the ‘haemogenic endothelium’, a 
precursor tissue for both endothelial cells and hematopoietic cells. In a recent study, 
dynamic real time imaging captured the emergence of cells from the endothelium of 
mouse and fish embryos (147, 148). This study, along with others, resolved debates 
regarding the existence of the haemogenic endothelium. Although the site of 
haematopoiesis changes during embryonic development, bone marrow remains the 
major site of haematopoiesis throughout adult life, where the HSCs are maintained in a 
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 The maintenance of haematopoietic stem cells - the stem cell niche 1.5.2
 
The adult bone marrow niche is a highly specialised microenvironment which plays a 
crucial role in regulating the balance between self-renewal, differentiation and 
proliferation of HSCs. HSCs are a subject of intense research; however they are yet to be 
maintained in vitro. This is primarily due to their requirement for this highly specialised, 
dynamic microenvironment which includes various cellular components and signalling 
pathways. It is the lack of complete understanding of all the factors involved which may 
be hindering their successful culture in vitro (153). 
The HSCs within the bone marrow can exist in either of the two identified anatomical 
niches; the vascular or the osteoclastic niche. These spatially distinct niches are also 
functionally distinct, although the understanding of their precise roles is incomplete. It 
has been proposed that the two niches work together, performing complementary roles, 
to ensure the correct regulation of the cells within. The hypoxic osteoclastic niche is 
believed to promote a quiescent cellular state, whereas the vascular niche is oxygen rich 
and promotes the proliferation and further differentiation of the HSCs (154). 
 Hierarchical differentiation of haematopoietic stem cells 1.5.3
 
The blood stem cell differentiation process is the best-defined adult stem cell system, and 
has long served as a model for stem cell research. In recent years considerable progress 
has been made in characterising the transition from a HSC into a mature blood cell. 
Primarily via multicolour flow cytometry and transgenic mouse studies, a hierarchical 
model of differentiation has been established. Much of the pioneering research was 
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conducted by the Weismann laboratory, who successfully identified the phenotypically 
distinct precursor cell populations that a HSC will progress through on its differentiation 
path (155, 156). 
Several models of haematopoietic differentiation have since been proposed. In the 
original Weissman model (figure 1-9), the first group of cells, at the ‘top’ of the hierarchy, 
are the long-term HSCs (LT-HSC). These are the only population able to differentiate into 
any lineage and self-renew throughout adult life. The cells maintain multilineage 
potential, but lose some self-renewal capacity, as they transition to short-term HSCs (ST-
HSC) (157). Self-renewal is then lost completely in the next cell population, the 
multipotential progenitors (MPPs). As the name suggests, these cells still have the 
potential to differentiate into any lineage. However, the developmental potential of these 
cells is already restricted as they cannot de-differentiate into a ST-HSC or LT-HSC (158) 
.The next stage in this model is the transition into either a common lymphoid progenitor 
(CLP) or common myeloid progenitor (CMP); the earliest branch point in the 
differentiation process. CLPs give rise to blood cells of the lymphoid lineage (B-cells, T-
cells and dendritic cells) and have lost the potential to generate cells from the myeloid 
lineage. Conversely, GMPs can give rise to blood cells of the myeloid lineage, but cannot 
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Prior to the generation of mature blood cells, CMPs progress into more specified 
progenitors; granulocyte/macrophage progenitors (GMPs), megakaryocyte/erythroid 
progenitors (MEPs) and basophil progenitors (159, 160). The origin of mast cells has been 
under scrutiny. There is evidence that mast cells can arise directly from MPPs, however 
an additional progenitor population has recently been identified in the spleens of mice; 




Figure 1-9: Classical Weissman model of haematopoietic differentiation 
The HSC undergoes a step wise transition into a mature blood cell. The first step of lineage 
commitment is the divergence into either a CMP or CLP. HSC, hematopoietic stem cell; CLP, 
common lymphoid progenitors; CMP, common myeloid progenitor; MEP, 
megakaryocyte/erythrocyte progenitors; GMP, granulocyte/monocyte progenitors; MKary, 
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The initial model outlined above suggests that the first step of lineage commitment is the 
binary decision between myeloid or lymphoid potential. Since this model was proposed, a 
subset of progenitor cells, marked by the expression of lymphoid genes and Fms-like 
tyrosine kinase 3 (FLT-3), has been identified. It was observed that these cells had lost 
erythroid and megakaryocytic potential but had maintained the ability to generate 
lymphocytes, monocytes and granulocytes. This subset of progenitor cells was termed 
lymphoid-primed multi-potent progenitors (LMPPs). The new model therefore suggests 
that the first branch point is the decision of a MPP to differentiate into a CMP, MEP or 
LMPP (figure 1-10). The megakaryocytic and erythroid cells are generated from the MEPs, 
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Figure 1-10: The updated model of haematopoietic differentiation 
Here the first step of lineage commitment is the formation of GMPs, LMPPs or MEPs. LMPPS can 
give rise to any blood cell, excluding megakaryocytic or erythroid cells. HSC, hematopoietic stem 
cell; LMPP, lymphoid primed progenitors; CMP, common myeloid progenitor; MEP, 
megakaryocyte/erythrocyte progenitors; GMP, granulocyte/monocyte progenitors; MKary, 




However, there is still controversy regarding the correct scheme of differentiation. A 
subsequent study showed that a significant proportion of the LMPP cell population can 
differentiate into megakaryocytic and erythroid cells, which is contrary to the model 
outlined above (164). Furthermore, Arinobu Y, et al. propose that LMPPs are too 
heterogeneous to be deemed a separate stage in the differentiation tree and, as the 
classical model suggest, the CMP and CLP remain the first ‘branching point’ in 
hematopoiesis (165).  
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In the above studies haematopoietic progenitor populations were primarily defined using 
surface marker expression, detected via flow cytometry. Single cell RNA-seq analysis and 
single-cell fate determination methods have since been developed. With these exciting 
new technologies researchers have highlighted the heterogeneity that resides in each 
progenitor compartment. Therefore, new models have been proposed in which there are 
no progenitor cells with mixed potential, but instead multiple sub-groups transcriptionally 
primed towards alternative differentiation fates (166) (167, 168). 
Notta et al., for example, dispute the  dogma that haematopoiesis always begins with 
multipotent stem cells and progresses through a series of progenitor ‘tiers’ of increasingly 
restricted lineage potential. They propose a new ‘two tier’ model (figure 1-11). Using 
single cell assays they mapped the origins of myeloid, erythroid and megakaryocytic cells 
in the foetus and in adults. They found that the previously defined MPP, CMP and MEP 
populations were all heterogeneous. Furthermore, they identified a change between 
foetal and adult haematopoiesis.  In the adult, multipotent cells were only found in the 
stem cell compartment and oligopotent progenitors were almost non-existent. In 
contrast, in the foetus the ratio of multilineage to unilineage cells was constant between 








Figure 1-11: A new model of haematopoiesis - multipotent cells differentiate directly into 
unipotent cells by adulthood  
Classical models of haematopoiesis include oligopotent progenitors (left). The model has been 
redefined (right). The new model proposes that there is a shift between foetal and adult 
development, which changes the progenitor cell architecture. In the foetus there are multipotent 
progenitors whereas in the adult only the stem cell compartment is multipotent. Progenitors are 
unipotent (figure taken from (167)). 
 
 
Drissen R, et al. focused on redefining the model of myelopoiesis. Using single cell 
analysis, they found that the previously defined GMP progenitor population actually 
contains two main myeloid progenitor populations; one gives rise to eosinophils and mast 
cells, and the other gives rise to neutrophils and monocytes-macrophages. The separation 
of these two populations is driven by expression levels of GATA-1 and FLT3 in multipotent 
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 Myelopoiesis is controlled by transcription factors 1.5.4
 
The process of stem cell specification is characterised by a loss of self-renewal and 
gradual acquisition of lineage specificity. The process is brought about by alterations in 
gene expression; differentiation is mediated by the down-regulation of self-renewal 
genes and up-regulation of lineage specific genes. These gene sets both counteract and 
co-operate with each other in a finely controlled network. This strict control is 
orchestrated by the carefully timed expression of specific transcription factors. This 
concept has been most clearly demonstrated in the processes of myelopoiesis; the 
regulated production of myeloid blood cells.  
The first step in myeloid differentiation is the decision made by the MPP to differentiation 
into either an LMPP (has both myeloid and lymphoid potential) or GMPs (has only 
myeloid potential). A long standing theory was that the decision is primarily determined 
by the relative expression levels of two important transcription factors; PU.1 and GATA1. 
Early transgenic mouse studies revealed that PU.1 is needed for the production of LMPPs, 
whereas GATA1 is crucial for generation of GMPs (169, 170).  
This theory was based on In vitro experimentation in which the forced expression of PU.1 
led to a block in the erythroid pathway, and likewise the forced expression of GATA1 
blocks myelopoiesis (171-173). Co-immunoprecipitation and Chromatin 
Immunoprecipitation (ChIP) experiments suggested that the observed antagonistic 
relation was due to a direct protein-protein physical interaction (173).  
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The paradigm that PU.1 and GATA-1 levels determine cell fate has been disputed. A very 
recent publication using advance single cell analysis, states that the early myeloid lineage 
fate decisions is not triggered by random relative levels of GATA1 and PU.1 proteins 
(174). Instead of driving the lineage decision, the role of PU.1 and GATA.1 expression is to 
reinforce the choice once it has been made.  
More complicated regulatory networks are required for the further specification of MEPs 
and LMPPs. The MEPs can either differentiate into a megakaryocytic or an erythrocytic 
precursor cell. The expression levels of the transcription factors EKLF and Fli-1 are the key 
determinants of this decision. EKLF is implicated in the inhibition of the transcription 
factor activity of Fli-1, thus inhibiting the production of megakaryocytic genes. Similarly, 
Fli-1 can inhibit the EKLF mediated transcription and therefore megakaryocytic cell fate 
(175).  
The resolution of an LMPP into either the lymphoid (CLPs) or the myeloid lineage (GMPs) 
is determined by the level of PU.1 expression. Via the gradual, targeted depletion of PU.1 
from hematopoietic progenitor cells it was established that low levels of PU.1 favour B 
cell development, whilst a higher concentration encouraged myeloid cell development 
and inhibits B cell development (176). It has since been discovered that the different 
expression levels in different cells types is achieved by the ability of PU.1 to regulate its 
own expression in a cell type specific manner, by associating with cell type specific 
transcription factors (163, 177). C/EBPα levels are also very important; without C/EBPα 
mice show a complete absence of GMPs and therefore lack granulocytic differentiation 
(178).  
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At the GMP stage, cells have only the potential to generate cells of the myeloid lineage. 
They then branch, specifying into either a neutrophil of macrophage precursor. This 
decision is thought the be determined by PU.1 and C/EBPα levels (179). At the GMP stage, 
PU.1 levels are at low ‘sub-threshold’ levels and the transcription factor regulates genes 
characteristic of both neutrophils and macrophages. Once PU.1 levels are elevated, the 
gene expression profile is tailored towards macrophage development, via a complicated 
network involving the transcription factors GFI1 and ERG. PU.1 acts in a ‘feed-forward’ 
loop with ERG, activating macrophage specific genes and repressing neutrophilic genes. 
The neutrophilic gene expression profile is activated via a similar feed-forward loop 
involving C/EBPα and GFI1 (180).  
An additional transcription factor, IRF8, is also believed to be fundamental to the 
generation of macrophages. IRF8 null mice have fewer macrophages relative to wild type. 
Furthermore, the subsequent expression of IRF8 in null mice restores macrophage 
differentiation. IRF8 was also found to repress the expression of granulocytic specific 
genes and inhibit granulocytic differentiation. This suggests IRF8 has a key role in the 
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1.6 Acute myeloid leukaemia 
Acute myeloid leukaemia (AML) is a haematopoietic malignancy defined by more than 
20% of the bone marrow consisting of immature precursor cells. The incidence is most 
common in adults, with AML accounting for 25% of all adult leukaemias. It is caused by 
genetic abnormalities in HSCs, which render them unable to undergo the normal 
differentiation process. The result is an accumulation of immature cells and an 
interference with the generation of normal blood cells. This aggressive disease will spread 
rapidly and, if left untreated, bone marrow failure and infection can cause fatality within 
weeks (182). 
A system devised by the World Health Organization (WHO) is used for the classification of 
AML. It takes into account the differentiation state of the cell and more detailed 
classification such as cytogenetic abnormalities. In 2008 the WHO classification was 
revised in order to incorporate more recently characterized genetic features (183). 
 AML can be caused by mutations in haematopoietic transcription factors 1.6.1
As outlined in section 1.4.3, the transcription factors involved in myelopoiesis display a 
clear stage and lineage restricted expression pattern, which highlights the importance of 
their careful regulation. If any of these factors are mutated or de-regulated, the result can 
be an arrest in differentiation. In normal conditions, progenitor cells proliferate rapidly 
then undergo differentiation. The failure or inhibition of differentiation prolongs this 
proliferative stage, thus predisposing cells to further mutation and the development of 
myeloid leukaemia. 
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The most commonly perturbed transcription factor is RUNX1. It is frequently involved in 
chromosomal translocation, for example RUNX1/ETO (t;(8;21)),RUNX1/EVI1 (t(3;21)), 
RUNX1/ETV6 (t(12;21)). In fact, the chromosomal translocation of RUNX1 is the most 
common cytogenic abnormality in leukaemia.  Furthermore, several different point 
mutations of RUNX1 have been found in myeloid malignancies (184). The cofactor of 
RUNX1, CBFβ, is also mutated in AML. For example, inv(16) leads to the fusion of CBFβ 
with smooth muscle myosin heavy chain (SMMHC) (185) (details regarding RUNX1 
function will be given later in section 1.7.1). 
 
Another commonly mutated transcription factor is C/EBPα; C/EBPA mutations are found 
in approximately 9% of acute myeloid leukaemia (AML) patients (186).  In addition to 
point mutation there are several ways in which C/EBPα function can be altered in 
haematological malignancies. These include aberrant gene expression and post- 
transcriptional or post-translational suppression (186). The role of C/EBPα in leukaemia 
development will be explained in more detail in section 1.6.2 and section 1.7.8.  
GATA-1 exists in long and short isoforms and its function can be impaired via disruption to 
the ratio of their expression. A mutation in the N –terminus of GATA-1 results in the loss 
of expression of the long isoform. The short isoform is expressed and binds target genes; 
however it lacks the transactivation domain thus significantly hindering its ability to 
regulate gene expression (187). The dominant activity of the GATA-1 mutation, and its 
involvement in disease generation, has been demonstrated in a transgenic mouse study 
(188). 
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Thus far, no mutations in the IRF8 transcription factor gene have been reported in 
myeloid leukaemia patients, despite its important role in myelopoiesis (181). However, 
there is substantial evidence supporting its involvement in pathogenesis. For example, 
IRF8 is significantly down regulated in AML and chronic myeloid leukaemia (CML) 
patients. In addition, knock down of the gene from mice results in a CML-like phenotype 
(189). Furthermore, IRF8 has also been show to encourage malignant myelopoiesis via its 
synergy with the RUNX1/ETO fusion protein, the result of the t(8;21) translocation (190).  
In contrast to the other transcription factors involved in myelopoiesis, details of the link 
between PU.1 and the transformation process are less clear. An in vivo study involving the 
gradual reduction of PU.1 expression in mice demonstrated that low PU.1 levels initiate a 
leukemic state. Interestingly, the complete abolition and a 50% reduction of PU.1 had no 
effect, whereas a clear pathogenic effect was seen with an 80% reduction. This 
emphasizes the requirement for precise PU.1 levels for correct myelopoiesis (191). In this 
study, the PU.1 levels were reduced via targeted disruption of the enhancer driving PU.1 
expression.  A subsequent study identified a single nucleotide polymorphism (SNP) within 
this highly conserved region which leads to reduced PU.1 expression levels. This SNP is 
common in human AML (192). This suggests that aberrant PU.1 expression levels, possibly 
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 CEBPA mutations and expression levels in AML 1.6.2
 
One of the most commonly mutated transcription factors is the CCAAT enhancer binding 
protein alpha (C/EBPα). C/EBPα is a member of the basic region leucine zipper family of 
transcription factors. It is encoded by an intronless gene and consists of two 
transactivation domains at the N-terminal region, and a leucine zipper region at the C-
terminus (193). The leucine zipper enables dimerization dependant DNA binding. C/EBPα 
can promiscuously dimerise with other C/EBPα family members. Dimerisation is 
dependent on specific orientations of the basic amino acid residues. Any mutations that 
effect these exact positions can hinder DNA binding.  CEBPA mRNA can be translated at 
two different AUG codons, giving rise to two different isoforms; p30 and p42. The short 
p30 protein begins at the AUG codon further downstream, so lacks the N terminal 
sequences. This means the p30 isoform lacks the regions which interact with the 
transcriptional machinery, whereas the ability to dimerise and bind to the DNA is 
preserved (194). The cellular ratio of p42/p30 is regulated by extracellular signalling via 
the protein kinase R and target of rapamycin signalling pathways (195). 
As outlined previously, the role of mutations in lineage-specific transcription factors to 
leukaemia development has been an intense area of research over the past decade. 
CEBPA mutation is the most frequently studied, probably, at least in part, due to the fact 
that CEBPA mutation are found in approximately 9 % of all AML cases (196). This high 
prevalence of CEBPA mutation in myeloid-lineage leukaemia is consistent with the effect 
of CEBPA knockouts in mice. C/EBPα deficient mice display impaired myelopoiesis, 
specifically a block in granulocyte maturation, and die at birth due to hepatic dysfunction 
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(197). A conditional CEBPA knockout in adult mice blocks the CMP to GMP transition and, 
as a consequence, myeloid blasts accumulate. In patients, null mutations are extremely 
rare. Instead the CEBPA gene can be subject to a variety of different point mutations.  
There are two main groups of point mutation. The first are N-terminal frame shift 
mutations which truncate the p42 isoform but leave the p30 is unaffected. The p30 
isoform then inhibits the remaining wildtype p42 in a dominant negative fashion. The 
second group are mutations at the C-terminal which affect the structure of the basic 
zipper region and therefore DNA binding.  Most AML patients with CEBPA mutation have 
more than one, usually a combination of both N and C terminal mutations, positioned on 
different CEBPA alleles.  
As well as abnormalities effecting genomic sequence, C/EBPα function can be significantly 
affected at the expression level. For example, expression levels are extremely low in 
t(8;21) AML. This is due to repression of the CEBPA promoter by RUNX1/ETO and a 
physical interaction between C/EBPα and RUNX1/ETO proteins, which inhibits CEBPA 
autoregulation (198). Furthermore, analysis in t(8;21) cell lines and patient samples has 
shown binding of the repressive RUNX1/ETO at the +42 kb enhancer, an enhancer 
essential for CEBPA expression in myeloid cells specifically (199, 200).  
In addition, C/EBPα protein is subject to posttranslational modifications which can affect 
its activity. Phosphorylation at specific serine residues on the transactivation domain 
affects its structure and means the C/EBPα molecules in a dimer are further apart from 
each other, thus activity is inhibited. The differentiation block in leukaemia with 
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constitutively active FLT3 may be mediated by this phosphorylation, and therefore 
inhibition, of C/EBPα by downstream ERK1/2 (201).  
It is well established that CEBPA mutations, and aberrant expression, are linked to 
leukemic transformation. How these abnormalities mediate this oncogenic effect is now 
under investigation. One theory is that the tumour suppressive role of C/EBPα comes 
from its repression of stem cell genes, like SOX4. HSCs from CEBPA null mice have 
upregulated SOX4 expression. Upon knockdown of SOX4 in these cells, self-renewal was 
blocked. Consistent with this finding, SOX4 was found to be highly expressed in patients 
with abnormal C/EBPα function (202). Therefore a dual role for C/EBPα has been 
proposed; the upregulation of the myeloid gene expression programme and the 
suppression of genes associated with stemness and self-renewal. In patients with 
abnormal C/EBPα activity, the inhibition of both of these processes is likely to be the 










Figure 1-12: C/EBPα dysregulation in acute myeloid leukaemia.  
This image shows the functional domains of C/EBPα and some of the ways in which C/EBPα can be 
dysregulated in human AML. There are two transactivation domains (TAD1 and TAD2). The basic 
region (Basic) mediates DNA binding and the leucine zipper region (Zip) mediates dimerization. 
C/EBPα mRNA can be translated from either of the two ATGs (p42 or p30) to yield a 42-KDa and 
30-KDa C/EBPα protein respectively. The p42 protein can be truncated by frame shift mutation at 
the N-terminus. Mutations at the C-terminus can affect DNA binding. Phosphorylation at serine 21 
can lead to C/EBPα inactivation. This can be caused by constitutive activation of the Mitogen-
activated protein kinase (MAPK) pathway by FLT3-ITD. Physical interaction with RUNX1/ETO, and 
RUNX1/ETO mediated repression of the C/EBPα promoter, inhibits C/EBPα autoregulation and 
leads to low expression levels.  
 Clonal evolution of leukaemia 1.6.3
The clonal evolution theory of leukemia development is based on the expansion of a 
single cell after the initiating mutation. This initial mutation in the origin cell blocks its 
maturation and increases proliferation, driving clonal expansion and cancer progression. 
As the leukemia continues to grow, some cells will obtain additional mutations that are 
favorable for survival, generating sub-clonal populations. As a consequence, all cells of 
the leukemia will contain the initiating mutation, but the entire population is 
heterogeneous. Due to this, drugs targeting the products of initiation mutations, such as 
the t(8;21) translocation, are attractive drugs targets (203). 
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 AML with the t(8;21) translocation 1.6.4
The first of the four WHO subtypes is ‘AML with recurrent genetic abnormalities’. The 
majority of AML cases fall into this category and are associated with non-random 
chromosomal translocations (204). One such translocation is the t(8;21) translocation; the 
most common and first chromosomal abnormality to be identified in AML (205). The 
abnormality is identified in approximately 10% of all AML patients; the exact figure 
depends on the geographical location and genetic background of the considered 
population (206).  The figure is also dependent on the age of the patients, as the t(8;21) 
translocation is more common in children/younger patients (207). 
The t(8;21) translocation event leads to the fusion of the RUNX1 gene on chromosome 21 
with almost the entire ETO gene on chromosome 8. As a result of the translocation, 
RUNX1 loses its transactivation domain but keeps its runt homology domain (RHD), thus 
retaining the ability to bind DNA. The transactivation domain is primarily responsible for 
the recruitment of transcriptional activators, such as p300/CBP. Its replacement, ETO, 
possesses nervy homology regions which recruit transcriptional repressors such as the N-
CoR/mSin3/HDAC1 complex (208). The result is the transcriptional repression of genes 
which would normally be activated by RUNX1 (figure 1-13). As many RUNX1 target genes 
are critically involved in granulocytic differentiation, it is not surprising that this 
abnormality results in a block in differentiation and inhibits the maturation of progenitor 
cells. Cell survival is also increased, thus cells are predisposed to develop leukemia (209). 
 




Figure 1-13: The t(8;21) chromosomal translocation 
A) The t(8;21) translocation event results the in the replacement of the transactivation domain 
(TAD) with almost the entire ETO gene. The runt homology domain (RHD) is retained. B) RUNX1 
can act as a transcriptional activator, via the recruitment of the p300 and transcription factors 
(TF). The fusion with ETO leads to its transformation into a transcriptional repressor, via the 
recruitment of the N-CoR/mSin3/HDAC1 complex. Both RUNX1 and RUNX1/ETO heterodimerise 
with CBFβ (redrawn from (210)). 
 
  Secondary mutations are required for the development of t(8;21) AML 1.6.5
The t(8;21) translocation is not sufficient to cause leukaemia; secondary mutagenic 
events are required for the development of overt disease. Evidence of this is that, in some 
cases, the abnormality is detected in utero but disease does not occur until later life 
(211). Furthermore, adult mice engineered to express RUNX1/ETO via an inducible system 
(to circumvent embryonic lethality) do not develop the disease (212). However, upon 
administration of mutagenic agents, mice harboring the fusion protein develop AML 
whereas wild type mice do not (213). This is supported by findings by Nina Cabezas 
Wallscheid et al. which demonstrated, using a mouse model, the very slow disease 
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progression following RUNX1/ETO expression (214). These experiments suggest that the 
translocation is necessary, but insufficient, for the development of AML; there is a clear 
requirement for one or more additional mutations.  
Further evidence for the requirement of additional mutation is the disproportionate 
number of t(8;21) AML patients harbouring additional cytogenetic abnormalities, such as 
the loss of a sex chromosome (215). Table 3 presents the frequency of various 
cytogenetic abnormalities in t(8;21) AML,  as well as the gene mutations associated with 
t(8;21) leukaemia (216). The secondary mutations can occur in pathways involved in 
proliferation, differentiation, avoidance of apoptosis, escape from anti-growth signals and 
enhanced self-renewal (the hall marks of cancer) (217). The most common are mutations 
in growth factor receptors such as stem cell growth factor receptor (c-KIT) and FMS-
related tyrosine kinase 3 (FLT3). Mutations in the transcription factor gene SPI1 and the 
oncogene N-RAS are also associated with t(8;21) AML (216).  
Mutations Frequency, no./total (%) 
Cytogenetic abnormalities  
-X in female patients 115/331 (35) 
-Y in male patients 235/419 (56) 
Del (9q) 80/454 (18) 
Trisomy 4 8/75 (11) 
Trisomy 8 28/454 (6) 
Others 77/454 (16) 























FLT3 D853 activating 
mutations 
5/184 (2.7) 
c-KIT (D>Y, D>V, D>H, D>I) 43/351 (12.3) 
c-KIT N822K 10/54 (19) 
NRAS: codons 12, 13, 61 40/469 (8.5) 
PU.1 1/19 (5.3) 
RUNX1 1/26 (3.8) 
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Table 3: The cytogenetic abnormalities and gene mutations associated with t(8;21) leukaemia 
(table modified from (189)).  
 
1.7  Molecular pathogenesis of t(8;21) leukaemia 
It is well established that RUNX1/ETO expression leads to a differentiation block and 
primes hematopoietic cells for oncogenic transformation. The exact mechanism by which 
is does so is currently under investigation by various research groups. The classical model 
suggests RUNX1/ETO  is oncogenic due to dominant inhibition of RUNX1 function, as a 
result of the fusion of RUNX1 with a transcriptional repressor (218). More recent research 
has led to the questioning of this model, with the suggestion of a more complex 
disturbance in gene regulation, gene expression and chromatin structure (217) (219). This 
will be outlined in the rest of this section. 
 The function of RUNX1 transcription factor 1.7.1
 
Runt Related Transcription Factor 1 (RUNX1), belongs to the Runt family of transcription 
factors. These transcription factors share a runt homology domain, a region homologous 
to the Drosophila gene Runt, which is essential for normal Drosophila embryogenesis 
(220).  It is via this Runt homology region that RUNX1 binds DNA. The Runt domain is also 
required for the interaction of RUNX1 with CBFβ, forming a heterodimeric complex 
termed the core binding factor (CBF) complex. This interaction enhances the DNA binding 
ability of RUNX1 (221). The (CBF) complex is essential for definitive haematopoiesis and 
its deregulation can lead to haematological disorders, such as t(8;21) leukaemia (222).  




RUNX1 is versatile in its interactions and can cooperate with various transcriptional co-
regulators in addition to CBFβ. As a result, it has the ability to both activate and repress 
genes. For example, RUNX1 can interact with the histone acetyltransferase, p300, to 
activate genes. Conversely it can interact with co-repressors, such as the histone 
deacetylase mSin3A, an interaction which is regulated by RUNX1 phosphorylation (223, 
224). 
RUNX1 plays a critical role in the specification of the definitive HSC. The presence of 
RUNX1 marks the earliest HSC; it is detected in the AGM and foetal liver during 
embryogenesis (225). The fundamental role of RUNX1 in definitive haematopoiesis was 
clearly demonstrated using knock out mouse studies. Mice lacking RUNX1 had no 
significant problems with primitive haematopoiesis, whereas definitive haematopoiesis 
was completely absent and mice exhibited embryonic lethality between 12.5 and 13.5 
days. Furthermore, in a chimeric mouse experiment the RUNX1 null embryonic stem cells 
gave no contribution to adult haematopoiesis (226). More recent studies have shown this 
is because RUNX1 is required for the generation of haematopoietic progenitors and HSCs 
from the endothelial cells of the vasculature (227).  
It is well established that RUNX1 is absolutely required for the generation of HSC. 
However, the importance of RUNX1 during adult life is less clear. A study in which RUNX1 
function was inhibited using a conditional gene-targeting strategy showed that RUNX1 is 
not absolutely crucial for adult haematopoiesis; mature blood cells were still present in 
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peripheral blood and bone marrow of mice (227, 228). However, RUNX1 must play a role 
as its absence in adult mice leads to several hematopoietic abnormalities. Such as the 
significant expansion of putative HSC and myeloid progenitor cells, demonstrative of a 
myeloproliferative phenotype (228). Moreover, the RUNX1 gene locus is commonly 
mutated in AML, which strongly suggest RUNX1 has a role in adult haematopoiesis.  
The transcription factor activity of RUNX1 may help explain the phenotypic difference 
between wild type and RUNX1 null mice. During adult haematopoiesis RUNX1 is known to 
regulate the expression of genes involved in myeloid growth factor signalling, by directly 
binding to their promoters at the consensus DNA sequence PyGPyGGT. These include IL-3, 
GM-CSF, CSF1R and c-MPL. (206). Furthermore, RUNX1 regulates PU.1, a transcription 
factor gene which is critical for terminal myeloid differentiation; PU.1 null mice exhibit a 
complete block in myeloid differentiation (229, 230).  
 RUNX1/ETO exhibits dominant inhibition of RUNX1 function 1.7.2
 
The classical model of RUNX1/ETO driven leukaemogenesis suggests that the presence of 
RUNX1/ETO results in malignant haematopoiesis by interfering with RUNX1 function. 
RUNX1/ETO is believed to exhibit dominant inhibition of RUNX1 function via the 
recruitment of co-repressors to RUNX1 target genes. This simple model was based on 
various observations. The principal observation being that the translocation event does 
not affect the DNA binding ability; RUNX1/ETO can still bind RUNX1 target genes. This 
lead to the presumption that it is through these genes that RUNX1/ETO has a leukemic 
effect (231).  
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The classical model was supported by a transgenic mouse study. A RUNX1/ETO ‘knock-in’ 
mouse demonstrated embryonic lethality and a block in definitive haematopoiesis. This is 
a phenotype almost identical to that of a RUNX1 knockout mouse (232, 233). The 
similarity of the two phenotypes was regarded as in vivo evidence of dominant RUNX1 
inhibition.  
The ability of RUNX1/ETO to repress RUNX1 target genes, via the recruitment of 
transcriptional repressors, has also been demonstrated experimentally. Using amino-
terminal deletions in a transcriptional repression assay, a research group characterised 
the ETO modular structure and its interaction with the corepressors N-CoR and mSin3A 
(234). Further support is offered via experiments with inhibitors of HDACs; one group 
found that treatment of RUNX1/ETO expressing cells with trichostatin and phenylbutyrate 
partially relieved the ETO-mediated repression and differentiation block (235).  
 RUNX1/ETO has effects distinct from RUNX1 inhibition 1.7.3
 
There is significant evidence for the classical model of RUNX1/ETO mediated 
leukaemogenesis. However, more recent reports suggest that this model, although 
logical, is an oversimplification of RUNX1/ETO action. For example, the observed 
phenotypic similarity between RUNX1/ETO knock-in and RUNX1 null mice does indeed 
suggest a mechanism of dominant RUNX1 inhibition. However, further investigation 
revealed the phenotypes are not identical. RUNX1/ETO knock-in mice lived one day 
longer than RUNX1 null mice. In addition, the foetal liver contained absolutely no 
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progenitor cells in the RUNX1 null, whereas a small number were detected in RUNX1/ETO 
knock-in mice. This suggests that the presence of RUNX1/ETO has effects distinct from 
the deregulation of RUNX1 target genes (233). This theory was further supported by a 
study which showed that RUNX1/ETO can affect the expression of genes not normally 
controlled by RUNX1. The study identified 24 RUNX1/ETO target genes and of these 24 
genes, only 10 were also RUNX1 regulated targets (236).  
The classical model suggests the leukemic effect of RUNX1/ETO is mediated via the 
repression of genes normally activated by RUNX1, via the recruitment of various co-
repressors. However, unexpectedly, micro-array analysis revealed RUNX1/ETO can also 
lead to the activation of genes, and the proportion of activated and repressed genes is 
actually similar. Furthermore, the genes interrogated were all directly bound by 
RUNX1/ETO, suggesting the phenomenon seen was not exclusively a downstream effect 
of RUNX1 inhibition (199). This offers convincing evidence that RUNX1/ETO mediated 
pathogenesis is likely to be far more complex than the simple direct repression of RUNX1 
targets. 
Based on the classical model, repression of RUNX1 genes is pivotal to the 
leukaemogenicity of RUNX1/ETO. It was therefore hypothesised that if RUNX1/ETO lost 
its repressor function, the leukemic effect of the fusion protein would dramatically 
decrease. One research group investigated this question by truncating RUNX1/ETO at the 
C-terminus, rendering it unable to recruit co-repressors. They obtained very interesting 
results; the truncated RUNX1/ETO in fact promoted leukaemia development (237). This 
offers more evidence that RUNX1/ETO has other pathogenic activities beside the down 
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regulation of RUNX1 targets. However, it must be noted that subsequent experiments by 
Link, K et al. demonstrated that the levels of truncated RUNX1/ETO required to cause 
leukaemia are supraphysiological, in both murine and human experimental systems (238).  
Another research group investigated if RUNX1/ETO mediates its oncogenic effects 
primarily via gene repression, via the use of histone deacetylase inhibitors (HDACi) in 
leukemic cells. In this case, the inhibition of RUNX1/ETO repressor function partly 
alleviated the myeloid differentiation block (236, 239). However, a more recent in vivo 
study showed that the treatment of RUNX1/ETO expressing leukemic mice with HDAC 
inhibitors gave no reduction in disease progression and no survival benefit (240).  This 
suggests that, although RUNX1/ETO does repress genes via co-repressor recruitment, it 
must have additional oncogenic activities.  
 RUNX1/ETO interferes with the activity of various transcription factors 1.7.4
There is now substantial evidence that RUNX1/ETO does indeed have additional activities 
beside the modulation of RUNX1 activity. Numerous studies have demonstrated that 
RUNX1/ETO can alter the behaviour of several other transcription factors that are 
implicated in haematopoiesis, such as PU.1, GATA and C/EBPα (8). 
PU.1 is essential for normal myelopoiesis; without PU.1, mice have a severe block in 
differentiation and no mature myeloid cells are present. RUNX1/ETO has been shown to 
repress PU.1 via a direct physical interaction. This interaction leads to the dissociation of 
PU.1’s co-activator JUN, dramatically hindering the transcription factor activity of PU.1. As 
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PU.1 regulates the expression of several genes involved in haematopoiesis, it is likely that 
this mechanism contributes to the leukaemogenicity of RUNX1/ETO (241).  
Another transcription factor key to normal haematopoiesis is C/EBPα. It has been 
observed that AML patients with the t(8;21) translocation have very low C/EBPα 
expression relative to other AML subtypes. Research has provided a mechanism to 
explain this observation. Via conditional expression of RUNX1/ETO in vitro,  it was 
established that the fusion protein suppresses C/EBPα mRNA levels via the inhibition of 
positive autoregulation at the C/EBPα promoter (242). The role of C/EBPα in AML 
development is discussed is in more details in sections 1.6.2 and 1.7.8. 
GATA-1 is a transcription factor crucial for erythroid lineage commitment. During normal 
erythropoiesis, GATA-1 is acetylated by p300, a mechanism which is essential for 
appropriate GATA-1 function. RUNX1/ETO binds to GATA-1 and blocks this acetylation 
step, resulting in an inhibition of normal differentiation. This RUNX1/ETO mediated 
interference with erythroid lineage commitment is believed to contribute to leukaemia 
development (243).  
Another mechanism featuring p300 has been described, which involves the E protein 
transcription factors, E2A and HEB. E2A is essential for early B cell differentiation and is a 
potential tumor suppressor. HEB has been implicated in both myogenesis and 
hematopoiesis. Both transcription factors interact with p300 via their AD1 domain, an 
interaction which is required for their activity. RUNX1/ETO stably binds to the AD1 
domains of E2A and HEB, thus displacing p300 and inhibiting their transcriptional 
activation (244).  
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 RUNX1/ETO alters the epigenetic landscape 1.7.5
 
This chapter has already described several examples of how RUNX1/ETO interferes with 
normal haematopoiesis via inhibition of key transcription factors. We know that 
transcription factors interact with epigenetic modifiers (see section 1.2.2). It is therefore 
perhaps not surprising that RUNX1/ETO presence can interfere with the epigenetic 
environment of the cell. This has been described by several publications over the last 
decade and it is believed that these epigenetic alteration are pivotal to the pathogenesis 
of t(8;21) leukaemia (199, 204, 206, 245-247).  
The first investigation of RUNX1/ETO mediated chromatin modification was focused on 
the c-FMS locus. The gene is normally bound by RUNX1 at the promoter, however in 
t(8;21) AML the gene is also bound by RUNX1/ETO at an intronic regulatory region. 
RUNX1/ETO binds as part of a complex (see section 1.7.6) and is associated with the 
reduction of gene expression. The binding of this complex correlated with specific 
epigenetic modifications; the de-acetylation of histones and the tri methylation of histone 
H3K27. A very interesting observation was that, although RUNX1/ETO binds to the 
intronic regulatory region and represses gene expression, the promoter region is still 
accessible to, and is bound by, other transcription factors. This demonstrates that, as the 
RUNX1/ETO complex does not completely block binding of other transcription factors, 
RUNX1/ETO target genes should not be irreversibly silenced. Therefore, the continuous 
presence of RUNX1/ETO is perhaps required to maintain the established epigenetic 
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modifications (206). This prompted investigation into the effect of RUNX1/ETO 
knockdown in t(8;21) AML (see section 1.6.6). 
With the advent of affordable next generation sequencing, genome wide analysis of the 
t(8;21) epigenetic landscape is now possible. One research group used ChiP-seq and 
unsupervised clustering analysis to measure histone modifications, DNA methylation and 
p300 localisation. These data were used to define 6 classes of chromatin accessible 
regions; each class was distinct in its functional make up. It was shown that RUNX1/ETO 
bound to the class characterised by p300 enrichment and lower than normal histone 
acetylation levels. This offers evidence that alterations to the histone modification 
pattern, via the abnormal recruitment of epigenetic modifiers, is a key part of RUNX1/ETO 
mediated pathogenesis (245).  
Another genome-wide study confirmed that RUNX/ETO binds to acetylated sites involved 
in haematopoiesis, and provided a mechanism by which is does so. ERG and FLI1 are ETS 
transcription factors that play a key role in normal haematopoiesis, by the acetylation of 
histones and subsequent gene activation. The study proposed a model in which 
RUNX1/ETO is recruited to these acetylated sites, via an interaction with ERG/FLI1, and 
removes the acetyl groups thus repressing haematopoetic genes (204). This is another 
example of how RUNX1/ETO disrupts the epigenetic landscape via its aberrant 
recruitment of histone modifiers. 
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 RUNX1/ETO functions in an oligomeric complex 1.7.6
 
Figure 1-13A demonstrates that RUNX1/ETO is made up of different domains. It has a 
RUNT domain for DNA binding and four nervy homology regions. The nervy homology 
region 2 (NHR2) is responsible for the oligomerisation of RUNX1/ETO, which is essential 
for RUNX1/ETO mediated leukaemogenesis (248-251). As individual molecules of 
RUNX1/ETO complex with each other, RUNX1/ETO has a preference for double RUNX1 
binding motifs (252). 
Over several years separate studies showed that RUNX1/ETO has many interaction 
partners, such as the corepressor N-CoR/mSin3/HDAC1 complex (208), C/EBPα (198) and 
GATA1 transcription factors (243, 253) and E-proteins (204, 254, 255) . Following these 
findings, Sun, XJ et al. published detailed analysis of RUNX1/ETOs interaction partners. 
They found that RUNX1/ETO forms a high molecular weight, oligomeric complex which is 
stable in vivo. To determine the components of the RUNX1/ETO complex, the authors 
isolated the complex and performed SDS-polyacrylamide gel electrophoresis and mass 
spectrometry analysis (256).  
The main components were found to be the E proteins HEB and LYL1, the RUNX1 binding 
partner CBFβ, LIM-domain binding protein LMO2 and its interacting partner LBD1. They 
characterised the pairwise interactions within the complex and discovered a network of 
strong interactions that join all these constituents, one by one. It is likely that this 
interaction network plays a role in the assembly of the complex (figure 1-14). Weaker 
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Figure 1-14: Schematic of interactions within the RUNX1/ETO complex 
Thick lines represent strong interactions and thin lines represent weak interactions. All 
components of the complex may homodimerise (figure adapted from (256)).  
 
 The effect of RUNX1/ETO knockdown in t(8;21) AML  1.7.7
 
The above findings suggest that the RUNX1/ETO mediated epigenetic reprogramming 
may not be permanent. To investigate this, Dunne, J et al. designed a small interfering 
RNA (siRNA) specific to RUNX1/ETO for depletion of RUNX1/ETO expression. They used 
this knockdown system in both t(8;21) AML cell lines and patient blasts, followed by gene 
expression profiling (257). They found that RUNX1/ETO depletion led to alterations in the 
expression of 76 genes. The gene expression changes were indicative of initiation of 
myeloid differentiation and inhibited leukemic cell proliferation (258). Furthermore, cell 
staining showed an increase in myeloid maturation following RUNX1/ETO depletion. 
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These results indicated that the maintenance of t(8;21) AML is dependent on the 
continued expression of RUNX1/ETO, and highlights RUNX1/ETO as a potential 
therapeutic target.  
It was now clear that the presence of RUNX1/ETO disrupts the gene expression profile of 
t(8;21) AML cells (258). Ptasinska, A et al. investigated how RUNX1/ETO does so, in a 
genome wide fashion. The binding pattern of RUNX1/ETO and RUNX1 was assessed via 
ChIP-seq analysis, before and after RUNX1/ETO knockdown. As their shared DNA binding 
domain would suggest, the analysis showed binding of both transcription factors to a 
subset of RUNX1 targets.  Post RUNX1/ETO depletion there was an increase of RUNX1 
binding. Interestingly, this increase in RUNX1 enrichment was not only at sites previously 
blocked by RUNX1/ETO. RUNX1 was found to bind at thousands of new, ‘de novo’ sites 
that were not previously bound by RUNX1/ETO (see figure 1-16 B) (199). These results 
gave more insight into how RUNX1/ETO interferes with wild type RUNX1 to reprogram 
AML cells.  
The RUNX1/ETO ChIP-seq data was used to identify RUNX1/ETO target genes. The effect 
of RUNX1/ETO knockdown on the expression of these target genes was then investigated. 
The depletion of RUNX1/ETO resulted in both the upregulation and downregulation of 
target gene expression. In agreement with Dunne, J et al., functional analyses revealed 
that a disproportionate number of upregulated genes are involved in differentiation, 
whereas down regulated genes are involved in cell cycle progression.  
To gain further insight into the mechanism of these complex gene expression changes, 
the researchers assessed the effect of RUNX1/ETO knockdown on the epigenetic profile. 
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To this end, they conducted a genome wide analysis of the enrichment of RNA 
polymerase II and Histone H3K9 with ChIP-seq. The results showed that a significant 
proportion of genes upregulated by RUNX1/ETO knockdown had increased RNase 
Polymerase II enrichment. There was also a genome wide increase in Histone H3K9 
acetylation, which is in accordance with the recruitment of HDACs by RUNX1/ETO (199).  
The above findings suggested that the RUNX1/ETO mediated epigenetic reprogramming 
and the leukemic phenotype is dependent on the persistent expression of RUNX1/ETO. 
The complexity of the response to RUNX1/ETO knockdown prompted further 
investigation into the mechanisms involved. It was clear that the myeloid differentiation 
response is more complex than the alleviation of repression, as wild type RUNX1 is 
recruited to new sites distinct from those previously bound by RUNX1/ETO. Furthermore, 
the gene expression alterations were strikingly complex. The researchers wish to find out 
how RUNX1 was redistributed, and how such extensive changes in the epigenetic profile 
were mediated. It was hypothesised that other transcription factors and chromatin 
modifying regulators were likely to be involved. 
 In the next study the relationship between RUNX1 and RUNX1/ETO binding was 
investigated in more detail. Previous ChIP-seq analysis detected both RUNX1 and 
RUNX1/ETO binding at the same sites in the genome (199). However, as these results 
came from analyses on a population of cells, it was not possible to determine whether 
they bind together at the DNA as a complex. To circumvent this issue, re-ChIP 
experiments were conducted. The results of these experiments showed that the binding 
of RUNX1 and RUNX1/ETO is mutually exclusive (158). These findings suggest that RUNX1 
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and RUNX1/ETO may bind the DNA in a dynamic equilibrium, taking it in turns to bind 
genomic sites (figure 1-15).  
ChIP-seq then used to determine which other transcription factors and regulatory 
proteins RUNX1 and RUNX1/ETO associate with. It was shown, for the first time in vivo, 
that both proteins differ in their preference for transcriptional repressors and activators.  
However, they form complexes with similar accessory transcription factors. The factors 
included LMO2, ERG, FLI1, PU.1 and HEB/LYL. These ChIP sequencing analyses supported 
proteomic experiments which show co-occupancy of RUNX1 and RUNX1/ETO with the 
transcription factors HEB and LYL1 and the bridging factors LMO2 and LDB1 at their target 
sites (see section 1.7.6 for more details on the RUNX1/ETO complex) (256, 259). Below is 
a diagram showing competing RUNX1 and RUNX1/ETO complexes. 
 
 
Figure 1-15: RUNX1 and RUNX1/ETO compete for the same DNA binding sites 
 
 




Figure 1-16: RUNX1/ETO knockdown leads to a genome wide increase in the binding of CEBPα 
and RUNX1 
A) Western blots detecting RUNX1/ETO, CEBPα, LMO2 and PU.1 protein expression in Kasumi-1 
cells treated with control (siMM) and with RUNX1/ETO siRNA (siRE) for 48 hours. B) Venn 
diagrams showing the overlap between RUNX1/ETO, RUNX1, CEBPα, LMO2 and PU.1 ChIP-seq 
peaks in Kasumi-1 cells treated for 48 hrs with siMM and with siRE. Experiments were conducted 
by Dr Anetta Ptasinska (199, 219) 
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 The role of C/EBPα in t(8;21) AML 1.7.8
The role of other transcription factors in reprogramming the transcriptional network after 
RUNX1/ETO knockdown was investigated. C/EBPα was an obvious candidate for 
investigation as, out of the several transcription factors analysed, it was the only 
transcription factor which showed dramatic and rapid changes in protein expression 
following RUNX1/ETO knockdown (figure 1-16 A). Furthermore, as outlined in earlier 
sections, it is a key driver of myeloid differentiation during normal haematopoiesis and 
RUNX1/ETO is known to interfere with its activity (see section 1.7.4).  
 
ChIP sequencing experiments revealed that C/EBPα binding increased considerably after 
RUNX1/ETO knockdown; C/EBPα bound to almost four times more sites in the genome. 
This was not a phenomenon universal to all transcription factors. PU.1 and LMO2 binding 
was also analysed and they exhibited no change and a loss of binding respectively (figure 
1-16 B) 
DNaseI-seq was then conducted and the results show that the majority of the C/EBPα and 
RUNX1 binding alterations occurred within pre-existing open chromatin sites. However, 
there was a subset of DNaseI sites that showed increased hypersensitivity after 
RUNX1/ETO depletion (figure 1-17). Intriguingly, these sites had an over representation of 
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Figure 1-17: Bar graph demonstrating the fold change of DNaseI peaks after RUNX1/ETO 
knockdown 
The majority of DNaseI peaks exhibit a low fold change after RUNX1/ETO knockdown. Subsets of 
DNaseI peaks are reduced (blue bars) and increased (red bars) after knock down. DNaseI was 
conducted by Dr Anetta Ptasinska (219). 
 
 
Figure 1-18: The CEBP motif is enriched at DNaseI hypersensitive sites that are unique to 
RUNX1/ETO knockdown 
Genome wide DNaseI site mapping was conducted on cells transfected with siMM and cells 
transfected with siRE for 10 days. Motif enrichment was conducted, using HOMER software, on 
the DNaseI footprints that show an increase in hypersensitivity after RUNX1/ETO knockdown. The 
table indicates the enrichment score of various transcription factor motifs. DNaseI was conducted 
by Dr Anetta Ptasinska (219). The motif analysis is not published. 
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1.8 The role of SP1 in t(8;21) AML 
Sp1 is a transcription factor involved in haematopoietic differentiation (178, 260, 261). 
The first study into its role in t(8;21) AML found that Sp1 physically interacts with 
RUNX1/ETO via the Runt domain. This interaction inhibits the transcriptional activity of 
Sp1. It was therefore proposed that Sp1 deregulation could be involved in the 
RUNX1/ETO mediated oncogenic differentiation block (262).  
Another group investigated the relationship between Sp1 and RUNX1/ETO and, using 
ChIP-on-ChIP, mapped the gene promoters which are subject to RUNX1/ETO driven 
epigenetic repression. They found that many of these genes were involved in 
haematopoiesis. Furthermore, a significant proportion of these genes were co-occupied 
with RUNX1/ETO and Sp1. Using an Sp1 inhibitor, they demonstrated that co-occupancy 
of RUNX1/ETO with Sp1 may promote the repression of these genes, thus suggesting an 
important role for Sp1 in RUNX1/ETO mediated pathogenesis and identifying SP1 as a 
new potential therapeutic target (263).   
Work from the same research group further investigated the role of Sp1 in t(8;21) AML 
(264). Their results suggest that Sp1 is important, not only for differentiation block, but 
also for leukemic cell maintenance. The authors found that the elevated MAPK signalling 
in t(8;21) AML stabilises Sp1 and thus increases its intracellular levels. They suggest that 
this increase in Sp1 protein levels enhances leukemic cells growth, as knockdown of Sp1 
in these cells led to reduced cell growth and increased apoptosis.  These finding suggest 
an oncogenic role for SP1 in t(8;21) and provide more evidence that it would be a good 
target for treatment of t(8;21) AML. 
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Recent data from our lab appears to offer support for a role of Sp1 in the differentiation 
block which we see after RUNX1/ETO knockdown. DNaseI foot printing analysis suggests 
that there were alterations in Sp1 binding after RUNX1/ETO knockdown. When the 
DNaseI cutting frequency was aligned around the Sp1 motif across all binding sites, there 
appears to be an increase in protection of the Sp1 motif after RUNX1/ETO knockdown, 
presumably by Sp1. This suggests that RUNX1/ETO presence effects Sp1 binding, which is 
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1.9 t(8;21) AML is dependent on wild type RUNX1 for survival 
RUNX1 is a commonly mutated in myeloid malignancies, so is generally considered to be a 
tumour suppressor. However, several recent studies have shown that the presence of 
wild type RUNX1 promotes t(8;21) AML cell survival (265, 266). This result is supported by 
the fact RUNX1 mutation is almost always heterogeneous in AML with CBF abnormalities, 
whereas RUNX1 can be fully inactivated in other types of leukemia (267). Ben Ami et al. 
showed that knockdown of RUNX1 from a t(8;21) AML cells line leads to apoptosis, which 
could be rescued with knockdown of RUNX1/ETO (265). Goyama et al. propose that a 
certain level of wild type RUNX1 is crucial for leukaemogenesis. RUNX1 was knocked 
down from an engineered t(8;21) AML cells line (cord blood cells expressing RUNX1/ETO). 
Cell growth was inhibited and the same was true when mutant RUNX1 was expressed 
(266).  This is suggestive of a oncogenic role for RUNX1. However, interestingly, over 
expression of wild type RUNX1 also inhibited AML cell growth by driving myeloid 
differentiation. They therefore propose a ‘dosage-dependent’ function of RUNX1 in 
t(8;21) AML. These unexpected findings highlighted the potential for using wild type 
RUNX1 as a therapeutic target in t(8;21) AML.  
 Targeting transcription factor interaction 1.9.1
RUNX1 heterodimerises with CBFβ, via its Runt domain - an interaction which stabilizes 
DNA binding and protects RUNX1 from proteasomal degradation (268, 269). The 
dimerisation is essential for adequate RUNX1 function. This is clearly demonstrated by the 
shared phenotype between CBFβ mutant mice and RUNX1 null mice (270). The Runt 
domain is retained after t(8;21) translocation and RUNX1/ETO also interacts with CBFβ. In 
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contrast to the wild type RUNX1, the importance of CBFβ to RUNX1/ETO function is less 
certain. Roudaia et al. state that CBFβ is critical for RUNX1/ETO activity (271), whereas 
Kwok et al. found that the interaction of RUNX1/ETO to CBFβ is not needed for 
RUNX1/ETO mediated transformation of primary cells (250). Furthermore, although a 
recently published genome-wide study showed that CBFβ enrichment was detected at 
thousands of RUNX1/ETO binding sites, the majority RUNX1/ETO sites (59%) were not co-
occupied by CBFβ (204). It is therefore reasonable to predict that blocking the interaction 
between the Runt Domain and CBFβ could abolish RUNX1 activity, and may hinder 
RUNX1/ETO activity. Considering the literature outlined above, inhibiting the CBFβ-Runt 
interaction in t(8;21) AML cells could trigger apoptosis and/or differentiation, thus making 
this an attractive therapeutic approach.  
 
The targeting of protein-protein interaction is a relatively new field, and transcription 
factors have long been considered ‘undruggable’ (272, 273). However, attempts have 
been made to disrupt the Runt domain- CBFβ interaction therapeutically. RNA aptamers 
were designed against recombinant Runt-β complex and successfully inhibited RUNX1 
DNA binding in vitro (269). However, unfortunately no subsequent in vivo work has been 
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 Targeting RUNX1 with small molecule inhibitors 1.9.2
 
John Bushweller’s group designed small molecules that inhibit the Runt- CBFβ interaction 
by an allosteric mechanism. The compounds bind to CBFβ at a region distinct from the 
Runt domain interaction interface, and induce a conformational change that is 
transmitted through the protein structure. This alters the dynamics of residues within the 
interface, dramatically decreasing interaction strength. These residues were previously 
shown to be vital for interaction via mutagenesis studies (274). In vitro experiments 
proved an inhibition of RUNX1 DNA binding upon treatment with the compound (275). 
Since the initial in vitro studies, the chemical structure of the compound has been subtly 
modified several times to increase its efficacy and decrease toxicity.  
Impressive results were seen with another allosteric inhibitor compound designed to 
block the interaction between the Runt domain and the CBFβ fusion protein found in 
inv(16) AML cells. This inversion leads to the fusion of the smooth-muscle myosin heavy 
chain (SMMHC) to CBFβ. This CBFβ-SMMHC is oligomeric and out competes wild type 
CBFβ for RUNX1 binding. When initially tested, the compound had only moderate potency 
and specificity for blocking CBFβ-SMMHC interaction. They therefore generated a bivalent 
derivative with the aim to target the oligomeric nature of the fusion complex (figure 1-
19). Treating inv(16) cells with the bivalent molecule (AI-10-49) lead to an inhibition of 
the CBFβ-SMMHC interaction with restoration of wild type CBFβ–RUNX1 heterodimers. 
This was accompanied by cell death of AML patient samples and delayed leukaemia 
progression in mice (276). This offers proof of principle that targeting interactions 
between RUNX1 and CBFβ is a feasible therapeutic option. 
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Figure 1-19: Targeting Runt domain to CBFβ-SMMHC interaction with allosteric small molecule 
inhibitors 
The CBFβ – SMMHC fusion protein binds to the Runt domain of RUNX1, blocking wild type CBFβ-
Runt domain interaction. The polyvalent inhibitor AI-10-49 interacts with the CBFβ – SMMHC 
fusion protein, altering its conformation allosterically, rendering it unable to bind RUNX1. RUNX1 
can then associate with wild type CBFβ and can drive the expression of its target genes (figure 




Since the above study, the focus has been targeting the Runt domain-CBFβ interaction in 
other AMLs. The researchers found that the monomeric version of AI-10-49 had a modest 
inhibitory effect on the interaction between the RUNT domain and wild type CBFβ; the 
interaction between RUNT domain and wildtype CBFβ is dimeric, so a monovalent 
compound is more appropriate. From this compound a series of analogues were 
prepared. They then established which features of the compound are necessary for 
inhibition of the Runt domain-CBFβ interaction. They did this via sequential substitution 
of the functional groups, followed by assessment of inhibition via FRET. The next 
challenge was metabolic stability in vivo. This was achieved via the introduction of a 
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trifluoromethoxy group, to yield the compound named AI-10-104 (278), which will be 
tested in this study. Administration of AI-10-104 to mice unfortunately had significant 
sedative effects. Therefore attempts were made to decrease the toxicity of AI-10-104. 
Analogues of AI-10-104 were engineered by appending a morpholine ring to the pyridine 
ring. In vitro experiments to validate inhibition of Runt domain-CBFβ interaction showed 
that the analogue ‘AI-14-91’ was as effective as the original (AI-10-104) but was well 
tolerated by mice. AI-14-91 and AI-10-104 were found to inhibit the growth of both 
leukemic and breast cancer cell lines. In embryonic stem cells, AI-14-91 was shown to 
reduce the binding of RUNX1 to RUNX1 target genes and decrease their expression (see 
section 4.1.2). 
1.10 Aims and Objectives 
The Bonifer group have lead the way in characterising the effect of RUNX1/ETO 
knockdown from t(8;21) AML. We have established that the persistent expression of 
RUNX1/ETO is required to maintain the leukemic phenotype; RUNX1/ETO knockdown 
triggers myeloid differentiation and supressed self-renewal.  We have also determined, in 
a genome wide fashion, that there are epigenetic and gene expression changes which are 
accompanied by the extensive reorganisation of transcription factor binding, primarily 
wild type RUNX1 and C/EBPα. We also see the appearance of thousands of new DNaseI 
hypersensitive sites, which are enriched for the C/EBP motif. However, several questions 
still need to be answered so we can gain more insight into the mechanisms RUNX1/ETO 
uses to reprogram haematopoietic cells. 
This thesis will systematically present the findings to the questions below: 
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1) Can we target wild type RUNX1 and/or RUNX1/ETO with small molecules inhibitors 
of the Runt domain-CBFβ interaction? 
Other research groups have recently found that t(8;21) AML depends on wild type RUNX1 
for survival (265, 266). We wish to determine whether the inhibition of wild type RUNX1 
and RUNX1/ETO with small molecule inhibitors of the Runt domain-CBFβ interaction is 
possible in t(8;21) AML cell (278). We will test the ability of the AI-10-104 compound to 
inhibit survival of t(8;21) AML cells and the effect of the compound on RUNX1 and 
RUNX1/ETO DNA binding. The experiments have the potential induce cell death via 
inhibition of RUNX1 and/or trigger differentiation via inhibition of RUNX1/ETO, which has 
exciting therapeutic implications.  
 
2) Which transcription factors drive the differentiation response after RUNX1/ETO 
knockdown? 
Our existing genome wide data points towards an important role for the myeloid 
transcription factor C/EBPα in the reprogramming of cells after RUNX1/ETO knockdown. 
We wished to determine whether this is the case by performing RUNX1/ETO knockdown 
in the absence of C/EBPα and determining how the response to knockdown is affected. 
We will also investigated if C/EBPα upregulation is the key event in reprogramming 
t(8;21) AML cells, by over expressing  C/EBPα and analysing the effect on the 
transcriptional programme.   
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Data primarily from the Alvarez lab suggest that the association between Sp1 and 
RUNX1/ETO may contribute to RUNX1/ETO mediated leukemic transformation. 
Furthermore, we have found that RUNX1/ETO knockdown may have an effect on the 
binding of proteins to the Sp1 motif. To further investigate the role of Sp1 in t(8;21) AML 
we will assess the effect of RUNX1/ETO knockdown on genome wide Sp1 binding.   
 
3) Are the epigenetic changes triggered by RUNX1/ETO knockdown reflected by 
alterations to specific promoter-cis regulatory element interactions? 
It is well established that alterations in gene expression can be reflected by changes in 
DNA looping interactions (63, 118). There is an increasing body of evidence that 
transcription factors initiate and maintain these DNA loops (63, 279-281). We therefore 
hypothesise that the changes to gene expression and transcription factor binding after 
RUNX1/ETO knockdown may be accompanied by alterations in specific promoter-
enhancer interactions. We will test this by performing chromatin conformation capture 
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Chapter 2. METHODS 
2.1 Cell line culture  
 Kasumi-1 cells were maintained at 5x105 cells/ml in Roswell Park Memorial Institute 
(RPMI) 1640 (Sigma) supplemented with 15% heat-inactivated foetal calf serum, 1% 
Pen/Strep and 1% glutamine (GIBCO).  HL60 cells were maintained at 5x105 cells/ml in 
Iscove’s modified Dulbecco’s medium (Sigma)  with 10% heat-inactivated foetal calf 
serum, 1% pen/strep and 1% glutamine (GIBCO). Human Embryonic Kidney (HEK) 293T 
cells were maintained in Dulbecco’s Modified Eagle Medium, supplemented with 1% 
pen/strep and 1% glutamine (GIBCO). All cells lines were incubated at 37° C, with 
humidified air and 5% CO2 (Carbon Dioxide) supplementation. 
2.2 Small molecule inhibitor treatment 
The small molecule inhibitors and control compounds (see table 4 for details) were 
dissolved in DMSO and added to cell media at the concentration stated in the results (gift 











AI-4-88 Control  
 
Table 4: Small molecule inhibitors of the core binding complex 
2.3 siRNA and shRNA mediated RUNX1/ETO and C/EBPα depletion 
Cells were electroporated with 200nm siRNA, in 700 μl of culture medium at a density of 
1 × 107/ml. The Fischer EPI 3500 electroporator (Fischer, Heidelberg,Germany) was used 
for all transfections with the parameters set as 350V for 10ms. Post transfection, cells 
were maintained as described in section 2.1. RUNX1/ETO knockdown was conducted with 
the following siRNAs: RUNX1/ETO siRNA (sense, 5′-CCUCGAAAUCGUACUGAGAAG-3′ 
antisense, 5′-UCUCAGUACGAUUUCGAGGUU-3′), mismatch control siRNA (sense, 5′-
CCUCGAAUUCGUUCUGAGAAG-3′ antisense, 5′-UCUCAGAACGAAUUCGAGGUU-3′). 
C/EBPα knockdown was conducted with the following siRNAs: 
GAAGUCGGUGGACAAGAAC and mismatch control UAGGAGCUGGUGAACAAGAC 
RUNX1/ETO was depleted from SKNO-1 R/E cells via an doxycycline inducible shRNA 
expression system. The SKNO-1  R/E cells (courtesy of Olaf Heidenreich) are SKNO-1 cells 
stably transduced with a pTRIPZ-derived vector (Open Biosystems) encoding shRNA for 
RUNX1/ETO. Cells were incubated with 1µg/ml doxycyline to induce expression of the 
shRNA, via a Tet-On® system. 
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2.4 Western blotting 
Cells were lysed in RIPA buffer (Cell Signalling).Western Blotting was conducted following 
a standard protocol (13). In short, proteins were separated using gel electrophoresis with 
a 10% SDS polyacryl amide gel at 40 mA for ~1.5 hrs. The proteins were transferred on to 
a nitrocellulose membrane (Thermo Scientific Pierce) at 70 V for 1 hour 15 minutes at 4 °C 
using transfer buffer (192 mM glycine, 25 mM Tris).  The membrane was blocked with 5 % 
non-fat dry milk (Marvel) in TBST (Tris-buffered saline, 0.1% Tween 20) solution for 1 
hour and then incubated with a primary antibody overnight at 4°C. A horse radish 
peroxidise-conjugated antibody (Abcam) was added and detected via enhanced 
chemiluminescence after incubation with Super-Signal® west Pico Chemiluminescent 
substrate (Thermo Scientific) and visualised by exposure to an X-ray film. Films were 
developed with a Compact X4 imaging system (Xograph Healthcare Limited). The primary 
antibodies used were as follows:  
Table 5: Western blot antibodies 
Antibody target Manufacturer Serial number 
ETO Santa Cruz sc-9737 
RUNX1 Abcam 23980 
C/EBPα Abcam 40761 
SP1 Santa Cruz Sc-17824 X 
GAPDH Abcam 8245 
H3 Abcam 1791 
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2.5 Flow cytometry  
For each analysis, 2 x 105 cells were counted and centrifuged for 5 minutes, at 300 x g at 
room temperature. The pellet was washed twice with MACS buffer (PBS, 0.5% BSA and 2 
mM EDTA). After the second wash, the pellet was resuspended in the remainder of the 
supernatant (approximately 200 µl). 2 µl of antibody was added and the cell suspension 
was incubated at 4 °C, in the dark, for 30 minutes. The cell suspension was then washed 
with MACs buffer and analysed with a CyAn™ ADP flow cytometer (Beckman Coulter).  
Table 6: Flow Cytometry Antibodies 
 
Antibody target Manufacturer Serial number 
Annexinv-FITC/PI kit BD Pharminogen 556547 
CD11b – APC Miltenyi-biotech 130091241 
CD117-APC  Miltenyi-biotech 130091733 
IgG FITC Miltenyi-biotech 130093192 
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2.6  Apoptosis detection assay 
Apoptosis was assessed using an Annexin V-FITC Apoptosis Detection Kit II (BD 
Pharminogen). At the time points stated in the results, 105 cells were collected, washed 
with phosphate buffered saline, and then stained with Annexin V-FITC and propidium 
iodide (PI) according to the manufacturer’s protocol.  Analysis of Annexin V-FITC binding 
was determined by flow cytometry with a CyAn™ ADP Analyser (Beckman Coulter).  
2.7 Extraction of RNA, cDNA synthesis and analysis of gene expression analysis 
Approximately 5 x 106 cells were centrifuged (300xg, 5 minutes, room temperature) and 
lysed with 350μl of RLT buffer with ß- mercaptoethanol (Qiagen). Total RNA was 
extracted using RNeasy columns, according to the manufacturers protocol (Qiagen).  An 
on-column DNase I digestion was conducted using an RNase-Free DNase kit, according 
to the manufacturers protocol (Qiagen). The RNA was quantified using a NanoDrop™ 
2000 (Thermo Scientific) and cDNA was synthesized as follows: 2 µg of total RNA 
extracted was annealed to 1 µl of oligo dT (deoxythymidine) primers (80µM) in a total 
volume of 15µl and incubated at 70°C for 5 minutes. Samples were then placed on ice for 
5 minutes. Reverse transcription was conducted via the addition of 5 µl of 5 x Reaction 
Buffer (Invitrogen), 5 µl of 10mM dNTPs, 1 µl of 200 U/µl MLV- Reverse Transcriptase 
(Invitrogen), 0.625µl of 400 U/µl of RNase inhibitor (Invitrogen) and the reaction was 
incubated at 42 °C for 60 minutes. 
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cDNA was quantified by Real-Time qPCR, with the  primers listed below and SYBR® Green PCR 
master mix (Applied Bio systems). Analysis was conducted using an ABI 7500 Real-Time PCR 
system (Applied Biosystems), with the step one software. The expression of individual genes was 
calculated relative to GAPDH expression. A cDNA standard curve was made using cDNA 
synthesized from mRNA extracted from the cell line undergoing analysis. The standard cDNA was 
diluted to 1:10, 1:50, 1:250, 1:1250 and 1:6250 with water. cDNA to be tested was diluted 1:50 
times. Genomic DNA derived from chromatin immunoprecipitation was analysed by qPCR as 
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Table 7: Primers used for qPCR 
 
Gene target Forward Primer Sequence Reverse Primer Sequence 
CEBPA GAGGGACCGGAGTTATGACA AGACGCGCACATTCACATT 
CEBPE ATGTCCCACGGGACCTACTACGA ACAGTGTGCCACTTGGTACTGCAG 
CSF1R AGCACGAGAACATCGTCAACC TTCGCAGAAAGTTGAGCAGGT 
CST7 CCAACCACACCTTGAAGCAGA  GGGTCAGTGACAACGGAGAAC 
CTSG TCAGTTGCTGCTGTGCTTC  TTCTCAATCCCCTGTCCCCAC 
ERG ATGGAGGAGAAGCACATGCC ATAGCGTAGGATCTGCTGGC 
GAPDH CCTGGCCAAGGTCATCCAT GGGGCCATCCACAGTCTT 
IGFBP7 GAAGTAACTGGCTGGGTGCTG GCTGATGCTGAAGCCTGTCC 
MPL TCAGCAGCCAAGATGTCTCC TGCCTCTTCCTCATCCCAGA 
MS4A3 CCAAGCCATAAACAACCCCA  TTCTGGTCCCGTCTCACTGC 
NFE2 CCAAGGTGTGTTCAAAGAGGC GGAGCCGAGTCAGGGAAGAC 
NKG7 CTGATTGCTTTGAGCACCGA CCTGATATGATGTCCCCATGC 
PU.1 TCTTGGCCACCAGGTCTCCTA CGCCCTCCTCCTCATCTGA 
RNASE2 CCCCTGAACCCCAGAACAA ACCATGTTTCCCAGTCTCCG 
RUNX1/ETO TCAAAATCACAGTGGATGGGC CAGCCTAGATTGCGTCTTCACA 
SOX4 AAGATCATGGAGCAGTCGCC CGCCTCTCGAATGAAAGGGA 
SP1 GCACCTGCCCCTACTGTAAA TGGATGTGGCAAATATGCTGT 
UBASH3B ACCATCAAGCATGGATCGGC GGTCACCGACATGGGAGAAT 
Table 8: Primers used for ChIP-qPCR 
 
Gene target Forward Primer Sequence Reverse Primer Sequence 
IVL promoter GCCGTGCTTTGGAGTTCTTA CCTCTGCTGCTGCCACTT 
PU.1 14Kb enhancer  AACAGGAAGCGCCCAGTCA TGTGCGGTGCCTGTGGTAAT 
IGFBP7 promoter  GTCAAGCACTAAAAGGACAAACCG TGAATGCCACTGGGAGACAAAG 
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2.8 Chromatin Immunoprecipitation (ChIP) 
2x107 cells were counted, centrifuged (300 xg, 5 minutes, 4 oC) and resuspended in media. 
Whole cells were treated with 1% formaldehyde (Sigma) at room temperature for 10 
minutes to crosslink protein to DNA. 0.5M glycine was added and the reaction was 
quenched for 5 minutes at room temperature. Cells were pelleted via centrifugation (300 
xg, 5 minutes, 4 oC) and washed  twice with ice cold PBS and resuspended in buffer A (10 
mM HEPES pH 8.0, 10 mM EDTA, 0.5 mM EGTA, 0.25% Triton X-100, proteinase inhibitor 
cocktail (Roche UK) and 0.1 mM PMSF)) and rotated at 4 oC for 10 minutes. The solution 
was centrifuged (500 xg, 5 minutes, 4 oC) and pelleted nuclei were resuspended in buffer 
B (10 mM HEPES pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.01% Triton X-100, 
protease inhibitor cocktail and 0.1 mM PMSF ) by rotation for 10 minutes at 4 oC. 
Chromatin was pelleted (500g, 5minutes, 4 oC), snap frozen with liquid nitrogen and 
stored at -80 oC. For immunoprecipitation, the chromatin pellet was resuspended in 600 
μl ChIP buffer 1 (25 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 
0.25% SDS, protease inhibitor cocktail and 0.1 mM PMSF) and sonicated twice, for 10 
minutes of 30s ON 30s OFF each time with the Bioruptor™ sonicator (Diagenode). 
Chromatin was pelleted (16,000xg, 5 minutes, 4 oC) and the supernatant was diluted 1:3 
with ChIP buffer 3 (25 mM Tris-HCl pH 8.0,150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 
7.5% glycerol, protease inhibitor cocktail and 0.1 mM PMSF).  
Dynabeads® Protein G beads (Invitrogen) were used for immunoprecipitation. 15μl 
beads were added to 0.5% BSA, phosphate buffer and 2 μg of antibody; RUNX1 (Abcam), 
ETO (Santa Cruz), CBFβ (Abcam) and PU.1 (Santa Cruz). The immunoprecipitation mixture 
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was incubated at 4 oC for 1 hour, with rotation and then added to chromatin and 
incubated for 4 hours at 4 oC with rotation (5% of the volume of chromatin added was 
taken as an input control). The following wash steps were performed (a magnet was used 
to collect the beads); once with wash buffer 1 (150 mM NaCl, 1% Triton X-100, 20 mM 
Tris-HCl, 0.1% SDS and 2mM EDTA), twice with wash buffer 2 (500 mM NaCl,1% Triton X-
100, 20 mM Tris-HCl, 0.1% SDS and 2mM EDTA), once with LiCL buffer (250 mM LiCl , 
0.5% NP-40, 10 mM Tris-HCl pH 8.0, 0.5% Na-deoxycholate  and 1 mM EDTA) and finally 
twice with 1 ml TE/NaCl buffer (50 mM NaCl,10 mM Tris-HCl pH 8.0 and 1 mM EDTA). 
Using a shaker for 15 minutes at room temperature, DNA was eluted twice with 50 μl of 
elution buffer (1% SDS, 100mM NaHCO3). The input control was made up to 100 μl with 
the same elution buffer. The crosslink was reversed overnight at 65 oC with 50 μg 
proteinase K. DNA purification was conducted using Agencourt AMPure beads (Beckman 
Coulter) following the manufacturers standard protocol. DNA was eluted with 50 μl of 
water (6).  
Genomic DNA was assessed via qPCR (see section 2.7). Relative enrichment was 
calculated by normalizing data to the input chromatin. Data is also presented with 
normalisation against the input chromatin and the enrichment observed at negative 
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Table 9: ChIP Antibodies 
 
Antibody target Manufacturer Serial number 
RUNX1 Abcam 23980 
ETO Santa Cruz sc-9737 
PU.1 Santa Cruz sc-352 X 
SP1 Santa Cruz sc-17824 X  
 
2.9 Retroviral production 
A retrovirus was used to stably transduce Kasumi-1 cells with the C/EBPA-ER vector (see 
figure 3-8 A), a generous gift from Dr Chris Van Oevelen (University Pompeu Fabre, 
Barcelona). This vector was constructed using the MSCV-IRES-GFP retroviral vector back 
bone. Viral particles were made in HEK293T cells. The virus was collected and 
concentrated and then used to transduce Kasumi-1 cells. The genes encoding the packing 
and envelope proteins are on a separate plasmid. Therefore, virus cannot be produced in 
the Kasumi-1 cells following transduction.  
 Transfection of HEK293T cells for retroviral production  2.9.1
For virus production HEK293T were cultured to a 80-90% confluency. Following the 
manufacturers protocol, Trans-IT (Mirus, USA) was used to transfect three 10 cm plates of 
HEK293T cells with three construct: 30µg C/EBPA-ER vector, 30µg gag/pol, 9 µg Envelope 
(gift from Dr James Mulloy, Cincinnati, USA). Viral supernatant was harvested at 12 hours, 
36 hours and 48 hours after transfection. 
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 Virus concentration 2.9.2
To pellet cell debris, the viral supernatant was centrifuged for 15 minutes at 4 °C at 3000 
rpm. The supernatant was collected and filtered (0.45 µM filter disc). Following the 
manufacturer’s instructions, a Centricon Plus 70 100kDa filter column (Millipore, USA) 
was used for concentration. Centrifugation was conducted at 1000 x g for 25 minutes at 4 
°C. 
 Retroviral transduction with RetroNectin 2.9.3
RetroNectin (Takara, Japan) assists viral transduction efficiency by bringing together viral 
particles and the target cell.  A 6 well, non-tissue culture plate was coated with 
RetroNectin. To do this a 24 µg/ml solution of RetroNectin in PBS was added to the plate 
for 2 hours at room temperature. The solution was subsequently removed and the plate 
was blocked with BSA (2% BSA in PBS) at room temperature for 20 minutes. The plate was 
then washed with 2.5% HEPES in HBSS (Hank’s Balanced Salt Solution, SIGMA).  
The concentrated virus was then bound to the RetroNectin coated plates, by two 45 
minutes centrifugations at 2000 xg. Finally, 1 x 106 Kasumi-1 cells were added to each well 
of the plate, in a 1:1 ratio with the remaining concentrated virus. Polybrene was then 
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The plate was incubated overnight at 37 °C with 5% CO2 (standard tissue culture 
conditions). The following day, cells were pelleted at 300 xg for 5 minutes at room 
temperature. The cell pellet was resuspended in standard tissue culture medium (see 
1.1). The efficiency of transduction is indicated by the proportion of GFP positive cells. 
GFP expressing cells were isolated by Florescence Activated Cell Sorting (FACS) with the 
MoFlo Astriso EQ (Beckman Coulter Life Sciences).  
2.10  Circularised chromosome conformation capture (4C-seq)  
  Fixation and cell lysis 2.10.1
1x107 Kasumi-1 cells, transfected with mismatch siRNA (siMM) or siRNA specific to 
siRUNX1/ETO (siRNA), were fixed with 2% formaldehyde and incubated for 10 minutes at 
room temperature. 1.425 ml of 1M glycine was added to quench the cross-linking 
reaction. Fixed cells were immediately centrifuged for 8 minutes at 4°C, 500 xg. 
Supernatant was removed and the pellet resuspended in 1ml lysis buffer (500µl 1M TRIS 
pH 7.5, 300µl 5M NaCl, 100µl 0.5M EDTA, 250µl 20% NP-40 and 100µl Triton X-100 made 
up to 10ml with H2O) and incubated at room temperature for 5 minutes, followed by 5 
minutes at 65°C. Cells were then kept on ice whilst complete cell lysis was determined via 
Trypan blue (Gibco) staining. Cells were centrifuged at 800 xg for 5 minutes and the pellet 
was taken up in 440 µl H20 and 60 µl 10X RE buffer 2 (NEB).  
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  Digestion with primary restriction enzyme 2.10.2
 15 µl of SDS was added and the tube placed at 37°C for 1 hour. 75 µl of 20% Triton X-100 
was added and the tube incubated at 37°C for 1 hour. A 5 µl aliquot was removed as an 
‘undigested control’ sample before 200 units of the restriction enzyme DpnII was added. 
The tube was incubated for 4 hours at 37°C, and then another 200 units of DpnII was 
added, followed by overnight 37°C incubation. The following day 200 units of DpnII was 
added for 4 hrs at 37°C. A 5 µl aliquot was removed as a ‘digested control’ sample. To 
this, along with the ‘undigested’ sample, 90 µl of 10mM Tris pH 7.5 and 5µl Proteinase K 
(10 mg/ml) was added to reverse the cross links. These control samples were run on a 
0.6% agarose gel to assess the digestion efficiency. All 37°C incubations were conducted 
in a heated block, shaking at 900 RPM. DpnII was selected as the restriction enzyme as it 
functions in SDS, and combined with the second restriction enzyme (Csp6I) it generates 
restriction fragments near the target loci, with a suitable size for efficient ligation and PCR 
amplification. Both of these enzymes are 4bp cutters, so will cut the genome into 256 bp 
fragments, on average. This allows for a high resolution assay.  
  Ligation and DNA purification 2.10.3
The DpnII was inactivated by incubation at 65°C for 20 minutes. On ice, 700 µl of 10X 
ligation buffer, 7 ml of milli-Q H20 and 10 µl T4 Ligase (Roche 5U/µl) were added then 
samples were incubated overnight at 16 °C. The following day, to assess ligation 
efficiency, a 100 µl aliquot of the sample was taken as the ‘ligated control’. The crosslinks 
were reversed as above and the sample run on a 0.6% agarose gel (as previously 
described).  
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To reverse the crosslinks, 30 µl Proteinase K (10mg/ml) was added and samples were left 
overnight at 65°C. The next day, 30 µl RNAse A (10mg/ml) was added and samples were 
incubated for 45 minutes at 37°C. DNA was extracted by adding 7 ml phenol-chloroform. 
Samples were mixed thoroughly then centrifuged at 3000 xg at room temperature. The 
water phase was transferred to a new 50 ml tube to which 7 ml of milli-Q H20, 7 µl of 
glycogen, 1.5 ml 2M NaAC pH 5.7 and 35 ml ethanol was added. Samples were placed at –
80°C overnight. The next day samples were centrifuged at 4°C for 30 min, 3000 xg. The 
supernatant was removed and 10 ml of cold 70% ethanol was added. Samples were 
centrifuged again for 15 min, 3000 xg at 4°C. The supernatant was removed and the pellet 
left to dry at room temperature. The pellet was dissolved in 150µl 10mM Tris pH 7.5. 
 Digestion with secondary restriction enzyme 2.10.4
 Each sample was transferred to a 1.7 ml tube, 50 µl 10X restriction buffer and 50 units of 
the restriction enzyme Csp6I (Fermentas # ER0211) was added and the volume made up 
to 500 µl with milli-Q H20. After an overnight incubation, 500 RPM shaking, at 37°C, a 5 µl 
aliquot of the sample was taken. This ‘digestion control’ was run on a 0.6% agarose gel.  
  Second ligation and DNA purification 2.10.5
The enzyme was inactivated as previously describe and the samples transferred to a 50 ml 
tube. 1.4 ml of 10X ligation buffer and 20 µl of ligase (100 U) (Roche Catalogue # 
10799009001) was added, then the reaction made up to 14ml with milli-Q H2O. After an 
overnight ligation at 16 °C, 1.4ml 2M NaAC pH 5.6, 14µl glycogen and 35ml of 100% 
ethanol were added.  Samples were stored at –80°C overnight. The next day samples 
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were centrifuged at 4 °C for 45 minutes, at 3750 RPM. The supernatant was removed and 
15 ml of cold 70 % ethanol was added. The samples were then centrifuged again for 15 
minutes, at 20°C and 3750 RPM.  Again, the supernatant was removed and the pellet then 
left to dry at room temperature. Once dry the pellet was dissolved in 150 µl 10mM Tris 
pH 7.5 at 37°C. Samples were then purified using a QIAquick PCR purification kit, 
according to the manufacturer’s protocol. Samples were eluted in 50 µl 10mM Tris pH 7.5 
and pool samples. DNA concentration of each 4C template was determined via analysis 
with a NanoDrop™ 2000 (Thermo Scientific). 
  View-point fragment selection and primer design 2.10.6
Restriction fragments greater than 350 bp and within 2kb of the target genomic region 
were selected as viewpoint fragments, dependent on the ability to design specific 
primers. A 5’ Illumina adapter sequence was added so the inverse-PCR products did not 
need further processing prior to sequencing. Reading primers were designed as close to 
the primary restriction site as possible, to reduce reads from the known viewpoint 
sequence. Non-reading primers were designed to regions less than 120kb from the 
secondary restriction site (table 10). 
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 PCR amplification and sequencing 2.10.7
200 ng of 4C template was used per PCR reaction. For each viewpoint and template, 16 
PCR reactions were conducted using an Expand Long Template system (ROCHE # 
11681834001) (see table 10 for primer sequences). The pooled PCR products (total 
volume 800 µl) were then purified using the High Pure PCR Product Purification Kit (Roche 
# 11732676001), to remove any adaptor containing primers (<120 bp). Samples were 
centrifuged to pellet any beads that escaped the column. The supernatant was taken, 
then the concentration and purity of this 4C template was assessed by a NanoDrop™ 
2000 (Thermo Scientific) (260/280 ration > 2 and 260/230 ratio > 1.8 was required). The 
libraries were then visualized on a 1.5% agarose gel. All 8 of the 4C libraries were pooled, 
and then multiplexed sequencing was performed on the HiSeq 2500 platform. The 
libraries were de-multiplexed, mapped and normalized using a published bioinformatic 
pipeline (282). 
 Differential analysis of 4C interactions 2.10.8
Individual fragment counts were calculated for every 1kb bin. A median was calculated, 
with a 3kb sliding window, and data from both biological replicates was merged. The R 
package DESeq2 was used to calculate the log2 fold change (RUNX1/ETO knockdown vs 
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Table 10: Viewpoint specific 4C-seq PCR primers 
 
Sample View point Primer sequence 
siMM REP 1 SPI1 PROMOTER FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTAGTGAGGAGCAGTGGCGATC 
siRUNX1/ETO REP 1  SPI1 PROMOTER FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTGAGTGAGGAGCAGTGGCGATC 
siMM REP 2 SPI1 PROMOTER FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTAAGTGAGGAGCAGTGGCGATC 
siRUNX1/ETO REP 2 SPI1 PROMOTER FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTTAGTGAGGAGCAGTGGCGATC 
 SPI1 PROMOTER REVERSE CAAGCAGAAGACGGCATACGAACTATGCCCTGGCTCAGA 
siMM REP 1 SPI1 URE FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTTGTCCAGGGAAGCCCAGATC 
siRUNX1/ETO REP 1  SPI1 URE FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTGTGTCCAGGGAAGCCCAGATC 
siMM REP 2 SPI1 URE FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTATGTCCAGGGAAGCCCAGATC 
siRUNX1/ETO REP 2 SPI1URE FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTCTGTCCAGGGAAGCCCAGATC 
 SPI1 ENHANCER REVERSE CAAGCAGAAGACGGCATACGATTCACCAGGCACAGACTT 
siMM REP 1 CD34 PROMOTER FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTAGTGATAGCCTCACCAGATC 
siRUNX1/ETO REP 1  CD34 PROMOTER FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTCAGTGATAGCCTCACCAGATC 
siMM REP 2 CD34 PROMOTER FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTGAGTGATAGCCTCACCAGATC 
siRUNX1/ETO REP 2 CD34 PROMOTER FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTTAGTGATAGCCTCACCAGATC 
 CD34 PROMOTER REVERSE CAAGCAGAAGACGGCATACGAGTGCGTCTCTCTAGGAGC 
siMM REP 1 CD34 URE FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGTGGCCCCATACAGATC 
siRUNX1/ETO REP 1  CD34 URE FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTACGTGTGGCCCCATACAGATC 
siMM REP 2 CD34 URE FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTGCGTGTGGCCCCATACAGATC 
siRUNX1/ETO REP 2 CD34 URE FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTTCGTGTGGCCCCATACAGATC 
 CD34 URE REVERSE CAAGCAGAAGACGGCATACGAAGGAAGCAATAGAGTGGAGG 
siMM REP 1 CD34 DRE FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTCTTTTTCCCCCTGCTCGATC 
siRUNX1/ETO REP 1  CD34 DRE FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTACTTTTTCCCCCTGCTCGATC 
siMM REP 2 CD34 DRE FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTTTTTCCCCCTGCTCGATC 
siRUNX1/ETO REP 2 CD34 DRE FORWARD AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTTCTTTTTCCCCCTGCTCGATC 
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Table 11: Genomic co-ordinates of selected viewpoint restriction fragments 
 
View point Primer sequence 
SPI1 Promoter  chr11:47399040-47398740 
SPI1 Upstream Regulatory Element (URE) chr11:  47414944-47414201 
CD34 Promoter  chr1:208,081,333-208082113 
CD34 Upstream Regulatory Element (URE) chr1:208,095,318-208,095,781 
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Figure 2-1: Overview of the 4C method 
A) Schematic of 4C-seq experimental procedure. After formaldehyde cross-linking and digestion 
with the first restriction enzyme (DpnII) the chromatin is religated under dilute conditions to fuse 
interacting fragments. The DNA is digested with a second restriction enzyme (Csp6I) then ligated 
to form small DNA circles, which should now contain only one primary ligation junction. Inverse 
PCR primers designed to the view-point (restriction fragment of interest) allow specific 
amplification of fragments ‘captured’ by the viewpoint. The resultant library of fragments is 
subject to high throughput sequencing. B) Outline of 4C-seq primer and inverse PCR design. 
Inverse PCR primers specific to the viewpoint carry an illumina sequencing adaptor which means 
the resultant library does not require further processing. Sequencing reads consequently begin 
with the reading primer binding site. Therefore reading primers are designed as close to the 
primary restriction site as possible, to maximise coverage of the un-known sequence. Non-reading 
primers are designed to a sequence less than 120kb from the secondary restriction site. 
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2.11 Capture HiC  
 
 
Figure 2-2: Schematic of Capture Hi-C experimental procedure 
Chromatin is fixed and digested as in 4C. In this case, biotin is incorporated into the ligation 
junction, allowing enrichment for ligation junctions via streptavidin pull down. Sequencing 
adapters are added during PCR amplification. The library is then enriched for promoter containing 
ligated fragments with biotinylated baits, designed to hybridize to 22,000 promoters. Streptavidin 




 Fixation and lysis of cells 2.11.1
 
5× 107 Kasumi-1 cells were fixed via suspension in 37 ml of RPMI-1640 supplemented with 
15% FBS and 2% formaldehyde. The cells were fixed for 10 minutes at room temperature 
while mixing. 6 ml of 1M glycine (0.125 M final concentration) was added to quench the 
reaction. Cells were incubated at room temperature for 5 min, followed by 15 minutes on 
ice. Cells were then pelleted by centrifugation at 400 x g for 10 minutes at 4 °C. The 
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supernatant was discarded and cells were washed in ice cold PBS. The cells were then 
pelleted and after removing the supernatant, each sample was flash frozen in liquid 
nitrogen, and stored at −80 °C. 
Cells were lysed in a tight dounce homogeniser (ten cycles) with 3ml of cold lysis buffer 
(10 mM Tris-HCl pH 8, 10 mM NaCl, 0.2% Igepal CA-630, one tablet protease inhibitor 
cocktail (Roche complete, EDTA-free, 11873580001)). Cells were left on ice for five 
minutes then homogenised another ten times. The lysed cells, in 3 ml lysis buffer, were 
added to 47ml of lysis buffer and incubated on ice for 30 minutes with occasional mixing.  
The chromatin was pelleted at 1800 rpm for 5 minutes at 4C and the supernatant 
discarded. The pellet was resuspended in 1ml of 1.25x NEBuffer 2 and split into four. Each 
sample was then pelleted at 1000 rpm and resuspended in 358 µl of 1.25x NEBuffer 2. 11 
µl 10% SDS was added and each tube was incubated at 37°C for 60 minutes, rotating at 
950 rpm. Samples were mixed by pipetting up and down every 15 minutes. The SDS was 
quenched with 75µl 10% Triton X-100 and incubated at 37˚C for 60 minutes, rotating at 
950 rpm. During the incubation, samples were mixed by pipetting up and down every 15 
minutes. 
 HindIII digestion, biotinylation and ligation of digested DNA ends 2.11.2
The chromatin was digested overnight with 1500 units of HindIII (NEB R0104T), rotating 
(950 rpm) at 37 °C. The HindIII cleavage of its restriction site (5’ AAGCTT 3’) generates a 5’ 
overhang (5’-AGCT-3’), which was repaired to include a biotinylated nucleotide, allowing 
the enrichment of Hi-C ligation products. To do this, 6µl 10x NEB2, 2µl H2O, 1.5µl 10mM 
  101 
 
dCTP, 1.5µl 10mM dGTP, 1.5µl 10mM dTTP, 37.5µl 0.4mM biotin-14-dATP (Life 
Technologies 19524-016), and 10μl 5U/μl Klenow (DNA polymerase I large fragment, NEB 
M0210L) were added to each tube. Samples were mixed carefully and incubated for 60 
minutes at 37˚C, with mixing by pipetting every ten minutes. 
The digested chromatin mixture was added to a falcon tube with 8 ml of ligation buffer 
(750µl 10x ligation buffer (NEB B0202S), 75 μl 10mg/ml BSA (NEB B9001S) and 50 μl  
1U/μl T4 DNA ligase (Invitrogen 15224-025). These dilute conditions favour ligation of 
fragments crosslinked within the same chromatin complex (intra-molecular ligation). The 
tubes were mixed by inversion and incubated overnight at 16 °C. The following day, 
samples were incubated for a further 30 minutes at room temperature. 
 Crosslink reversal and DNA purification 2.11.3
Crosslinks were reversed and proteins degraded by incubating the tubes over night at 65 
˚C, with 60µl 10mg/ml proteinase K (Roche 03115879001). After the overnight 
incubation, another 60 µl of 10 mg/ml proteinase K per tube was added, followed by a 2 
hour incubation at 65˚C. 
 
The reaction mixtures were cooled to room temperature and 12.5 µl of 10 mg/ml RNase 
A (Roche 10109142001) was added. Samples were incubated at 37˚C for 60 minutes. The 
DNA in these tubes was purified with two phenol extractions. After ethanol precipitation, 
the DNA pellets were resuspended in 25µl 1x TE and the four samples were pooled. The 
Quant-iT assay was used to determine the DNA concentration of the resultant HiC library 
using a Qubit® 3.0 Fluorometer (Thermo Scientific).  
  102 
 
 HiC ligation efficiency and quality controls 2.11.4
To check the library was sufficiently ligated, a 1/10 dilution was resolved on a 0.8% 
agarose gel. The majority of the library should run at around 10 kb. To confirm that blunt-
end ligation was successful, the fact that fill-in and ligation of a HindIII site (AAGCTT) 
creates a NheI restriction site (GCTAGC) was exploited. A particular ligation product 
formed by the MYC promoter and a known 1.8 MB long range interaction was amplified 
with 3C PCR (see table 12 for primer sequences). The same was done for a ligation 
product formed by the MYC promoter and an adjacent restriction fragment. 200ng of the 
purified PCR products were split into four and digested with HindIII, NheI or both 
enzymes, with undigested DNA is used as a control. The resultant DNA samples were run 
on a 1.5% gel (see figure 2-3) 
Table 12: 3C PCR primers 
 
Target restriction fragment Primer Sequence 
MYC promoter GGAGAACCGGTAATGGCAAA 
Restriction fragment < 1 kb from MYC promoter  TGAGGTCCCAGGCATTCTTT  
Restriction fragment 1.8 MB from MYC promoter AATAACAAGGCCCCCAAATTCT 
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Figure 2-3: Capture-HiC quality controls 
A) Hi-C libraries were resolved on a 0.8% agarose gel. The majority of DNA runs at approximately 
10 kb, which is indicative of sufficient ligation. The ligation efficiency is not 100%, hence the 
smear below. B) The purified HiC DNA is used as a template for PCR amplification. The DNA 
fragments generated from ligation of the MYC promoter with a neighbouring restriction fragment, 
and the MYC promoter with a 1.8MB distal fragment, is amplified using standard 3C PCR 
conditions. The amplicon is then digested with HindIII and/or NheI. Ligation products which have 
been efficiently biotinylated can be cut by NheI but not HindIII. C) After biotin pull down, one 
tenth of the immobilised Hi-C library was amplified from the streptavidin beads with 6, 9 or 12 
PCR cycles. The resultant DNA was resolved on a 1.5% agarose gel. A smear is just about visible at 
6 cycles. Therefore 7 cycles was selected for bulk amplification. D) Bioanalyser traces of HiC 
libraries pre and post sure select promoter enrichment. 
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 Removal of biotin from non-ligated DNA ends 2.11.5
To avoid pulling down any non-ligated fragments, biotin was removed from free ends 
using the exonuclease activity of T4 DNA polymerase. 8 reactions of  5μg of Hi-C library, 
0.5μl 10 mg/ml BSA, 5μl 10x NEBuffer 2, 2μl 2.5mM dATP, and 5μl T4 DNA polymerase 
(NEB M0203L) in a total volume of 50μl were made and incubated at 20˚C for 4 hours. 
The reaction was stopped by adding 2ml of 0.5M EDTA pH 8.0. Two reactions were 
pooled to generate four tubes of approximately 10ug DNA. The DNA was purified via 
phenol:chloroform extraction and ethanol precipitation. Each sample was reconstituted in 
130 μl H2O 
 DNA shearing and end repair 2.11.6
 An E220 focused-ultrasonicator (Covaris) was used to fragment the DNA with the 
intensity set to 4, the duty cycle set to 10% and with 200 cycles per burst for 55 seconds. 
After sonication,  the entire volume of each sample was transferred into a fresh 
Eppendorf tube and 18μl 10x ligation buffer (NEB B0202S),18μl 2.5mM dNTP mix, 6.5μl T4 
DNA polymerase (NEB M0203L),6.5μl T4 DNA Polynucleotide kinase (NEB M0201L) and 
1.3μl Klenow (NEB M0210L) were added. The reaction was left for 30 minutes at room 
temperature. Each sample was then split into two and purified with a MinElute column 
(Qiagen 28004), according to the manufacturer’s instructions. Each column was eluted 
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  A-taling and size selection 2.11.7
To the sheared and end repaired DNA , 5 μl of NEBuffer 2 10x, 11.5 μl dATP 1mM and 3.5 
μl Klenow exo- (NEB M0212L) were added. The reaction was incubated for 30 minutes at 
37 ˚C. To inactivate the enzyme, each reaction was incubated at 65˚C for 20 minutes, and 
put on ice immediately afterwards. Fragments between 200 and 650 base pairs were size 
selected by double-sided SPRI bead (ampure) size selection (0.6x followed by 0.9x), 
following the manufacturers protocol.  All Hi-C library samples were then pooled and 
quantified with the Quant-iT™ High-Sensitivity DNA Assay Kit (Invitrogen) and assayed on  
the  Qubit™ Fluorometer (Invitrogen).  
 Biotin-streptavidin pulldown and adapter ligation 2.11.8
The biotin marked fragments were immobilized via MyOne Strapavidin C1 DynaBeads 
(Invitrogen) following manufacturers protocol. The fragments were ligated to illumina 
paired-end adaptors. The immobilized Hi-C fragments were amplified via PCR, using PE 
PCR primers 1 and 2 with 7 cycles. 
PE PCR 1 - AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT  
PE PCR 2- CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGA  
The Hi-C library was then purified twice with solid phase reversible immobilization (SPRI) 
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 Test PCRs to determine conditions for Hi-C library amplification 2.11.9
To determine the optimal number of PCR cycles for Hi-C library, test PCRs were set up 
with 6, 9 and 12 amplification cycles. Each reaction contained 2.5 µl of Hi-C library DNA 
on beads, 5 µl of phusion buffer 5x (NEB F531), 0.7 µl dNTP mix, 0.75 ul PE PCR primer 1, 
0.75 µl PE PCR primer 2, 0.3 µl Phusion polymerase (NEB F531)  and 16.35 µl of H2O. The 
PCR programme was set as follows: 
 
1 cycle 98°C  30 seconds 
 65°C 30 seconds 
 72°C 30 seconds 
n - 2 cycles  98°C 10 seconds 
 65°C 30 seconds 
 72°C 30 seconds 
1 cycle: 98°C 10 seconds 
 65°C 30 seconds 
 72°C 7 minutes 
 
The amount of amplified DNA was assessed by running the entire reaction (25 μl) on a 1.5 
% agarose gel. A smear in the range of 300 bp to 600 bp was be just about visible at 6 
cycles of amplification and increased in intensity with increasing number of PCR cycles. 7 
cycles were selected for bulk PCR amplification. 
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 Final PCR amplification of Hi-C library 2.11.10
The remaining volume of HiC library DNA on beads was amplified following the above PCR 
reaction set up (i.e. 2.5 µl of beads per reaction). The beads were separated from the 
reaction mixture with a magnet and the supernatant was purified twice with solid phase 
reversible immobilization (SPRI) beads (Beckman Coulter Ampure XP beads A63881), 
following the manufacturer’s instructions. The library was quantitated with the Quant-iT™ 
High-Sensitivity DNA Assay Kit (Invitrogen) and assayed on the Qubit™ 
Fluorometer (Invitrogen) and run on the bioanalyzer (Agilent).  
 Hybridization of Hi-C library with biotin-RNA 2.11.11
750 ng of each library was desiccated with a SpeedVac. After evaporation of all liquid, the 
HiC DNA pellet was suspended in 3.4 μl of H2O. 2.5 μl of custom block 1, 2.5 μl of custom 
block 2 μl and 0.6 μl of custom oligo block (Agilent Technologies) were added. After 
thorough mixing the solution was transferred into a PCR strip and kept on ice. 49 µl of 
hybridisation buffer was made per sample. Hybridisation buffer consists of 25 μl 
SureSelect Hybridization solution 1 (Agilent Technologies), 1 μl SureSelect Hybridization 
solution 2 (Agilent Technologies), 10 μl SureSelect Hybridization solution 3 (Agilent 
Technologies) and 13 μl SureSelect Hybridization solution 4 (Agilent Technologies). The 
buffer was mixed thoroughly, heated to 65˚C for 5 minutes, then transferred into a PCR 
tube strip and kept at room temperature.   
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The SureSelect RNase Block (Agilent Technologies) was diluted 1:4 with nuclease free 
water. 2 µl of the dilution was added to 5 μl biotinylated RNA baits (custom made, Agilent 
Technologies (77).After thorough mixing, the whole 7 μl was transferred to a PCR tube 
strip and kept on ice.  
A PCR machine (Thermocycler, Biometra) was set to 95 ˚C for 5 minutes at 65 ˚C forever, 
with the lid heated to 98 ˚C. The PCR strip containing the HiC library and custom blockers 
was added to the pre-heated PCR machine and the protocol was started.  After just over 5 
minutes (once the temperature had reached 65˚C) the PCR strip with the hybridization 
buffer was added to the PCR machine.  After 5 minutes (10 minutes since the start of the 
PCR program), the PCR strip with the biotinylated RNA bait was transferred to the PCR 
machine.  After 2 minutes, 13 μl of hybridization buffer from the PCR strip was added to 
the 7 μl of RNA bait (grey into cross-hatched).  The PCR strip containing the hybridization 
buffer was discarded. Immediately after, all of the HiC library and custom blockers (9 μl) 
was added into the 20 μl of RNA bait with hybridization buffer.  
After 24 hours at 65˚C, a biotin pulldown and washes were performed as follows. Per 
capture HiC sample, 60 μl of Dynabeads MyOne Streptavidin T1 (Life Technologies 65601) 
were washed three times with binding buffer (Agilent). With the streptavidin beads in 200 
μl of binding buffer, the entire hybridization reaction was taken from the PCR machine 
and transferred into the tube containing the streptavidin beads. This was incubated on a 
rotating wheel for 30 minutes at room temperature. 
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After 30 minutes, the beads were washed with 500 μl wash buffer I (agilent). The beads 
were incubated in wash buffer I at room temperature for 15 minutes and vortexed every 
2 to 3 minutes for 5 seconds. The beads were then washed with wash buffer II (pre-
warmed to 65˚C). The beads with wash buffer II were incubated at 65˚C for 10 minutes 
and vortexed for 5 seconds every 2 to 3 minutes. This was repeated for a total of 3 
washes. After removing the supernatant, the beads were washed in 200 μl 1xNEB2, then 
resuspend in 30 μl of 1xNEB2 and transferred to a fresh tube.  
 Capture HiC library amplification 2.11.12
A post-capture PCR amplification step was carried out, using PE PCR 1.0 and PE PCR 2.0 
primers, following the previously describe protocol with only 4 PCR cycles.  DNA was 
purified twice with 1.8x volume of SPRI beads (Beckman Coulter Ampure XP beads 
A63881), following the manufacturer’s instructions and resuspend in nuclease free H2O. 
The library was quantitated with the Quant-iT™ High-Sensitivity DNA Assay Kit 
(Invitrogen) and assayed on the Qubit™ Fluorometer (Invitrogen) and run on the 
bioanalyzer (Agilent).  
 Capture HiC data analysis 2.11.13
 
The capture Hi-C paired-end sequencing reads were put through a publically available 
pipeline called HiCUP (283).  The raw sequencing reads are separated and mapped against 
the positions of the human genome (hg19). The reads were then filtered for experimental 
artefacts and duplicate reads, and then re-paired.  By aligning the reads a read count per 
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restriction fragment was obtained. Statistically significant interactions were called with 
another bioinformatic package called GOTHiC (284). This uses a cumulative binomial test 
to detect interactions between distal genomic loci that have significantly more reads than 
expected by chance, by using a background model of random interactions. This analysis 
assigns each interaction with a p-value, which represents its significance. Differential 
interactions (control vs RUNX1/ETO depletion) were determined by comparing the p-
values with HOMER bioinformatic software (285). A difference with a p-value of less than 
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Chapter 3. RESULTS 
3.1 CBF complex inhibition in t(8;21) AML cells 
 Treatment of HL60 and Kasumi-1 cells with CBF complex inhibitor induces 3.1.1
apoptosis in a dose dependant manner 
Experiments using RUNX1 specific siRNA have shown that RUNX1 is essential for the 
viability of t(8;21) AML cells  (265, 266). This identified wild type RUNX1 as a novel 
therapeutic target in t(8;21) AML. However siRNA is not an easily feasible therapeutic 
option. For this reason, as well as several others, efforts have been made to generate 
small molecule inhibitors of RUNX1. One such compound is an allosteric inhibitor 
designed to block the Runt domain-CBFβ interaction, and thus inhibit RUNX1 DNA binding 
and transcriptional activity.  
As RUNX1/ETO also interacts with CBFβ via its runt domain, the compound may also 
inhibit RUNX1/ETO function. The effect of RUNX1 knockdown on cell viability is not seen 
with a combined knockdown of RUNX1/ETO and RUNX1 (266). This suggests that the 
extent to which the compound affects either protein will determine the outcome on cell 
viability. We therefore set out to test whether these compounds were efficient at 
inhibiting DNA binding of RUNX1 and RUNX1/ETO. 
Firstly, it was necessary to determine the cytotoxicity of the compounds, in order to 
accurately assess the effect of the inhibitor in subsequent gene expression and Chromatin 
immunoprecipitation (ChIP) experiments. To this end, Kasumi-1 and HL60 cells were 
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treated with increasing concentrations of the inhibitor compound, in increments of 10 
μM. Kasumi-1 cells are a widely used and well characterised model of t(8;21) AML (199, 
204, 219, 256, 265). HL60 cells, a promyelocytic leukaemia cell line with only wild type 
RUNX1, was included in the analysis to examine whether RUNX1 dependence was specific 
to AML cells with CBF abnormalities. The same titration was conducted with the inactive 
control compound. An additional DMSO vehicle control was included. In this condition, 
the DMSO concentration applied was equal to the amount of DMSO administered with 
the inhibitor and control compounds.  
The proportion of apoptotic cells was assessed by staining cells with PI and Annexin V 
followed by flow cytometry analysis at 6 hrs, 24 hrs and 48 hrs after inhibitor application. 
The results from treatment with 10 μM, 50 μM and 100 μM concentrations are presented 
in figure 3-1.  An increase in inhibitor concentration was associated with an elevated 
percentage of apoptotic cells at 24 hrs and 48 hrs. In contrast, at 6 hrs, cell viability was 
unaffected. HL60 cells were more sensitive to the inhibitor than Kasumi-1 cells (figure 3-
1).  











































































Figure 3-1: Treatment of HL60 and Kasumi-1 cells with CBF complex inhibitor induced apoptosis 
in a dose dependant manner 
Titrations of 10 μM -100 μM CBF complex inhibitor, the control compound, and a vehicle control 
(the concentration of DMSO used in each condition) were applied to Kasumi-1 and HL60 cells. 
Annexin V and propidium iodide (PI) staining followed by flow cytometry analysis was used to 
assess cell viability at 6 hours, 24 hours and 48 hours. Annexin V-FITC (x-axis; log scale) and PI (y-
axis; log scale) plots are shown from 10 μM, 30 μM and 100 μM of each compound, and from the 
DMSO control for each concentration. An untreated control was also included. The percentage 
stated to the right of each plot represents the sum of the proportion of cells in quadrants R3 (cells 
positive to for Annexin V) and R5 (cells positive for Annexin V and PI). A) Kasumi-1 cells treated for 
6 hours. B) Kasumi-1 cells treated for 24 hours. C) Kasumi-1 cells treated for 48 hours. D) HL60 
cells treated for 6 hours. E) HL60 cells treated for 24 hours. F) HL60 cells treated for 48 hours. The 
results presented are from one of three experiments with the same findings. 
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 The CBF complex inhibitor has no significant effect on transcription factor binding 3.1.2
Application of the CBF complex inhibitor led to cell death in both Kasumi-1 and HL60 cells. 
To determine whether this was due to the inhibition of Runt domain to DNA binding, 
Chromatin immunoprecipitation (ChIP) analysis was conducted and RUNX1 binding was 
measured at the Pu.1 enhancer where this factor, as well as RUNX1/ETO, is known to bind 
(199). ChIP analysis cannot be conducted on apoptotic cells since cell death will affect 
transcription factor binding, and mask the specific effects of the compound. To 
circumvent this issue a low, non-toxic concentration was applied for 24 hours and 48 
hours, and binding of RUNX1 to the target loci was assessed at these time points. 
Inhibitor treatment had no effect on RUNX1 enrichment (figure 3-2 A). We hypothesised 
that an effect was not seen due to an insufficient concentration of inhibitor. 100 μM of 
inhibitor killed both cell lines at 24 hours, thus suggesting the inhibitor is potent at this 
concentration. Therefore, ChIP analysis was conducted after 6 hr incubation with 100 μM 
compound; under these conditions inhibitor treated Kasumi-1 and HL60 cells had not yet 
gone into apoptosis. We also measured PU.1 binding as a control, as it is a protein that 
should not be affected by the compound. The ChIP results, in both cell lines, suggested 
the inhibitor still had no effect on the binding of RUNX1, CBFβ, PU.1 or RUNX1/ETO to the 
Pu.1 enhancer, despite the increase to the concentration of inhibitor applied (figure 3-2 
B).  
In conclusion, the application of the CBF complex inhibitor led to the death of Kasumi-1 
and HL60 cells. However, the inhibitor treatment resulted in no detectable effect on the 
DNA binding of RUNX1 or RUNX1/ETO.  








Figure 3-2: The CBF complex inhibitor had no significant effect on transcription factor binding 
A) ChIP-qPCR showing RUNX1 enrichment at the PU.1 enhancer and IGFBP7 promoter in Kasumi-1 
cells treated with 10 µM control compound and 10 µM CBf complex inhibitor for 24 hours (left) 
and 48 hours (right). Bar graph presents two biological replicates (REP 1 and REP 2). B) To 
circumvent issues with cell death; a high concentration (100 µM) was applied for a short incubation 
time (6 hours). Cell viability was not effected (data not shown). Bar graphs present ChIP-qPCR data 
showing RUNX1, RUNX1/ETO, CBFβ and PU.1 enrichment at a shared target, the - 14 kb PU.1 
enhancer. 
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3.2 The effect of RUNX1/ETO depletion on gene expression and the role of Sp1 in 
t(8;21) AML 
Work published by the Alvarez lab suggests that an association between the transcription 
factor Sp1 and RUNX1/ETO may contribute to RUNX1/ETO mediated leukemic 
transformation. Furthermore, our DNaseI data revealed that RUNX1/ETO knockdown may 
have an influence on the binding of Sp-factor family binding proteins to the SP1 motif. 
Therefore, to investigate the role of Sp1 in t(8;21) AML we assessed the effect of 
RUNX1/ETO knockdown on genome wide Sp1 binding via ChIP-seq. 
These experiments involved depletion of RUNX1/ETO from t(8;21) AML cells. An efficient 
siRNA mediated knockdown system has already been established (199, 219, 257). We 
recently obtained an inducible shRNA system for the depletion of RUNX1/ETO from 
SKNO-1 R/E cells. These are SKNO-1 cells (a t(8;21) AML cell line) transduced with a 
doxycycline inducible shRNA specific to RUNX1/ETO (courtesy of Olaf Heidenreich). This is 
a favourable system as it allows prolonged, stable RUNX1/ETO depletion and circumvents 
the need of repeat transfections, which will allow more accurate time course analysis of 
gene expression. Furthermore, it will facilitate the manipulation of t(8;21) AML cells in the 
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 RUNX1/ETO depletion leads to the upregulation of genes involved in 3.2.1
myelomonocytic differentiation 
The reversible nature of the RUNX1/ETO mediated block in differentiation has already 
been demonstrated via targeted depletion of RUNX1/ETO with siRNA (199). Here we wish 
to test a doxycycline inducible shRNA specific to RUNX1/ETO and see if comparable 
results are obtained. 
We performed RUNX1/ETO knockdown with both systems (siRNA and shRNA), followed 
by quantitative PCR. These experiments were conducted to confirm efficient RUNX1/ETO 
knockdown for use in future experiments and will also manually validate our existing 
microarray data (obtained with the siRNA system) (199). Quantitative PCR analysis was 
conducted to quantify RUNX1/ETO mRNA levels at 24 hrs, 48 hrs and 72 hrs after 
transfection or doxycycline induction. In order to avoid depletion of wild type RUNX1, the 
siRNA and shRNA sequences were designed to target the RUNX1-ETO junction within the 
transcript of RUNX1/ETO (199).  The specificity of the siRNA and shRNA to RUNX1/ETO 
was assessed by RUNX1 mRNA quantification. As shown in Figure 3-3, effective 
knockdown of RUNX1/ETO mRNA was achieved with both systems, on the protein and 
mRNA level; a greater than 50% mRNA knockdown was seen at each time point. 
Knockdown efficiency was similar with both systems. With the exception of SKNO-1 R/E 
cells at 72 hours, RUNX1/ETO siRNA and shRNA appeared to have no effect on RUNX1 
expression.  
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Next we investigated the effect of RUNX1/ETO depletion on the expression of known 
RUNX1/ETO target genes and control genes. The level of mRNA was measured at 24 hrs, 
48 hrs and 72 hrs after siRNA transfection/shRNA induction in Kasumi-1 or SKNO-1 R/E 
cells respectively. We observed a significant up regulation of RUNX1/ETO target genes in 
both (t8;21) cell lines. With the exception of CEBPA, all genes showed the greatest up 
regulation 48 hrs and 72 hrs post siRNA/shRNA induction. For example NFE2, a 
transcription factor gene involved in haematopoietic differentiation, displayed a 3-4 fold 
increase in both cell lines (286). There was also upregulation of CSF1R and IGFBP7. CSF1R 
is a gene encoding the receptor for colony-stimulating factor-1, a growth factor involved 
in the control of macrophage differentiation (287). IGFBP7 is gene that has recently been 










Figure 3-3: RUNX1/ETO depletion led to the up regulation of genes involved in haematopoietic 
differentiation  
Upper panels shows, via western blot and qPCR, the expression level of RUNX1/ETO following three 
days of RUNX1/ETO knockdown via siRNA transfection (A) or induction of RUNX1/ETO specific 
shRNA with doxycycline (B). Lower graphs show myeloid gene expression in Kasumi-1 and SKNO-1-
R/E cells, 24 hours, 48 hours and 72 hours after transfection with RUNX1/ETO specific siRNA for 
Kasumi-1 cells (A) or induction of RUNX1/ETO specific shRNA with doxycycline for SKNO-1-R/E cells 
(B). All data is normalised to GAPDH and relative to the control; the control for Kasumi-1 is cells 
treated with the control siRNA, the control for SKNO-1-R/E is non induced cells (- doxycycline). 
Results shown are the average of three biological replicates. Error bars represent the standard 
deviation between the three replicates.  
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 The SP1 motif is more protected from DNaseI digestion after RUNX1/ETO 3.2.2
knockdown 
Given the extensive gene expression changes and transcription factor binding alterations, 
we hypothesised that RUNX1/ETO knockdown may have an effect on chromatin 
accessibility. DNaseI digestion was therefore conducted on cells before and after 
RUNX1/ETO knockdown in order to determine the effect of RUNX1/ETO knockdown on 
chromatin accessibility (see section 1.8 and figure 1-13). This DNaseI experiment was 
conducted by Dr Anetta Ptasinska (219).  
Work primarily from Alvarez et al. has suggested that Sp1 may play an important role in 
t(8;21) AML leukaemogenesis, via an interplay with RUNX1/ETO (247, 262). We therefore 
used the above DNaseI-seq data to investigate whether Sp1 has a role in the response to 
RUNX1/ETO knockdown. Using footprinting analysis, we determined whether the Sp1 
motif (which is also bound by other members of the Sp-family) was differentially 
protected from digestion after RUNX1/ETO knockdown, which would indicate that Sp-
factor family binding was is affected by RUNX1/ETO. Interestingly, when all DNaseI cuts 
are aligned around the Sp1 motif, we see an increase in protection of the motif after 
RUNX1/ETO knockdown. This suggests that following RUNX1/ETO knockdown the 
genome wide binding of Sp proteins might increase (figure 3-4).  
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 RUNX1/ETO knockdown has no effect on the expression of Sp1 3.2.3
The apparent increase in protection of the Sp1 motif after RUNX1/ETO knockdown could 
be due to an increase in Sp1 expression. To determine the effect of RUNX1/ETO 
knockdown on Sp1 expression, Kasumi-1 cells were transfected with either control or 
RUNX1/ETO specific siRNA and after two days protein and mRNA levels were assessed. 
RUNX1/ETO knockdown appeared to have no effect on SP1 mRNA or protein expression 
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Figure 3-4: RUNX1/ETO knockdown increased protection of the Sp1 motif. 
 DNaseI cutting frequency data was aligned around the SP1 motif, across all binding sites. Data from 
siMM (red) and from siRE (grey) cells were compared. The reduction in cuts at the centre represents 
the protection of the motif from cleavage by DNaseI, presumably by transcription factor binding. 
DNaseI experiment conducted by Dr Anetta Ptasinska. 
Figure 3-5: RUNX1/ETO knockdown had no effect on the expression of Sp1 
A) qRT-PCR showing expression of SP1 over a 3 day time course of siRNA mediated RUNX1/ETO 
knockdown. Error bars represent the standard deviation between three biological replicates.  
B) Western blot detecting Sp1 protein in Kasumi-1 cells treated for 48 hrs with mismatch control 
siRNA (siMM) and with RUNX1/ETO siRNA (siRE). Both nuclear protein and protein from whole cell 
lysate are shown. GAPDH and H3 expression were used as loading controls for whole and nuclear 
protein respectively.  
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 Sp1 and RUNX1/ETO bind to distinct sites in the genome  3.2.4
The DNaseI footprinting analysis suggested that RUNX1/ETO knockdown has an effect on 
Sp1 binding (figure 3-4). To assess whether this was the case, we performed Sp1 ChiP-seq 
on Kasumi-1 cells transfected with either mismatch or RUNX1/ETO specific siRNA. 
RUNX1/ETO knockdown led to the loss of 2934 Sp1 binding sites, with the acquisition of 
only 415 new sites (3-6 A). Maiques-Diaz A et al. found that that there is an enrichment of 
Sp1 binding at RUNX1/ETO target genes and propose an important role for Sp1 in the 
DNA binding pattern of RUNX1/ETO (264). In order to determine whether, in our system, 
RUNX1/ETO and Sp1 are associated with each other at the DNA, we overlapped Sp1 ChIP-
seq peaks with RUNX1/ETO ChIP-seq peaks from control Kasumi-1 cells. We found that 
RUNX1/ETO and Sp1 do not bind the same genomic sites; less than 7% of Sp1 binding 
sites were co-occupied by RUNX1/ETO (3-6 B). This suggests that Sp1 and RUNX1/ETO do 
not associate with each other at the DNA.  
We then wished to see whether differential Sp1 binding was associated with the gene 
expression changes which occur after RUNX1/ETO knockdown. This would help us to 
determine if Sp1 plays a role in RUNX1/ETO mediated transformation and transcriptional 
reprogramming. To do this, we determined the number of genes differentially expressed 
by RUNX1/ETO knockdown that were within 1.5 Kb of a Sp1 peak. In control and 
RUNX1/ETO knockdown cells, Sp1 binds to less than 30% of genes which respond to 
RUNX1/ETO knockdown. This is the case for both up and down regulated genes (figure 
3.2.4 D). Sp1 is predominantly a promoter binding transcription factor, this was confirmed 
by our analysis (figure 3-6 C) (289). 
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In summary, we found no association between RUNX/ETO and Sp1 binding. RUNX1/ETO 
knockdown did not have a considerable effect on Sp1 binding and the two proteins do not 
associate with each other at the DNA. Sp1 is therefore unlikely to contribute to 


















Figure 3-6: Sp1 and RUNX1/ETO bound to distinct sites in the genome and RUNX1/ETO 
knockdown had no effect on Sp1 binding  
A) RUNX1/ETO knockdown has little effect on genome wide binding of Sp1. Kasumi-1 cells were 
electroporated with either RUNX1/ETO specific siRNA (siRE) or control siRNA (siMM) . Two days 
after siRNA electroporation, SP1 binding was measured by ChIP sequencing in both populations. 
The Venn diagram demonstrates the overlap between siMM SP1 ChIP-seq peaks and siRE SP1 
ChIP-seq peaks. B) Sp1 and RUNX1/ETO bind to primarily distinct sites in the genome. The Venn 
diagram shows the overlap between Sp1 ChIP-seq (siMM data set) and RUNX1/ETO ChIP-seq 
peaks. RUNX1/ETO ChIP-seq data from Ptasinska et al. was used in the analysis (198).  
C) RUNX1/ETO knockdown has no effect on the distribution of Sp1 peaks relative to transcription 
start site (TSS) of the nearest gene. The plot demonstrates the proportion of Sp1 ChIP-seq peaks 
that are proximal or distal to the TSS in both siMM and siRE data sets. D) There is no correlation 
between Sp1 binding and gene expression. The plot demonstrates the proportion of Sp1 ChIP-seq 
peaks in Kasumi-1 cells electroporated with either RUNX1/ETO specific siRNA (siRE) or control 
siRNA (siMM) which are within 1.5 kb of a gene differentially expressed by RUNX1/ETO 
knockdown. Blue bars are genes upregulated after RUNX1/ETO knockdown. Red bars are genes 
down regulated after RUNX1/ETO knockdown.  
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3.3 The importance of C/EBPα expression levels in t(8;21) AML 
Previous experiments have shown that CEBPA is strongly down-regulated in t(8;21) cells. 
The repression comes from inhibition of CEBPA auto-regulation via a direct interaction 
between the RUNX1/ETO and C/EBPα, as well as the direct repression of the CEBPA 
promoter and enhancer by RUNX1/ETO binding (199) (198). Of the several transcription 
factors analysed, C/EBPα was the only protein significantly upregulated after RUNX1/ETO 
knockdown. This was accompanied by an increase in genome wide C/EBPα binding by 
more than fourfold (figure 1-12), indicating that this factor plays an important role in re-
establishing a myelomonocytic gene expression program after knock-down.  Combined 
with the already established crucial role of C/EBPα in myeloid differentiation, these data 
led us to question whether C/EBPα is the key driver of the differentiation response seen 
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 C/EBPα is required for the full upregulation of myeloid genes after RUNX1/ETO 3.3.1
depletion 
To test the above hypothesis, we knocked down RUNX1/ETO with and without 
concomitant knockdown of C/EBPα. As seen in previous experiments (3-3), there was an 
approximately two fold increase in CEBPA expression following RUNX1/ETO knockdown 
(figure 3-7 A and B) and an increase in the expression of other RUNX1/ETO target genes 
(MS4A3, NKG7, RNASE2) (figure 3-7 C). The addition of C/EBPα knockdown to RUNX1/ETO 
knockdown significantly inhibited the upregulation of these genes. These data show that 
the alleviation of CEBPA repression by RUNX1/ETO knockdown is required for the full 
upregulation of at least a subset of RUNX1/ETO target genes.  
MS4A3, NKG7, RNASE2 genes had inhibited upregulation in response to the addition of 
C/EBPα knockdown to RUNX1/ETO knockdown. We found that these genes were 
upregulated in response to C/EBPα overexpression (see section 1.3.3 and figure 3-11). 














Figure 3-7: C/EBPα is required for the full upregulation of myeloid genes after RUNX1/ETO 
depletion  
A) qRT-PCR showing RUNX1/ETO and CEBPA mRNA expression levels in Kasumi-1 cells 72 hrs 
after electroporation with the indicated siRNAs. Results represent the mean ± SEM of five 
independent experiments. *p < 0.05 by paired student’s t test. B) Western blot indicating 
RUNX1/ETO and C/EBPα protein expression levels in mock transfected (no siRNA), RUNX1/ETO 
knockdown, C/EBPα knockdown and double knockdown Kasumi-1 cells. Cells were transfected 
with the indicated siRNAs. An antibody against H3 was used as a loading control. C) mRNA levels 
of MS4A3, NKG7, and RNASE2 72 hrs after electroporation with the indicated siRNAs. The bars 
represent the mean ± SEM of five independent experiments. *p < 0.05, **p < 0.01 by paired 
Student’s t test. Data published in Ptasinska et al 2014. 
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 Activation of a β-Estradiol inducible form of C/EBPα in t(8;21) AML cells alleviates 3.3.2
differentiation block  
Given that the alleviation of CEBPA from RUNX1/ETO mediated repression was critical for 
the full differentiation response, we tested if overexpression of C/EBPα is sufficient to 
override the differentiation block. C/EBPα was overexpressed using a 17β-Estradiol 
inducible system (290). Kasumi-1 cells were transduced with a retrovirus from which a 
C/EBPα – estrogen receptor fusion protein is constitutively expressed (see figure 3-8 A 
and methods section 1.9) (290). However, only upon 17β- Estradiol addition can the 
fusion protein translocate into the nucleus and have transcriptional activation activity 
(figure 3-8 A). Induction of C/EBPα over a time course of 8 days lead to a gradual increase 
in myeloid differentiation, demonstrated by an increase in the surface expression of the 
myeloid marker CD11b (figure 3-8 B). This was accompanied by a decrease in the surface 
expression of c-Kit (figure 3-8 C).  
C/EBPα is known to both drive the expression of myeloid genes and supress stem cell 
genes (202). This was also true in this study as manual qPCR gene expression analysis 
showed that C/EBPα induction led to an increase in the expression of myeloid genes such 
as CTSG and a down regulation of the stem cell genes MPL, SOX4, ERG and CD34 (figure 3-
8 D). 
 














Figure 3-8: Activation of a β-Estradiol inducible form of C/EBPα in t(8;21) AML cells alleviated 
differentiation block with a reduction in self renewal  
A) Kasumi-1 cells were transduced with a construct from which a C/EBPα – estrogen receptor fusion protein 
is constitutively expressed. Upon 17β- Estradiol addition, the fusion protein can dissociate from Hsp90 and 
translocate into the nucleus. B) C/EBPα activation in Kasumi-1 cells stably transduced with C/EBPα-ER 
fusion leads to an increase in CD11b cell surface expression. The flow cytometry plots show a gradual 
increase in CD11b expression over 8 days of 17β-Estradiol mediated C/EBPα activation. C) C/EBPα activation 
in Kasumi-1 cells stably transduced with C/EBPα-ER fusion leads to a decrease in Kit surface expression after 
4 days. D) C/EBPα activation in Kasumi-1 cells stable transduced with C/EBPα-ER fusion leads to a decrease 
in the expression of selected self-renewal genes and an increase in the expression of selected myeloid 
genes. Mock transduced Kasumi-1 cells were used as a control (Kasumi-1). Results shown are the average of 
three biological replicates and error bars indicate the standard deviation. ‘ctrl’ is no 17β-Estradiol ‘B-
Estradiol’ is four days 17β-Estradiol treatment  
D 
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 Genes that are differentially expressed after RUNX1/ETO knockdown are 3.3.3
correlated with genes that are differentially expressed by C/EBPα induction 
 
Our experiments so far suggest that C/EBPα overexpression may be sufficient to override 
the RUNX1/ETO mediated differentiation block and direct cells back on course for 
myeloid differentiation. Such a process entails that the changes in gene expression 
patterns observed during myelopoiesis would be restored. To test this theory, and 
directly compare the effect of RUNX1/ETO knockdown with C/EBPα over expression, we 
conducted a genome wide mRNA expression analysis. RNA-seq libraries were prepared 
from Kasumi-1 cells with and without C/EBPα induction, as well as mock transduced cells 
with and without 17β- Estradiol treatment as a control. These data were then compared 
to existing RNA-seq data sets generated from Kasumi-1 cells with and without 
RUNX1/ETO knockdown, which were generated in Olaf Heidenreich‘s lab (199).  
Expression data from genes which changed expression by at least two fold, in response to 
either C/EBPα or RUNX1/ETO knockdown, were subject to unsupervised hierarchical 
clustering and presented using a heat map (figure 3-9 A). The data show very few changes 
in gene expression in control cells whereas the induction of C/EBPα led to a dramatic 
alteration in the gene expression pattern. We then identified genes which changed 
expression by more than two-fold after 4 days of C/EBPα induction, as well as after 4 days 
of RUNX1/ETO knock-down. Figure 3-9 B displays an unsupervised clustering of fold-
change of gene expression, indicating common clusters of genes which were up- or 
downregulated by both RUNX1/ETO knockdown and C/EBPα overexpression.  
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To examine the significance of the association between the genes differentially expressed 
by RUNX1/ETO knockdown and those differentially expressed by C/EBPα induction, we 
performed Gene Set Enrichment Analysis (GSEA) (figure 3-9 C). GSEA analysis determines 
the enrichment of genes differentially expressed by C/EBPα in the set of genes 
differentially expressed by RUNX1/ETO knockdown. Furthermore, it determines whether 
the genes respond in the same way to each manipulation. The plots demonstrate that 
many of the differentially expressed genes are shared between the two gene sets. A p-
value of <0.001 indicates that the genes differentially expressed by induction of C/EBPα 
represent a statistically significant proportion of the set of genes differentially expressed 
by RUNX1/ETO depletion.  Furthermore, it shows that those genes upregulated by C/EBPα 
are often also upregulated by RUNX1/ETO. The same is true for genes which are down 
regulated by each condition. Examples of shared, upregulated genes include the myeloid 
genes CTSG, LAPTM5, LCP1, MS4A3, NKG7 and RNASE2. Examples of shared down 
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To visually compare the data sets in a genome wide fashion, principal component analysis 
was conducted with all expressed genes (figure 3-9 D). The three largest components 
were used to separate the gene sets. The expression of C/EBPα-ER (via the addition of 
17β- Estradiol) led to changes in the gene expression profile of Kasumi-1- C/EBPαER cells, 
leading to a separation of ‘ER plus and ER minus’ data sets by principal components two 
and three. In contrast, ‘CTRL plus and CTRL minus’ are positioned directly adjacent to 
each other, demonstrating the lack of gene expression change following doxycycline 
addition. The siMM and siRE gene sets are spread in the same direction by the same 
principal components (two and three), suggesting similar gene expression changes occur 
following RUNX1/ETO knockdown and C/EBPα overexpression. However, principal 
component one separates the RUNX1/ETO knockdown and C/EBPα over expression gene 
sets, suggesting there are some differences in the gene expression profiles.  






















Figure 3-9: Genes that are differentially expressed by RUNX1/ETO knockdown were correlated with 
genes that were differentially expressed by C/EBPα induction 
A) Hierarchical clustering of genes differentially expressed in response to 4 days CEBPα induction .The 
genes included in the heat map are those which are differentially expressed between ‘ER minus’ and ‘ER 
plus’ datasets i.e. genes that change expression following C/EBPα induction with 17β-Estradiol . The 
expression level of these genes in mock transduced Kasumi-1 cells with and without 17β-Estradiol is 
shown in lanes 1 and 2 respectively). B) Hierarchical clustering of genes differentially expressed, by at 
least twofold, in response to 4 days RUNX1/ETO knockdown and 4 days CEBPα induction in Kasumi-1 
cells. The heat map plots the RNA log2 raw expression derived from RNA-seq data. Dark red indicates 
highly upregulated genes and grey indicates highly downregulated genes. Note how there are subsets of 
genes which are upregulated/downregulated by both C/EBPα induction and RUNX1/ETO knockdown. 
These represent a significant proportion of the heat map. These are highlight by the yellow and light blue 
boxes. ‘ER plus’ and ‘ER minus’ are data sets from Kasumi-1 cells transduced with the CEBPα-ER 
construct, with and without 17β-Estradiol treatment respectively. siMM and siRE are data sets from 
Kasumi-1 cells transfected with mismatch siRNA and RUNX1/ETO specific siRNA respectively. C) Gene Set 
Enrichment Analysis (GSEA) of genes differentially expressed following CEBPα induction vs genes 
differentially expressed following RUNX1/ETO knockdown. The upper section of the plot (green line) 
indicates the running enrichment score for the gene set as the analysis goes along the ranked list of 
genes (gene differentially expressed siMM vs siRE). The middle section of the plots (black vertical lines) 
indicates where genes of the gene set appear in the ranked list of genes. The lower portion is the ranking 
metric of the ranked gene list  (siMM vs siRE genes). The iCEBPα and siMM vs siRE gene expression data 
were obtained via RNA-seq. D) 3D Principal component analysis using the three largest principal 
components to separate the gene expression data set, which were derived from RNA-seq experiments. 
‘CTRL plus’ is data from mock transduced Kasumi-1 cells treated with 17β-Estradiol. ‘CTRL minus’ is data 
from mock transduced Kasumi-1 cells without 17β-Estradiol treatment. See ‘B’ for explanation of point 
labels. 
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 Almost half of the genes differentially expressed by RUNX1/ETO knockdown are 3.3.4
also differentially expressed by C/EBPα induction 
The results so far suggest that RUNX1/ETO knockdown and C/EBPα overexpression have 
similar effects on the gene expression profile of Kasumi-1 cells. To directly quantify the 
extent to which C/EBPα induction mimics RUNX1/ETO knockdown, we overlapped the 
genes upregulated by RUNX1/ETO knockdown with genes upregulated by induction of 
C/EBPα, and presented the data in a Venn diagram (figure 3-10).  The same analysis was 
performed for down-regulated genes. Almost half the genes upregulated by C/EBPα 
induction were also upregulated by RUNX1/ETO knockdown. This was also the case for 
down regulated genes (figure 3-10 A) (See the appendices for a list of differentially 
expressed genes that are shared between RUNX1/ETO knockdown and C/EBPα 
overexpression). 
To try and determine if the effects seen by C/EBPα overexpression are directly due to 
C/EBPα binding, we calculated the proportion of genes differentially expressed by C/EBPα 
overexpression that are C/EBPα targets. We used existing C/EBPα ChIP-seq data to assign 
C/EBPα target genes (219). We found that the majority of upregulated genes are C/EBPα 
targets, however only 20% of down regulated genes are normally bound by C/EBPα 
(figure 3-10 B). 
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We next investigated whether the genes differentially expressed by C/EBPα induction 
were also bound by RUNX1/ETO, to examine whether C/EBPα up-regulation could directly 
override the repression mediated by RUNX1/ETO. The results suggest this could be the 
case; the majority of differentially expressed genes were RUNX1/ETO targets (figure 3-10 
B). 
Taken together, our data indicated that C/EBPα is necessary for the differentiation 
response seen after RUNX1/ETO knockdown, and C/EBPα overexpression was sufficient 
to override the RUNX1/ETO mediated blockade of differentiation. This demonstrated that 















Figure 3-10: Almost half of the genes differentially expressed by RUNX1/ETO knockdown 
were also differentially expressed by C/EBPα induction  
A) Left Venn diagram demonstrates the overlap between genes upregulated by induction of 
C/EBPα and those upregulated by siRE. Right Venn diagram demonstrates the overlap 
between genes downregulated by induction of C/EBPα and those downregulated by siRE. 
Data was obtained via RNA-seq and only genes with a greater than two fold expression 
change were included. B) The bar graph presents the proportion of genes upregulated (dark 
grey)/down regulated (light grey) by C/EBPα that are bound by RUNX1/ETO or C/EBPα or 
both. Binding was determined by ChIP-seq.  








 Figure 3-11: RUNX1/ETO target genes that were inhibited by C/EBPα knockdown were 
upregulated by induction of C/EBPα 
UCSC genome browser screen shot of RNA-seq data. Tracks represent, from top to bottom: mock 
transduced Kasumi-1 cells, mock transduced Kasumi-1 cells with 17β-Estradiol, Kasumi1-C/EBPαER 
cells and finally Kasumi1-C/EBPαER cells with 17β-Estradiol. Y-Axis represents normalised RPKM 
values for the expression of A) NKG7 B) MS4A3 and C) RNASE2. Data shown is from one of two 
biological replicates with similar results.   
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3.4  The effect of RUNX1/ETO knockdown on selected promoter-enhancer interactions 
It is well established that alterations in gene expression can be reflected by changes in 
DNA looping interactions (63, 118). There is an increasing body of evidence that 
transcription factors initiate and maintain these DNA loops (63, 279-281). We therefore 
hypothesised that the gene expression changes and alterations to the transcription factor 
binding profile after RUNX1/ETO knockdown may be accompanied by alterations in 
specific promoter enhancer interactions. To this end we used 4C-seq before and after 
RUNX1/ETO depletion to look at the contact intensity of specific DNA interactions.  
4C-seq is a method used to assess all the interactions taking place with a specific region of 
the genome, termed the ‘viewpoint’. The techniques follows the fundamental principles 
of chromosome conformation captures; DNA is crosslinked, then fragmented and re-
ligated to generate chimeric DNA fragments which represent regions of the genome that 
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We used 4C-seq to determine interactions at the CD34 locus and SPI1/PU.1 locus. CD34 
gene was of interest as CD34 expression is associated with the immature status of 
hematopoietic cells; expression is rapidly lost after hematopoietic cells differentiate. 
Moreover, its expression is also down-regulated after RUNX1/ETO depletion (199). 
Furthermore, at this locus we see significant alterations in the enrichment of transcription 
factors, namely the myeloid transcription factor C/EBPα (219). PU.1 is a myeloid 
transcription factor encoded by the SPI1 gene. It has a crucial role in haematopoietic 
differentiation. SPI1 also exhibits changes in C/EBPα enrichment after RUNX1/ETO 
depletion (219) (figure 3-12).  
 
SPI1 and CD34 gene expression is regulated by previously characterised enhancer regions. 
These enhancers physically loop to their respective promoters to regulate gene 
expression (292-294). Work from the Tenen lab has demonstrated that RUNX1 binding 
sites are crucial for the interaction between the promoter and enhancer of both the PU.1 
and CD34 loci (295) (63). As RUNX1 and RUNX1/ETO both contain a RUNT domain, and 
both bind to these genes (199), it is possible that removal of RUNX1/ETO could therefore 















Figure 3-12: SPI1 and CD34 loci were selected for 4C experiments as they are bound by RUNX1/ETO, 
RUNX1 and C/EBPα and are differentially expressed after RUNX1/ETO knockdown  
Transcription factor binding at the A) SPI1 and B) CD34 loci. Top track (grey) shows RUNX1/ETO ChIP – 
seq peaks in Kasumi-1 cells. Tracks 2 and 3 are C/EBPα ChIP-seq peaks in Kasumi-1 cells transfected 
with siMM and siRE respectively. Tracks 4 and 5 are RUNX1 ChIP-seq peaks in Kasumi-1 cells 
transfected with siMM and siRE respectively. Tracks 6 and 7 are RNA-seq data from Kasumi-1 cells 
transfected with siMM and siRE respectively. 
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 A reciprocal interaction between the SPI1 promoter and its upstream regulatory 3.4.1
element (URE) was detected 
In order to determine the effect of RUNX1/ETO expression on selected cis-regulatory 
element interactions, RUNX1/ETO was depleted from Kasumi-1 cells via a four-day siRNA 
mediated knockdown. Chromatin from two biological replicate experiments was 
harvested. The knockdown was efficient and consistent between the two replicates. We 
then assessed DNA interactions with the SPI1 and CD34 loci using 4C-seq.  
PU.1 expression is regulated by an enhancer element 14Kb upstream of the SPI1 
promoter (URE)(293). In agreement with previous findings (293) we detected a strong 
interaction between the two cis-elements which was indicated by a peak in the median 
contact intensity trend line at the SPI1 promoter, with a corresponding red region in the 
contact intensity heat map (figure 3-13 A). The interaction was confirmed by a reciprocal 
4C experiment in which the promoter was used as a viewpoint (figure 3-13 B).  The 
reciprocal 4C revealed another interaction -22kb from the SPI1 promoter which was 













Figure 3-13: 4C-seq detected a reciprocal interaction between the SPI1 promoter and URE  
Local 4C contact profile with a viewpoint from the PU.1 upstream regulatory element (URE) (A) and 
PU.1 promoter (B), using chromatin from Kasumi-1 cells transfected with control siRNA (siMM) 
RUNX1/ETO specific siRNA (siRE). In the top panel (main trend), the contact intensity (black line) is 
calculated using a running median analysis of normalised read counts with a 3 kb sliding window. 
The 20th and 80th percentile are visualised as a grey trend graph. In the bottom panel, contact 
intensities are computed using linearly increasing sliding windows (scaled 2–50 kb) and displayed 
as a colour-coded heat map of positive 4C signal (maximum interaction set to 1). Local colour 
changes are log-scaled to indicate changes of statistical enrichment of captured sequences, 
corresponding to the enhancer – promoter interaction. The results presented here are an average 
of two biological replicates.  
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 A reciprocal interaction between the CD34 promoter and its URE was detected 3.4.2
Experiments in transgenic mice have shown that CD34 expression in long-term 
haematopoietic stem cells is affected by the physical interaction between the promoter 
and a -19kb downstream regulatory element (DRE) (63, 292) . With the CD34 promoter as 
a viewpoint, an interaction between this DRE and the CD34 promoter was detected in our 
human t(8;21) AML model. We also detected an interaction between the CD34 promoter 
and an element +12kb upstream (URE) (figure 3-14 A). This interaction was confirmed via 
reciprocal 4C with the URE as the viewpoint (figure 3-14 B) 
Figure 3-14 also demonstrates that the neighbouring gene, LOC148696, interacts with the 
CD34 promoter, URE and the DRE. In addition, we detected several other intervening 
interactions. These correspond to DNaseI hypersensitive sites (data not shown), 
















Figure 3-14: 4C-seq detected specific interactions at the CD34 locus  
Local contact profile analysis with a viewpoint from the CD34 promoter (A), CD34 upstream 
regulatory element (URE) (B) and CD34 downstream regulatory element (DRE) (C) using 
chromatin from Kasumi-1 cells transfected with mismatch siRNA (siMM) RUNX1/ETO specific 
siRNA (siRE). In the top panel (main trend), the contact intensity (black line) is calculated using a 
running median analysis of normalised read counts with a 3 kb sliding window. The 20th and 80th 
percentile are visualised as a grey trend graph. In the bottom panel, contact intensities are 
computed using linearly increasing sliding windows (scaled 2–50 kb) and displayed as a colour-
coded heatmap of positive 4C signal (maximum interaction set to 1). Local colour changes are log-
scaled to indicate changes of statistical enrichment of captured sequences, corresponding to the 
enhancer – promoter interaction. The results presented here are an average of two biological 
replicates.  
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 4C-seq data was highly reproducible 3.4.3
Hierarchical clustering on pairwise correlation coefficients was used to determine the 
correlation between 4C-seq data from all samples (figure 3-15). The heat map 
demonstrates a strong correlation between biological replicates. This indicates the 
experiment was highly reproducible. There is also a strong correlation between samples 
of the same viewpoint but transfected with a different siRNA. There is no correlation 
between samples with different viewpoints. 
 Genomic proximity cannot always be used as a predictor of enhancer function 3.4.4
 
It is often assumed that cis-elements will preferentially target the nearest gene. However, 
Figure 3-13 shows that the SPI1 URE forms an interaction with the SPI1 promoter, rather 
than a gene 3 Kb closer (SLC9A13). A strong interaction is detected between the SPI1 
promoter and -14kb URE, but not between the -14kb URE and SLC39A13 promoter. This is 
despite the open chromatin conformation of SLC9A13 and the fact that its promoter is 
involved in an interaction with the SPI1 promoter. 
 






Figure 3-15: 4C-seq data was highly reproducible  
Hierarchical clustering on pairwise correlation coefficients of 4C-seq data from all samples with 
viewpoints at the A) PU.1 locus and B) CD34 locus. The heat map demonstrates a strong 
correlation between biological replicates. There is also a strong correlation between samples of 
the same viewpoint but transfected with a different siRNA. There is no correlation between 
samples with different viewpoints. 
  153 
 
  RUNX1/ETO depletion has no significant effect on the interactions between cis-3.4.5
regulatory elements at SPI1 and CD34 loci 
We sought to determine whether RUNX1/ETO knockdown had an effect on the 
interactions detected in the SPI1 and CD34 loci. Differential analysis was conducted with 
the R package ‘DESeq2’, to give a log2 fold change between the RUNX1/ETO knockdown 
and control data, at 1kb resolution. The log2 fold change for each genomic co-ordinate 
was then plotted (Figure 3-16). We saw no significant changes in interaction frequencies 
at the regions surrounding the viewpoint. 
In conclusion, although RUNX1 binding site elimination inhibits promoter-enhancer 
interactions at the PU.1 and CD34 loci (63, 295), RUNX1/ETO knockdown had no 
significant effect on the interactions taking place at these loci. This is despite the fact 
these genes are differentially expressed after RUNX1/ETO knockdown.  
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Figure 3-16: Differential analysis revealed no significant difference in interaction frequency 
after RUNX1/ETO depletion  
R package DESeq2 was used to calculate the log2 fold change between the median interaction 
frequency at each restriction fragment of the control (CTRL) and RUNX1/ETO knockdown (KD) 4C-
seq data, with viewpoints A) PU.1 promoter B) PU.1 URE C) CD34 promoter D) CD34 URE and E) 
CD34 DRE. The y axis represents the log2 fold change (RUNX1/ETO knockdown vs control) and the 
x-axis shows the genomic coordinates surrounding the viewpoint.    A fold change >2 was not 
detected at any restriction fragment of the genomic region analysed.  
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3.5 The effect of RUNX1/ETO knockdown on genome wide cis-regulatory element 
interactions 
RUNX1/ETO knockdown had no effect on the DNA interactions taking place at the PU.1 
and CD34 loci, despite the differential expression of these genes after knockdown. 
However we could not conclude that RUNX1/ETO had no influence on DNA interactions as 
we only interrogated two regions. There are hundreds of genes which alter their 
expression after knockdown; perhaps differences would be seen here. Preparing 
independent 4C libraries to assess all of these genes would be prohibitively expensive, as 
well as time consuming. Furthermore, this technique is limited by the ability to design 
specific and efficient primers to the region of interest.   
We therefore decided to use a genome wide approach so that we could look at thousands 
of interactions in just one experiment. The original genome wide interaction mapping 
method is called HiC. This technique is a true genome wide approach and the 
experimenter can therefore look at all ligation junctions. However, due to the massively 
complex nature of the resultant library, the level of signal for any given point in the 
genome is very low. This requires the use of an infrequently cutting enzyme and large 
windows of analysis, so that signal can be pooled in order to gain informative signal. As a 
result, resolution is low and this method is more suitable for mapping large scale domain 
structures of the genome, rather than detailed, specific promoter to cis-element 
interactions.  
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To circumvent this issue a technique was developed called Capture HiC (77, 141). In this 
method, traditional HiC library preparation is combined with solution hybridization 
selection to enrich HiC libraries for the long-range contacts of the 22,000 promoters to 
which the hybridization array is designed.  The required breadth of sequencing coverage 
is therefore reduced, so that the resolution and signal increases, enabling us to detect 
specific DNA interactions.  
 The majority of DNA interactions in Kasumi-1 cells are intrachromosomal 3.5.1
 
To map the genome wide DNA interactions we performed Capture HiC with the t(8;21) 
AML cell line, Kasumi-1. We wished to determine whether RUNX1/ETO had an effect on 
DNA interactions, so libraries were prepared using cells with and without 4 day siRNA 
mediated RUNX1/ETO knockdown. Two biological replicate samples were prepared.  
As a means of quality controlling our HiC data, we first looked for well-established 
features of genome organisation, such as chromosome territories (131). To do this we 
plotted a matrix of genome wide interactions at a 10 Mb resolution (figure 3-17). We 
found that the majority of chromosomal interactions occurred in cis i.e. within the same 
chromosome. This is clearly illustrated by the blocks of high contact intensity centred 
along the diagonal of the heat map. This trend should always occur, regardless of cell type 
or species (92, 99).  The depiction of chromosome territories offered reassurance that the 
experiment was successful. Figure 3-17 also demonstrated the reproducibility of the 
Capture HiC assay. The genome wide interactions matrices from biological replicate 1 and 
biological replicate 2 were almost identical.  








Figure 3-17: 10 Mb resolution genome wide contact matrix showed the majority of DNA interactions 
are intrachromosomal 
Contact matrix across the whole genome. Each pixel represents a 10 Mb section of the genome. Colour 
intensity represents interaction frequency. The blocks of high contact intensity centred along the 
diagonal demonstrate the fact the majority of interactions occur intrachromosomally. The t(8;21) 
chromosomal translocation is detected. A) Interaction matrix generated with data from kasumi-1 cells 
transfected with siMM for four days. B) Interaction matrix generated with data from Kasumi-1 cells 
transfected with siRE for four days. Left hand plots are from biological replicate 1 and right hand plots are 
from biological replicate 2. Interaction data was generated by Capture HiC. 
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To further validate our data, we looked for evidence of the t(8;21) translocation in our 
interaction matrix. The ability to detect translocations with chromosome conformation 
capture analysis has been demonstrated previously (296, 297). Encouragingly, we saw a 
block of high contact intensity representing apparent interactions between chromosomes 
8 and 21, which signifies the t(8;21) translocation.  
 Interaction frequency decreases with genomic distance 3.5.2
To generate figure 3-18 we focused on a single chromosome, chromosome 8, at higher 
resolution (1 Mb). Again we saw a strong diagonal of high contact intensity. This 
represents the well-established notion that the probability of DNA interaction decreases 
exponentially with genomic distance (92, 134). Based on this concept, a plot of expected 
contact intensity would decay to almost no signal after a relatively short distance. 
However, in the matrix constructed with our data, we can see regions of significant 
interaction at large genomic distances. This suggests that we have detected specific long 
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Figure 3-18: The 1 Mb resolution contact matrix of chromosome 8 showed a trend of decreased 
interaction frequency with genomic distance 
Contact matrix across chromosome 8, depicted in a heat map. Each pixel represents a 1 Mb section of 
the genome. Colour intensity represents interaction frequency. A) Interaction matrix generated with 
data from Kasumi-1 cells transfected with siMM for four days. B) Interaction matrix generated with data 
from Kasumi-1 cells transfected with siRE for four days. Interaction data was generated by Capture HiC. 
Data from replicate 1 one is shown here. 
A 
B 
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In summary, our promoter-capture HiC assays reproducibly detected interactions and 
they follow the expected trend. At the resolution of analysis used thus far it was not 
possible to define specific promoter-enhancer interactions; a higher resolution of analysis 
is required. Before doing so, it was necessary to determine which interactions are 
statistically significant. To this end, HOMER software was used to determine statistically 
significant interactions, taking into account the p-value and false discovery rate (FDR) 
relative to a background model. The heat map present in figure 3-19 shows the results of 
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Figure 3-19: Capture HiC interaction data was analysed to extract statistically significant interactions.  
Contact matrix across chromosome 19, depicted in a heat map. Each pixel represents a 50 kb section of 
the genome. The colour represents the p-value of the interaction. The more blue the interaction, the 
more statistically significant it is and the redder, the less statistically significant. A) Interaction matrix 
made with data from Kasumi-1 cells transfected with siMM for four days. B) Interaction matrix made 
with data from Kasumi-1 cells transfected with siRE for four days. Interaction data was generated by 
Capture HiC. To determine statistically significant interactions, reads from replicate 1 and 2 were 
merged. 
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 RUNX1/ETO knockdown led to alterations in specific promoter-cis element 3.5.3
interactions 
 
We next analysed our CHiC data to examine whether the knock-down of RUNX1/ETO led 
to changes in the interactions between cis-regulatory elements. At low resolution (50Kb), 
no obvious differences were visible between the genome wide interaction matrices of 
control and RUNX1/ETO depleted cells (Figure 3-17). This result suggests that RUNX1/ETO 
depletion has no effect on the overall large-scale genomic organisation in t(8;21) cells.  
However, differences between cell types are more likely to lie in specific promoter-cis –
regulatory element interactions (92). We therefore analysed our data at higher resolution 
to help us determine what was driving the gene expression changes triggered by 
RUNX1/ETO knockdown. We were particularly interested in identifying the transcription 
factors that could be driving changes in cis-regulatory element interactions. To this end, 
using HOMER bioinformatics software, we performed differential analysis between the 
Capture HiC interactions in Kasumi-1 cells with and without RUNX1/ETO knockdown. A p-
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To identify transcription factor binding sites within interacting cis-elements, all significant 
interactions were filtered against our DHS data, such that only those ligated HindIII 
fragments overlapping with DHS were included in the analysis. This enabled us to direct 
our analysis to the cis-regulatory elements that were likely to be controlling gene 
expression. To this end, we used previously published DNaseI data from control and 
RUNX1/ETO depleted Kasumi-1 cells (219). Figure 3-20 A shows that approximately 30% 
of the significant interactions detected were DNaseI hypersensitive, confirming that many 
of them are of a structural nature (77, 99). In contrast, the majority of the DNaseI 





Figure 3-20: Capture HiC interactions were filtered using DNaseI-seq data 
A) Percentage of Capture HiC interactions which are DNaseI hypersensitive B) Percentage of DNaseI 
hypersensitive sites involved in a Capture HiC interactions in Kasumi-1 cells transfected with mismatch 
(siMM) and RUNX1/ETO specific siRNA (siRE).  
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Figure 3-21 presents a comparison of all of the statistically significant interactions taking 
place in chromosome 19 between control and RUNX1/ETO depleted cells, with reduced 
interactions being plotted in blue and increased interactions plotted in red. This analysis 
shows that there were interactions which significantly change in intensity following 
RUNX1/ETO knockdown.  We found that 917 interactions were significantly upregulated 
and 1457 were significantly downregulated after RUNX1/ETO knockdown. This result 
suggests that the removal of RUNX1/ETO has an effect on promoter-cis element 
interactions. 
                 




Figure 3-21: RUNX1/ETO knockdown led to statistically significant differences in interaction strength.  
This heat map presents the differential interactions in chromosome 19 as determined by Capture HiC. 
Each pixel represents a 50 kb section of the genome. The colour intensity represents the significance of 
the difference between the interactions strength in control and RUNX1/ETO knockdown (p-value). Blue 
interactions significantly decrease after RUNX1/ETO knockdown. Red interactions significantly increase 
after RUNX1/ETO knockdown.  
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 Capture HiC data support the 4C-seq data at the CD34 and SPI1 loci 3.5.4
 
In order to validate our CHiC results, we extracted the interaction profiles from the Spi1 
(Pu.1) and CD34 genes, visualised them on the UCSC genome browser and compared the 
results to our 4C data (Figure 3-22). This analysis revealed a significant interaction 
between the CD34 promoter and both the known upstream and downstream regulatory 
elements. We also found that the Spi.1/Pu.1 promoter was involved in a significant 
interaction with the already characterised -14kb enhancer region. These interactions did 
not change significantly after RUNX1/ETO knockdown, as demonstrated by the lack of a 
peak in the ‘up’ or ‘down’ track. Our 4C-seq experiments, which demonstrate that 
RUNX1/ETO knockdown has no effect on these interactions (figures 3-13 and 3-14), were 
therefore in concordance with the data from Capture HiC.  








Figure 3-22: Capture HiC data agreed with 4C data 
Tracks 1 and 2 show 5 kb sections of the genome taking part in a significant interaction with the A) 
CD34 promoter or B) PU.1 promoter, in cells transfected for 4 days with siMM and siRE respectively. 
The height of the block presents the - log p-value. Tracks 3 and 4 mark interactions which change 
significantly after RUNX1/ETO knockdown. The height of the blocks represents the fold change. A) Red 
dashed lines mark the upstream and downstream regulatory elements. B) Red dashed line represents 
the -14 kb enhancer. 
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 The gene expression changes after RUNX1/ETO knockdown are associated with 3.5.5
alterations in cis-regulatory element interactions but are not directly correlated 
 
Alterations in gene expression can be reflected by changes in specific cis-regulatory 
element interactions (63, 118). This was true for gene expression changes after 
RUNX1/ETO knockdown. To examine whether differential interactions were directly 
correlated with the changes in gene expression before and after RUNX1/ETO knock-down, 
i.e. whether reduced interactions led to a loss and increased interaction led to an increase 
in gene expression, we conducted a Gene Set Enrichment analysis (GSEA). Figure 3-23 
shows that there was no direct correlation, meaning that genes which were upregulated 
after RUNX1/ETO knockdown were associated with both increased and decreased DNA 
cis-regulatory element interactions. The same was true for down regulated genes, 




















Figure 3-23: Differential interactions were not directly correlated with differential gene expression. 
Gene Set Enrichment Analysis (GSEA) based on interactions differentially increasing (left) or decreasing (right) 
by RUNX1/ETO knockdown. The upper section of the plot (green line) indicates the running enrichment score 
for the genes corresponding to the differential interaction in the ranked list of genes below (gene 
differentially expressed by RUNX1/ETO knockdown). The middle section of the plots (black vertical lines) 
indicates where genes corresponding to the differential interaction appear in the ranked list of genes. The 
lower portion is the ranking metric of the ranked gene list (gene differentially expressed siMM vs siRE). The 
siMM vs siRE gene expression data was obtained via RNA-seq.  
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The most likely reason for this observation is that, within a given gene locus, there is not a 
binary on/off interaction with a single enhancer, rather expression control involves 
multiple cis-regulatory elements with net positive or negative effects. After RUNX1/ETO 
knockdown gene promoters alter the cis-regulatory elements they interact with; 
increasing interactions with some elements and decreasing interactions with others. This 
was the case at several differentially expressed genes. Figure 3-24 presents examples of 
significantly upregulated haematopoietic genes (PRAM1, SELPG and SRGN) which have 
both increasing and decreasing interactions with their promoters. The same is true for the 
down regulated stem cell gene CD34 (figure 3-22 A). PRAM1 encodes PML-RAR Regulated 
Adaptor protein which is associated with granulocytic maturation (298). SELPLG encodes 
a glycoprotein expressed on the surface of myeloid cells (299). SRGN encodes a 
proteoglycan granule protein and is primarily expressed in haematopoietic cells (300) .  
To visualise interactions between cis-regulatory elements of specific genes, we uploaded 
the Capture HiC interaction data to the UCSC genome browser together with other 
genome-wide data sets generated by Dr Anetta Ptasinska (199, 219). For example, in 
figure 3-24 the Capture HiC interactions taking place with the PRAM1, SELPG and SRGN 
promoter are presented along with RUNX1/ETO, C/EBPα and RNA Polymerase II ChIP-seq 
data. In addition, DNaseI-seq data is presented.   
 
 






































Figure 3-24: Differentially expressed haematopoietic gene promoters, such as SELPLG, SRGN and 
PRAM1, had both increased and decreased cis-element interactions after RUNX1/ETO knockdown 
Dashed red line represents the ‘viewpoint’ of analysis i.e. the promoter from which the interactions are 
being assessed. Tracks 1 and 2 show 5 kb sections of the genome taking part in a significant interaction 
with the A) SELPLG B) PRAM1 and C) SRGN promoters (genes significantly upregulated after RUNX1/ETO 
knockdown), in cells transfected for 4 days with siMM and siRE respectively and measured via Capture 
HiC. The height of the block presents the -log p-value. Tracks 3 and 4 mark interactions which change 
significantly after RUNX1/ETO knockdown. The height of the blocks represents the fold change. Track 3 
marks interactions that increase after RUNX1/ETO knockdown. Track 4 marks interactions with decrease 
after RUNX1/ETO knockdown. Tracks 5 and 6 show DNaseI-seq data from siMM and siRE cells respectively. 
Tracks 7-10 show the binding patterns of P300, C/EBPα, RUNX1/ETO, RUNX1 and LMO2 p300 in siMM and 
siRE cells. D) UCSC genome browser screen shots of RNA-SEQ data demonstrating the upregulation of, 
from top to bottom, SELPLG, PRAM1 and SRGN after RUNX1/ETO knockdown. siMM data is from Kasumi-1 
cells transfected with control siRNA for four days. siRE data is from Kasumi-1 cells transfected with 
RUNX1/ETO specific siRNA  
D 
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 RUNX1/ETO depletion led to differential interactions at the CEBPA locus 3.5.6
 
This study has convincingly demonstrated that maintaining low levels of C/EBPα 
expression is critical for the maintenance of t(8;21) leukaemia. We therefore examined 
the interactions made by the CEBPA promoter in detail to gain more insight into how 
C/EBPα expression levels were regulated. Figure 3-25 illustrates the local interactions 
made by the CEBPA promoter. Interestingly, this promoter interacts with the 
neighbouring downstream gene CEBPG which encodes for another member of the C/EBP 
family, and with several upstream hypersensitive sites. One of these interactions 
corresponds to the already defined +40 kb enhancer (200). The interaction strength with 
this enhancer was not significantly altered by RUNX1/ETO knockdown. However, an 
interaction at +29 kb significantly increased after RUNX1/ETO knockdown. This site is 
hypersensitive and enriched for p300 binding. It is also bound by both C/EBPα and 
RUNX1/ETO. 
To further assess the reproducibility of our data, we checked to see whether the 
promoter-promoter interaction between the CEBPA promoter and the CEBPG promoter 
were detected when either promoter was used as the ‘view-point’. Reassuringly this was 
the case. Figure 3-26 demonstrates that the interaction detected between the CEBPA 
promoter and the CEBPG promoter (figure 3-25) is detected with CEBPG promoter as the 
‘viewpoint’. In both cases this interaction decreases following RUNX1/ETO depletion. 
In conclusion RUNX1/ETO knockdown had no effect on large-scale, domain structures of 
the genome. However, the presence of RUNX1/ETO does appear to influence the 
interaction profile of specific gene promoters.  










Figure 3-25: The C/EBPA promoter engaged in a strong interaction with a putative enhancer at +29 kb 
following RUNX1/ETO knockdown  
Dashed red line represents the ‘viewpoint’ of analysis i.e. the promoter from which the interactions are 
being assessed. Tracks 1 and 2 show 5 kb sections of the genome taking part in a significant interaction with 
the C/EBPA promoter, in cells transfected for 4 days with siMM and siRE respectively. The height of the 
block presents the – log p-value. Tracks 3 and 4 mark interactions which change significantly after 
RUNX1/ETO knockdown. The height of the blocks represents the fold change. Tracks 5 and 6 show DNaseI 
hypersensitivity in siMM and siRE cells respectively. Tracks 7-10 show the binding patterns of C/EBPα, 
RUNX1/ETO and p300.   









Figure 3-26: The CEBPG-CEBPA promoter-promoter interaction was detected with either CEBPA or CEBPG 
promoters as the ‘viewpoint’ 
Dashed red line represents the ‘viewpoint’ of analysis i.e. the promoter from which the interactions are 
being assessed. Tracks 1 and 2 show 5 kb sections of the genome taking part in a significant interaction with 
the CEBPG promoter, in cells transfected for 4 days with siMM and siRE respectively. The height of the 
block presents the – log p-value. Tracks 3 and 4 mark interactions which change significantly after 
RUNX1/ETO knockdown. The height of the blocks represents the fold change. Tracks 5 and 6 show DNaseI 
hypersensitivity in siMM and siRE cells respectively. Tracks 7-10 show the binding patterns of C/EBPα, 
RUNX1/ETO and p300.   
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 C/EBPα and CTCF play a major role in mediating differential cis-regulatory 3.5.7
element interactions before and after RUNX1/ETO knock-down 
 
To gain more insight into the mechanisms mediating the differential interactions, we 
investigated whether the change in interaction strength was associated with the level of 
DNaseI hypersensitivity, transcription factor occupancy and changes in gene expression. 
To this end, differential interactions were ranked by fold-change in p-value (figure 3-27). 
Fold change represents the difference in interaction strength between control and 
RUNX1/ETO knockdown. Associated DNaseI hypersensitive sites involved in differential 
interactions were plotted alongside. C/EBPα, RUNX1 and RUNX1/ETO ChIP-seq reads 
were then plotted around the summit of these DNaseI hypersensitive sites. In order to 
see whether CTCF was involved in changing interactions, we also examined whether its 
binding sites changed. We did not have CTCF ChIP-seq data, so CTCF motif enrichment 
was used instead. CTCF was included in this analyses as it is has a principal role in the 
global organisation of chromatin architecture (301).  
The resultant heat map, presented in figure 3-27, again supports the lack of direct 
correlation between the differential interaction fold change and gene expression change 
(figure 3-23). It also demonstrated that some genes with differential interactions are not 
differentially expressed (column 10). We also saw that differential interactions did not 
reproducibly correspond to alterations in the DNaseI hypersensitivity of the cis-regulatory 
elements involved (columns 2 and 3).  
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Figure 3-27 shows that the DHSs mediating the differential interactions were bound by 
RUNX1/ETO, RUNX1 and C/EBPα. The differential interactions exhibited an increase in 
C/EBPα binding. The interactions which went up after RUNX1/ETO knockdown appeared 
to have a greater increase in C/EBPα enrichment, relative to those interactions that went 
down. We plotted the average C/EBPα enrichment at all the differentially interacting 
DNaseI sites, to see whether this was indeed true. The average profile presented in figure 
3-28 A offers a clear depiction of increased C/EBPα binding at differential interactions, 
particularly those that increased in interaction after RUNX1/ETO knockdown. This 
suggests that C/EBPα may play a role in driving the changes to promoter-cis-regulatory 
element interactions which follow RUNX1/ETO knockdown. The data suggest that it does 
so by either mediating interactions itself or by displacing other factors involved in 
interactions prior to knockdown. The average profile for RUNX1 enrichment, presented in 
figure 3-28 B, shows that that RUNX1 binding also increases at differential interactions, 
but to a lesser extent. 
 




Figure 3-27: Differential interactions were bound by RUNX1/ETO, RUNX1 and C/EBPα, and 
contained the CTCF motif 
The first column shows the fold change (control vs RUNX1/ETO knockdown) of Capture HiC 
interactions. Red represents an increase in interaction strength and blue represents a decrease. 
Columns 2 and 3 represent the DNaseI-seq reads from the corresponding interacting region. 
Column 4 shows RUNX1/ETO ChIP-seq reads from control Kasumi-1 cells aligned to the summit of 
the DHSs. Columns 5 and 6 show RUNX1 ChIP-seq reads from Kasumi-1 cells, transfected with 
siMM and siRE respectively. For columns 2 – 8 colour intensity corresponds to the number of 
reads. Columns 7 and 8 show C/EBPα ChIP-seq reads from Kasumi-1 cells, transfected with siMM 
and siRE respectively. Column 9 shows the occurrence of CTCF motifs in the interacting DNaseI 
sites. Yellow dots represent motif enrichment. Column 10 shows gene expression fold change 
(siMM vs siRE) of the gene promoters which correspond to the differential interactions. 
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Figure 3-28: Differential interactions exhibited increased C/EBPα and RUNX1 binding after 
RUNX1/ETO knockdown, particularly those that increased in interaction strength. 
A) This plot shows C/EBPα enrichment, before and after RUNX1/ETO knockdown, at DNaseI sites 
which are involved in a differential interaction. The x-axis represents the distance from the centre 
of the DNaseI site corresponding to a differential Capture HiC interaction. Peaks represent the 
coverage of C/EBPα ChIP-seq reads. Dashed lines show ChIP-seq reads from control kasumi-1 cells 
(transfected with siMM). Full lines show ChIP-seq reads from Kasumi-1 cells with RUNX1/ETO 
knockdown (transfected with siRE). ChIP-seq data was generated by Dr Anetta Ptasinska (219) 
B) This plot is the generated by the same method as (A) but using RUNX1 enrichment obtained via 
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We found that the CTCF motif was present in the differentially interacting DNaseI 
hypersensitive sites (figure 3-27). We therefore conducted a de novo motif search in 
these sites, to verify the degree of CTCF motif enrichment. In support of figure 3-27, we 
found that the CTCF motif was significantly enriched in both interactions that increased 
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Figure 3-29: Differentially interacting DNaseI hypersensitive sites were enriched for CTCF motifs 
This table is the result of de novo motif search of differentially interacting DNaseI hypersensitive 
sites, using HOMER bioinformatics software (285). 
 
 
Figure 3-30: The density of CTCF motifs in DNaseI footprints decreased following RUNX1/ETO 
knockdown 
DNaseI footprints unique to RUNX1/ETO depleted cells (siRE, blue), unique to control transfected 
cells (siMM, red) and shared between the two (common, black) were assed for CTCF enrichment 
with HOMER software(285). The peak height represents the density of the CTCF motif in the 
DNaseI footprints.  
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Since the CTCF motif is enriched at differential interactions we hypothesised that CTCF 
may play a role in orchestrating the changes in DNA interactions triggered by RUNX1/ETO 
knockdown. In order to investigate this, we needed to see if these CTCF motifs were 
bound by CTCF and whether this was affected by RUNX1/ETO knockdown. As we did not 
have CTCF ChiP-seq data we re-ran libraries used to generate existing DNaseI data (219) 
at high sequencing depth. We then used the Wellington digital footprinting algorithm 
(302) to identify regions that were protected from DNaseI digestions, as a surrogate 
measure of factor occupancy, and then searched for the CTCF motif in the DNaseI 
footprints. We examined footprints shared between control and RUNX1/ETO knockdown; 
unique to the control data set and unique to RUNX1/ETO knockdown. Figure 3-30 shows 
that there were many more footprinted CTCF motifs in control cells indicating that CTCF 
binding changes after RUNX1/ETO knockdown. This finding, in combination with the 
enrichment of the CTCF motif at differential interactions, suggested that changes in DNA 
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Chapter 4. DISCUSSION 
4.1 CBF complex inhibition in t(8;21) AML cells 
Transcription factors have been considered an undruggable target (272, 273) until 
pioneering work from the Bushweller lab demonstrated the successful targeting of the 
CBF complex. They designed small molecule, allosteric inhibitors to block the RUNT 
domain to CBFβ interaction by inducing a conformation change in CBFβ (275, 278). We 
collaborated with the Bushweller lab to determine whether these inhibitor compounds 
could target RUNX1 or RUNX1/ETO in our t(8;21) AML model.  
 Treatment of HL60 and Kasumi-1 cells with a CBF complex inhibitor induces 4.1.1
apoptosis in a dose dependant manner 
 
We first tested the effect of the CBF complex inhibitor on the viability of Kasumi-1 and 
HL60 cells. The compound induced apoptosis in Kasumi-1 cells, in a dose dependant 
manner (figure 3-1). ‘RUNX1 dependence’ has been reported to be unique to AML cells 
with genetic abnormalities that affect the CBF complex (265, 266). However, we found 
that HL60 cell, which have no CBF abnormality, also die after inhibitor application. RUNX1 
knockdown in HL60 cells has been shown to have no reported effect on the cell viability 
(21). This suggests that the compound may induce cell death by additional mechanisms to 
RUNX1 inhibition, or that in these cells another RUNX family member compensates for 
the depletion of RUNX1. Furthermore, although published RUNX1 knockdown in Kasumi-1 
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cells does lead to increased apoptosis, it is not to the extent that we see after application 
of our inhibitors (265). However, it must be noted that knockdown and inhibitor 
experiments are not directly comparable; knockdown reduces RUNX1 protein levels 
whereas inhibitor treated cells retain protein expression.  
 The CBF complex inhibitor has no significant effect on transcription factor binding 4.1.2
 
The interaction between RUNX1 and CBFβ is known to dramatically enhance DNA binding 
(237, 269). ChIP experiments were conducted to determine whether the inhibitor could 
affect binding of RUNX1 and RUNX1/ETO to DNA. Allosteric CBF complex inhibitors have 
resulted in a reduction in the association of RUNX1 to its DNA binding motif in vitro and 
also in embryonic stem cells carrying an inducible version of RUNX1 (275, 278).  In 
contrast, our ChIP experiments at 6 hours showed there was no inhibition of DNA 
association upon inhibitor treatment (figure 3-2). This was despite the clear death 
response see at 48 hours after inhibitor application, which suggests RUNX1 inhibition may 
be taking place.  
Kasumi-1 cells undergo cell division approximately every 48 hours. During the process of 
mitosis, existing CBF complexes are likely to be dissociated from the DNA during DNA 
replication. New CBF complexes must then be formed and assembled on the DNA of 
daughter cells. We therefore hypothesised that the inhibitor may not be able to disrupt 
CBF complexes that are already assembled and bound to DNA. However, the compound 
might prevent the formation of new CBF complexes after mitosis and thus block RUNX1 
DNA binding. Without the expression of RUNX1 target genes, the cells die at this point. 
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Unfortunately by this stage the inhibition of DNA binding is undetectable due to the 
inability to do accurate ChIP experiments on dead cells.   
The above theory presumes that RUNX1 DNA binding and association with CBFβ is stable, 
unlike the highly dynamic behaviour exhibited by other transcription factors (303, 304). 
However, the majority of studies into transcription factor binding kinetics are conducted 
in vitro. It is likely that the kinetics will differ in vivo, due to the fact that chromosomal 
DNA is cluttered with other proteins and provides non-specific DNA sequences to which 
transcription factors can bind (305).  
A recent publication from our group suggests that the compound may indeed be specific 
to de novo binding (278). The CBF complex inhibitor was tested in an embryonic stem (ES) 
cell line with inducible RUNX1. Upon treatment with doxycycline, ES cells express a HA 
tagged RUNX1 which can bind to RUNX1 target genes and drive their expression. In this 
system there will be many new HA-RUNX1-CBFβ complexes generated following induction 
and no complexes at the DNA prior to induction. When doxycycline is added in the 
presence of the inhibitor compound, HA-RUNX1 DNA binding is inhibited (Figure 4-1). The 
inhibition of RUNX1 binding may be detectable in this case as the compound is effective 
at blocking the formation of the new, induced RUNX1-CBFβ complexes. This is supported 
by co-immunoprecipitation demonstrating an inhibition of RUNX1 and CBFβ interaction 
(278). This system is preferable for the detection of RUNX1 inhibition as cell are not 
dependent on RUNX1 for survival, thus it is possible to conduct accurate ChIP 
experiments.  
 




Figure 4-1: CBF complex inhibitors block de novo RUNX1 binding domain  
This bar graph, published by Illendula  et al., presents enrichment of HA-Runx1 at target loci, 
following either no RUNX induction (dox –), Runx1 induction by dox (dox +), RUNX induction with 
control compound (AI-4 88) and RUNX1 induction with the inhibitor compound (AI-14-91). This 
data was generated using ChIP with an anti-HA antibody recognizing HA tagged Runx1. Manual 
qPCR was used to detect enrichment at specific loci. Enrichment is normalised to input and a 
negative control (Chr2). Error bars represent standard deviation between 5 biological replicates. A 
one-way ANOVA test was used to analyse variance in HA enrichment values between the inhibitor 
and control compound, or between inhibitor and +dox treatment, * symbolises p < 0.05 and ** 
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Another explanation for the observation of cell death but lack of DNA binding inhibition is 
that the compound is hindering the transcription of RUNX1 genes, but not overtly 
blocking DNA binding. This could, for example, be due to the inhibition of the recruitment 
of co-activators additional to CBFβ. 
4.2 RUNX1/ETO depletion led to the up regulation of genes involved in myeloid 
differentiation 
The siRNA mediated knockdown of RUNX1/ETO has been used in several high impact 
publications (199, 219, 257) that investigate the effect of RUNX1/ETO on the gene 
expression and epigenetic profile of t(8;21) AML cells. We wished to manually validate the 
gene expression changes and assess a new, shRNA mediated knockdown system - SKNO-1 
cells with an inducible shRNA specific to RUNX1/ETO - and compare results with 
previously published data. This inducible system will facilitate experiments in which 
conditions with and without RUNX1/ETO are required. It also avoids having to repeatedly 
transfect cells with siRNA. 
RUNX1/ETO was successfully depleted from both Kasumi-1 and SKNO-1 R/E cells (Figure 
3-3), with no significant effect on RUNX1 expression. There was a slight reduction of 
RUNX1 expression in SKNO-1 R/E cells after 72 hours, which could be attributed to 
differentiation of the cells in response to RUNX1/ETO depletion (figure 3-3 B) (199, 306). 
With both systems, there was an upregulation of genes involved in myeloid 
differentiation, which is in accordance our previously published data where a depletion 
method with the same siRNA sequence was used (199, 257).  The shRNA depletion system 
gave comparable results to the siRNA system, allowing us to confidently use this model in 
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future experimentation. This system will provide prolonged RUNX1/ETO depletion, 
relative to siRNA depletion, which will allow more accurate time course analysis. 
Furthermore, it will streamline future experiments regarding RUNX1/ETO function, which 
could require analysis in the presence and absence of RUNX1/ETO.  
 RUNX1/ETO knockdown has no significant effect on SP1 DNA binding 4.2.1
We hypothesised that Sp1 may play a role in RUNX1/ETO mediated pathogenesis. This 
hypothesis was based on publications demonstrating a physical interaction between the 
two proteins and co-occupancy of RUNX1/ETO and Sp1 at the DNA. Furthermore, we 
observed that the Sp1 motif has increased protection after RUNX1/ETO depletion (figure 
3-4).  
This increased protection of the Sp1 motif suggests an increase in Sp1 binding after 
RUNX1/ETO knockdown. However, we actually saw a loss in the total number Sp1 ChIP-
seq peaks after RUNX1/ETO knockdown. This was not due to a decrease in Sp1 
expression, as mRNA and protein levels did not change (figure 3-5). Sp1 is known to 
exhibit positive autoregulation on its own promoter (307). As RUNX1/ETO is known to 
antagonise Sp1 transactivation activity, it is sensible to think that RUNX1/ETO knockdown 
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The loss of Sp1 DNA binding sites after RUNX1/ETO knockdown (figure 3-6A) could be 
because Sp1 is recruited to its binding sites by RUNX1/ETO; the two proteins have been 
shown to physically interact. However, it should be noted that the published interaction 
between Sp1 and RUNX1/ETO was detected via co-immunoprecipitation with proteins 
from 293T cells transfected with plasmids expressing AML1-ETO and HA-tagged Sp1 (262). 
This experiment has inherent limitations as often highly expressed proteins bind non-
specifically. When another group determined the constituents of the RUNX1/ETO 
complex via mass spectrometry, Sp1 was not detected (256). 
Our analyses showed that Sp1 and RUNX1/ETO bind to distinct genomic sites (figure 3-6 
B). This contradicts the work of another group, who showed RUNX1/ETO and Sp1 bind to 
the same sites (247). The reason for this could be the different cell models used. Maiques-
Diaz et al. used human stem/progenitor hematopoietic cells (HSPCs), from human 
CD34+ umbilical cord blood samples, stably transduced with retroviruses expressing HA-
tagged RUNX1/ETO. The HA tag is very short linear recognition sequence so is unlikely to 
effect the properties of RUNX1/ETO. However, this cannot be ruled out completely. One 
possible explanation for the discrepancy between our results is that the HSPCs expressed 
other transcription factors at different levels, thus RUNX1/ETO forms different complexes 
in this context. Furthermore, we performed genome wide Sp1 DNA binding analysis, 
whereas their conclusions were drawn from ChIP-Chip experiments which predominantly 
look at sequences around promoters, together with qPCR of specific loci. Perhaps the 7 
genes they analysed are indeed bound by both RUNX1/ETO and Sp1, whereas at most 
other loci their binding is unrelated. In other words, their findings may be accurate at the 
7 loci analysed, but not a genome wide phenomenon.  
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4.3 The importance of C/EBPα expression levels in t(8;21) AML 
 C/EBPα is required for the full upregulation of myeloid genes after RUNX1/ETO 4.3.1
depletion 
There is a large body of evidence suggesting that the down regulation of C/EBPα 
expression in t(8;21) AML is a critical mechanism for leukaemia maintenance (see section 
1.8.1). Our previously published ChIP-seq data suggested that alleviation of RUNX1/ETO 
mediated suppression of C/EBPα may be central to the differentiation response seen 
after RUNX1/ETO depletion, as we saw a considerable increase in C/EBPα expression and 
genome wide DNA binding following RUNX1/ETO knockdown (figure 1-16), a 
phenomenon not observed with other transcription factors. In this study we performed 
experiments in which RUNX1/ETO and C/EBPα were depleted together in order to directly 
test the importance of C/EBPα to the response to RUNX1/ETO knockdown.  
RUNX1/ETO depletion led to a rapid upregulation of C/EBPα expression (figure 3-7 A) 
which is in keeping with several studies providing evidence for direct repression of 
C/EBPα by RUNX1/ETO. A physical interaction between the two proteins has been 
reported, which inhibits C/EBPα positive autoregulation (198). In addition, RUNX1/ETO 
binds to and represses both the C/EBPα promoter and enhancer (199, 200).  
In our study, several myeloid genes were significantly upregulated after RUNX1/ETO 
knockdown (figure 3-7 C), which supports previously published gene expression data from 
our group (199). The effect of RUNX1/ETO depletion on gene expression is perhaps 
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unsurprising considering the results of gain of function studies, in which RUNX1/ETO is 
ectopically expressed in haematopoietic cells (308-310).   
When the upregulation of C/EBPα was blocked by C/EBPα siRNA, the induction of select 
myeloid genes was significantly inhibited (figure 3-7 C). We found that the same genes 
were upregulated in response to C/EBPα overexpression, which validates that C/EBPα 
inhibition is responsible for this effect (see section 1.3.3 and figure 3-11). These results 
clearly demonstrate the essentiality of C/EBPα upregulation to the differentiation 
response following RUNX1/ETO depletion. This is consistent with the known role of 
C/EBPα in driving myeloid differentiation. For example, C/EBPα deficient mice display 
impaired myelopoiesis (197). 
Not all myeloid C/EBPα target genes exhibited diminished upregulation following 
concomitant RUNX1/ETO and C/EBPα knockdown. This could be due to the compensatory 
effect of other C/EBP family members; C/EBPδ and C/EBPε are also upregulated upon 
RUNX1/ETO knockdown. These CEBP proteins may be able to drive the expression of 
myeloid genes which are not specifically dependant on C/EBPα. For example, C/EBPε 
drives the expression of genes involved in macrophage development and is primarily 
expressed in myeloid cells (311). Furthermore, gene replacement studies have shown that 
C/EBPα can be substituted for C/EBPβ in haematopoiesis (312). It is conceivable that the 
other C/EBP family members (C/EBPε and C/EBPδ) could exhibit similar redundancies and 
act synergistically with C/EBPα.  
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 Activation of a β-Estradiol inducible form of C/EBPα in t(8;21) AML cells alleviates 4.3.2
the RUNX1/ETO mediated differentiation block  
 
It has become clear that down-regulating C/EBPα repression is key to t(8;21) leukemia 
maintenance. When RUNX1/ETO is removed, thus alleviating repression, C/EBPα levels 
increase and cells undergo myeloid differentiation. To see whether the upregulation of 
C/EBPα is sufficient to override the RUNX1/ETO mediated differentiation block, we over- 
expressed an inducible form of C/EBPα (C/EBPα – ER) in t(8;21) AML cells. We found that, 
to a large extent, C/EBPα overexpression phenocopied RUNX1/ETO depletion. 
This result is supported by a previous publication from Pabst et.al who found that C/EBPα 
levels were undetectable in RUNX1/ETO expressing cells and ectopic C/EBPα expression 
triggered terminal neutrophilic differentiation; the RUNX1/ETO mediated block in 
differentiation was overcome (198). Pabst et al. demonstrated the cells undergo myeloid 
differentiation, but no further transcriptional or epigenetic analysis was conducted and it 
was not clear which gene expression patterns were induced. We therefore performed 
RNA-seq, genome wide gene expression analysis, on Kasumi-1 cells with and without 
CEBPα over-expression. 
We found that C/EBPα over expression led to both upregulation and down regulation of 
genes. A recently published study shows C/EBPα binds to and directly suppresses stem 
cell genes, such as SOX4 (202). Perhaps in our study C/EBPα is exhibiting a dual role, 
directly activating and repressing gene. However, we found that only a subset of the 
genes that are downregulated by C/EBPα overexpression are actual C/EBPα targets. This 
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suggests that C/EBPα may not be directly repressing these genes and that down-
regulation is an indirect effect of a shift in the transcriptional network towards the 
differentiated state. It must be noted that the ChIP-seq data used to classify a gene as a 
‘C/EBPα target’ was generated from Kasumi-1 cells (219) but not the very same cell line 
used in this study. Experiments examining the binding of the C/EBPα-ER fusion protein 
are therefore currently underway.  
Correlation and Principal Component Analysis (PCA) of gene expression patterns 
demonstrate that induction of C/EBPα has similar effects to RUNX1/ETO knockdown. 
However, ‘principle component one’ highlights that there are small differences in the 
gene expression profiles of the RUNX1/ETO knockdown and C/EBPα over expression gene 
sets, even at baseline, despite Kasumi-1 cells being used in both cases. This is likely to be 
an artefact of the experimental methods used. For example, the RUNX1/ETO knockdown 
data set was obtained from cells which have been electroporated with siRNA. The non-
specific effects of siRNA are well recognised and have been proven experimentally (313).  
We found that C/EBPα overexpression can mimic many of the transcriptional effects of 
RUNX1/ETO knockdown; 40% of all genes changing expression after RUNX1/ETO knock-
down also change expression by C/EBPα overexpression, despite RUNX1/ETO still being in 
the nucleus. Examples of shared, upregulated myeloid genes include NKG7, MS4A3, 
RNASE2 and LCP1. There were also many shared down regulated genes, including DUSP6 
and the stem cell gene CD34. DUSP6 gene encodes a signalling molecule which is involved 
in regulating proliferation and differentiation (314).  
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The significant overlap in gene expression change, between RUNX1/ETO knockdown and 
C/EBPα overexpression, is particularly impressive considering the majority of genes 
upregulated by C/EBPα are directly bound by RUNX1/ETO. This suggests that C/EBPα can 
override the repressive epigenetic effects of RUNX1/ETO. One possibility is that C/EBPα 
can displace the RUNX1/ETO complex from its target genes and/or transcriptional co-
regulators. C/EBPα has been shown to bind to PU.1 and displace the PU.1 co-activator 
JUN (315). Perhaps C/EBPα could interfere with the RUNX1/ETO complex in a similar 
manner.  
C/EBPα overexpression also has effects distinct from those of RUNX1/ETO knockdown. 
These are likely to be due to differences in total C/EBPα expression level in each 
experiment. C/EBPα levels in the overexpression experiments are likely to be much higher 
than those induced by RUNX1/ETO knockdown. The levels seen after 17β-Estradiol 
induction could be sufficient for C/EBPα to bind to relatively more accessible motifs, thus 
altering the expression of additional genes. There are publications suggesting that C/EBPα 
may act as a pioneer factor, thus enhancing its ability to manipulate the gene expression 
profile (316, 317).  Furthermore, we found an enrichment of CEBP motif in the DNaseI 
sites which appear after RUNX1/ETO knockdown (figure 1-18). Perhaps CEBPα is acting as 
a pioneer factor here, driving the formation of these new DNaseI hypersensitive sites. 
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4.4 The effect of RUNX1/ETO knockdown on specific cis-regulatory element interactions 
Since the advent of chromosome conformation capture methods, the notion that gene 
expression changes can be mediated by changes in DNA looping is well established (63, 
118). There is now an increasing body of evidence that transcription factors initiate and 
maintain these DNA loops (63, 279-281). We therefore hypothesised that the gene 
expression changes seen after RUNX1/ETO knockdown may be driven by alterations in 
promoter-cis element interactions, and these changes to DNA interactions could be 
mediated by alterations in the transcription factor binding profile. We tested this 
hypothesis by performing chromatin conformation capture experiments on t(8;21) AML 
cells with and without RUNX1/ETO expression.   
 RUNX1/ETO knockdown had no effect on specific cis-regulatory element 4.4.1
interactions at the SPI1 and CD34 loci 
Several studies have established the effect of RUNX1/ETO knockdown on the 
transcriptomic and epigenetic profile of t(8;21) AML cells. However, the effect of these 
changes on chromosome conformation was not investigated. Here the 4C-seq method 
was used as a means of interrogating specific cis-regulatory element interactions, in this 
case within the SPI1 and CD34 loci. These genes were of particular interest as they exhibit 
changes in their transcription factor binding profile and gene expression after RUNX1/ETO 
knockdown, and the level of their expression level has a clear role in haematopoietic 
differentiation (293).  
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We successfully detected reciprocal interactions between the SPI1 and CD34 promoters 
and their already characterised regulatory elements, from both selected viewpoints. 
Reassuringly, the assay appears to be specific as regions of high contact intensity 
correspond to transcription start sites, putative cis-elements and regions of DNase I 
hypersensitivity (figure 3-13 and 3-14). Furthermore the agreement between biological 
replicates indicates the experiment was highly reproducible (figure 3-15). 
Contrary to already published data, generated with manual 3C, we did not detect an 
interaction between the CD34 promoter and DRE (292) (63) (figure 3-14). This could be 
due to use of a different method, and/or the genomic distance of the selected view-point 
fragment from the defined DRE (282). Here specific 4C-seq primers were designed to a 
restriction fragment close to a RUNX1/ETO ChIP-seq peak at this element. The interaction 
may have been detectable if the viewpoint was shifted closer to the defined enhancer 
region (between +18.8 to +19.6 kb). A previous study, which used 4C-seq to detected 
interactions with the Oct4 promoter, demonstrated that minor variations in viewpoint 
positioning can significantly influence the resulting interaction profile (282).  
We had hypothesised that the reorganisation of transcription factor binding after 
RUNX1/ETO knock-down, within pre-existing open chromatin, could lead to alterations in 
specific DNA interactions. However, we saw that RUNX1/ETO depletion had no effect on 
interactions at the SPI1 and CD34 loci, despite the marked increase in CEBPα binding and 
change in gene expression (figure 3-16), indicating that changes in transcription factor 
occupancy did not impact on intra-nuclear interactions. Subsequent Capture HiC 
experiments confirmed the lack of differential interaction at these loci.  It is therefore 
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likely that the expression changes are not due to differences in enhancer - promoter 
looping. Perhaps the alleviation of RUNX1/ETO mediated repression of the promoter via 
the recruitment of co-repressors is accountable for the increase in PU.1 expression (318, 
319).  The down regulation of CD34 could be due to the increase in C/EBPα binding at the 
promoter. C/EBPα is known to repress stem cell genes by binding to gene promoters 
(202). 
The fact that we did not detect alterations in promoter-enhancer interaction, despite 
changes in gene expression and transcription factor binding profile, has also been 
observed by other researchers. For example, Eileen Furlong’s group investigated the 
interactions made by 103 loci, which were selected based on their dynamic changes in 
gene expression and transcription factor occupancy between two drosophila 
developmental stages. They found that the majority of these differences were not 
reflected in alterations in promoter-enhancer DNA interactions (320).  
However, from these limited data we could not conclude that RUNX1/ETO depletion has 
no effect on specific DNA interactions. Moreover, we only investigated loci which do not 
exhibit overt changes in DNaseI hypersensitivity after RUNX1/ETO knockdown. Although 
the majority of transcription factor binding alterations occur within pre-existing DNaseI 
sites, RUNX1/ETO knockdown does lead to the generation of many new DNaseI 
hypersensitivity sites at distal regions (figure 1-17). Interestingly, these regions are 
significantly enriched for C/EBPα motifs (figure 1-18). They may represent de novo 
enhancer regions, only engaging in promoter interaction after RUNX1/ETO depletion and 
the concomitant increase in CEBPα expression.  
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4.5 The effect of RUNX1/ETO knockdown on genome wide DNA interactions 
In Kasumi-1 cells 1,396 genes significantly change their expression after RUNX1/ETO 
depletion, and over 3000 DNaseI hypersensitivity sites form that are unique to 
RUNX1/ETO depleted cells (219).  Using 4C-seq to interrogate all of these regions would 
be very time consuming and prohibitively expensive. The logical next step was therefore 
an assessment of the conformation of the entire genome using other methods such as 
HiC, which looks at all interactions within the genome. However, the vast complexity of 
HiC libraries requires extremely deep sequencing in order to provide sufficient resolution 
to define specific DNA contacts. To circumvent this issue, a collaborator of ours recently 
developed a method which combines HiC with solution hybridization selection (“Capture 
HiC”), to enrich HiC libraries for promoter regions, thus allowing us to assess the 
interactions made by 22,000 promoters with their distal elements in a single experiment 
(figure 2-2) (77).  
Our results highlight the importance of genome wide interaction mapping. The SPI1 URE 
enhancer interacts with the SPI1 promoter and not with the promoter of the closest gene, 
SLC39A13. This supports already published data which demonstrates that not all distal cis-
elements interact with the promoter of the nearest gene (78). Therefore cis-element 
interactions must be mapped experimentally as genomic distance should not be used as a 
predictor of DNA interaction and enhancer function.  
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 The majority of DNA interactions are intrachromosomal with a trend of decreased 4.5.1
interaction frequency with genomic distance 
The aim of the ambitious Capture HiC experiments was to gain more insight into the 
global mechanisms governing the chromatin changes seen after RUNX1/ETO depletion, 
shining more light onto the molecular basis of the RUNX1/ETO mediated differentiation 
block. We therefore prepared Capture HiC libraries from Kasumi-1 cells, with and without 
siRNA mediated RUNX1/ETO knockdown.  
As a means of quality controlling our Capture HiC data, we first looked for well-
established features of genome organisation. We found that the majority of chromosomal 
interactions occur in cis i.e. within the same chromosome (figure 3-19). This should 
always be the case, regardless of cell type or species (92, 99).  This trend is due, primarily, 
to the presence of chromosome territories which separate individual chromosomes (131).  
To further validate our data, we looked for evidence of the t(8;21) translocation. The 
ability to detect translocations with chromosome conformation capture analysis has been 
demonstrated previously (296, 297). Encouragingly, we saw a block of high contact 
intensity representing apparent interactions between chromosome 8 and 21, which 
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We then focused on a single chromosome, chromosome 8, at higher resolutions (1 Mb) 
(figure 3-18) . We were able to display the well-established notion that the probability of 
DNA interaction decreases exponentially with genomic distance (92, 134). The same 
trends were seen in both biological replicates. This offered further reassurance that the 
experiment had been conducted effectively, and reproducibly, and we could continue to 
extract interaction data with confidence.  
The statistically significant interactions were determined and were then filtered against 
our DNaseI-seq data, so that only interactions involving DNaseI hypersensitive restriction 
fragments were included. This was in order to direct our analysis to the active cis-
elements which were likely to be regulating gene expression. Only approximately one 
third of the interactions were hypersensitive. This is in accordance with Mifsud, B et al. 
who generated Capture HiC libraries following the same protocol and found that 
interactions were often not enriched for DNaseI hypersensitivity, and this usually 
corresponded to a gene with low level expression (77). Some of these non-DNaseI 
hypersensitive interactions may, for example, be involved in polycomb mediated gene 
repression. Polycomb complexes have been shown to act by regulating promoter-
promoter interactions (321, 322). It would be interesting to see if these non-
hypersensitive interacting regions are predominantly promoter fragments. The non-
hypersensitive interactions may also serve a more indirect, structural role in gene 
regulation, by helping to bringing active elements together.  
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 RUNX1/ETO knockdown led to alterations in specific promoter-cis-element 4.5.2
interactions that did not correlate with gene expression change 
 
We found that the large-scale genomic structures were unaltered by RUNX1/ETO knock-
down (figure 3-19). This was expected given that features such as the topologically 
associated domains are conserved between different cell types and different species (92). 
However, when HOMER software was used to detect the interactions that were 
differential between control and RUNX1/ETO knockdown, we found that hundreds of 
promoter-cis regulatory element interactions changed significantly. These differential 
interactions were associated with differentially expressed gene promoters; however the 
change in interactions strength was not correlated with the direction of gene expression 
change (figure 3-23).  One explanation is that when the genes alter their expression, they 
both increase and decrease interactions within their profile of enhancers. This was indeed 
the case for several differentially expressed genes in this study (figure 3-24). This is in 
accordance with several studies, such as Choukrallah, MA et al. who demonstrated that, 
during B cell differentiation, enhancer repertoires are dynamically reorganised (323). 
 DNA interactions at the CEBPA locus 4.5.3
 
We have shown that low C/EBPα expression levels are critical for the maintenance of 
t(8;21) leukaemia. We investigated the interactions made by the CEBPA promoter to gain 
more insight into how CEBPA expression levels are regulated (figure 3-25). The CEBPA 
promoter is known to interact with a recently characterised +42 kb enhancer element 
(200). The interaction with this enhancer is needed for myeloid-lineage priming and to 
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drive sufficient CEBPA expression for neutrophilic differentiation (200). Prior to this study, 
we observed that RUNX1/ETO binding is highly enriched at this region. It would therefore 
be reasonable to propose that the rapid upregulation of CEBPA expression following 
RUNX1/ETO knockdown is due to the release of this enhancer from RUNX1/ETO mediated 
repression. However, our Capture HiC analysis showed that the interaction strength 
between the CEBPA promoter and this enhancer is not significantly altered by 
RUNX1/ETO knockdown. 
In contrast, an interaction at +29kb significantly increases after RUNX1/ETO knockdown. 
This element is highly DNaseI hypersensitive and enriched for p300. Avellino, R et al. also 
detected a +29kb C/EBPα promoter interaction, but only in monocytes. They found it was 
enriched for H3K27ac, thus suggesting enhancer function. Using our ChIP-seq data we can 
see that this region is also bound by RUNX1/ETO, so perhaps release of this element from 
RUNX1/ETO mediated repression is responsible for the rapid increase in CEBPA 
expression after RUNX1/ETO knockdown. This result is concordant with the finding from 
our published metagene analysis which showed that after RUNX1/ETO knock-down, the 
gene expression pattern of Kasumi-1 cell changes into a pattern resembling that of 
monocytes (199). 
We detected a strong interaction between the CEBPA promoter and the CEBPG promoter 
(figures 3-25 and 3-26). Alberich-Jordà, M et al. found that CEBPG is overexpressed in a 
subset of AMLs with silenced CEBPA, and proposed a model in which C/EBPα supresses 
CEBPG expression (324). Perhaps the physical interaction between the two promoters 
facilitates regulation of this CEBPA-CEBPG axis. 
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 CTCF and C/EBPα may play a role in reshaping the promoter-cis-element 4.5.4
interaction profile following RUNX1/ETO knockdown 
 
A de novo motif search of the differential DNA interactions revealed that these 
interactions were significantly enriched for CTCF motifs (figure 3-29). Furthermore, CTCF 
binding appears to be altered by RUNX1/ETO knockdown (figure 3-30). Taken together 
these data suggest that CTCF may play a role in reshaping the promoter-cis-element 
interaction profile following RUNX1/ETO knockdown.  
CTCF binding was long considered to be largely invariant, apart from during the imprinting 
process during which methylation of CTCF motifs disrupts CTCF binding (325). However, 
recently John Stamatoyannopoulos’s group found that CTCF binding is considerably 
different between different types of somatic cells and that these differences are strongly 
associated with DNA methylation (326). As methylation does not change significantly 
after RUNX1/ETO knockdown (data not published), methylation is unlikely to be a driver 
of CTCF binding alterations in our experiments.  Another mechanism for CTCF binding 
modification is the eviction of CTCF from its binding site, via transcription and 
nucleosome repositioning, followed by the binding of another transcription factor in its 
place (327). This mechanism is a more likely explanation for the differential CTCF binding 
that we found.  
We found a considerable increase in C/EBPα binding at the differentially interacting 
DNaseI hypersensitive sites, particularly at those which increase in interaction following 
RUNX1/ETO knockdown (figure 3-28). Perhaps C/EBPα is involved in forming these new 
promoter-cis-element interactions, and this is one of the mechanisms C/EBPα employs to 
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drive the differentiation response which follows RUNX1/ETO depletion. There is currently 
no published data proposing a role for C/EBPα in mediating DNA looping interactions. 
However, C/EBPα has been shown to co-associate with cohesin at the DNA (328), a 
protein known to be involved in maintaining promoter-enhancer interactions (329, 330). 
Furthermore, following RUNX1/ETO depletion, C/EBPα joins a transcription factor 
complex involving LMO2 which, in combination with its partner LBD1, is involved in DNA 
looping (331). 
In summary, this work demonstrates that the presence or absence of RUNX1/ETO has a 
profound impact on the intra-nuclear organisation of t(8;21) cells. It also gives a first 
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4.6 Future work 
 Targeting RUNX1 in t(8;21) AML 4.6.1
 
1. We have shown that CBF complex inhibition leads to the death of t(8;21) AML cells, 
suggesting that RUNX1 activity was inhibited. The compound was designed to block 
RUNX1 DNA binding. However inhibition of DNA binding was not detectable in our system 
(section 3.1). We hypothesised that the inhibitory effect was specific to de novo CBF 
complex formation. We could test this hypothesis by measuring the effect of the 
compound on the binding of RUNX1 to its de novo binding sites, which occur following 
RUNX1/ETO depletion (figure 1-16).  In these experiments we could use the shRNA 
knockdown system that was validated in this study (figure 3-3).  
 The role of C/EBPα in t(8;21) AML 4.6.2
 
1. We have convincingly demonstrated that low C/EBPα expression level are critical to 
t(8;21) AML maintenance, with the induction of C/EBPα largely phenocopying the effect 
of RUNX1/ETO depletion (section 3.3).  However, the mechanism by which C/EBPα drives 
this response is unclear. To answer this question, we will measure C/EBPα-ER binding by 
ChIP-seq before and after induction, and see how many of the differentially expressed 
genes are directly bound by CEBPαER. We will also measure the effect of C/EBPα-ER 
induction on the genome-wide binding of RUNX1/ETO to test whether C/EBPα 
overexpression can override the RUNX1/ETO mediated differentiation block and displace 
RUNX1/ETO from its binding sites.  
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2. Previous analysis revealed that the CEBP motif is enriched in DNaseI sites that are 
specific to RUNX1/ETO depleted Kasumi-1 cells (figure 1-18). It is therefore possible that 
C/EBPα is driving the formation of these de novo DNaseI sites. To see if this is the case, 
we could perform DNaseI-seq before and after C/EBPα induction. This experiment will 
enable us to gain more insight into how C/EBPα drives the differentiation response that 
follows RUNX1/ETO knockdown. 
3. In this study we show that upregulation of C/EBPα by RUNX1/ETO knockdown is 
necessary to drive the full differentiation response. However, it is unclear how important 
other C/EBP proteins are to this process. CEBPG and CEBPE are also significantly 
upregulated after RUNX1/ETO knockdown; it is possible that these proteins contribute to 
the differentiation response. To test if this is the case, we could block all CEBP protein 
activity with a dominant negative CEBP leucine-zipper peptide (332), in conjunction with 
RUNX1/ETO knockdown. We could then compare the results to those obtained by co-
depletion of C/EBPα and RUNX1/ETO (section 3.3.2).  
 Promoter-cis-element interactions in t(8;21)  4.6.3
 
1. We have successfully mapped the genome-wide promoter-distal-element interactions 
in a t(8;21) AML cell line (section 3.5). These results will be used to annotate genes to 
their respective cis-elements, which will enable us to accurately construct gene regulatory 
networks. Before doing so, we could determine which interacting elements are likely to 
be enhancers with our p300 and H3K9Ac ChIP-seq data. Additionally, we could perform 
H3K27Ac and H3K4Me1 ChIP-seq, as these modifications are indicators of potential 
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enhancer activity (333, 334). We could also assess the function of elements of interest, 
with luciferase reporter assays, such as the region +29kb of the C/EBPα promoter, which 
we found to strongly interact with the C/EBPα promoter, specifically in RUNX1/ETO 
depleted cells. 
2. This work demonstrates that RUNX1/ETO knockdown has a profound impact on the 
intra-nuclear organisation of t(8;21) cells. One of the most intriguing results from this 
study was that CTCF could play a role in reshaping the DNA interaction profile following 
RUNX1/ETO knockdown. This hypothesis was based on the enrichment of differential 
interactions for the CTCF motif and the differential protection of the CTCF motif following 
RUNX1/ETO depletion (figures 3-29 and 3-30). We will now perform CTCF ChIP-seq, 
before and after RUNX1/ETO knockdown, to directly measure CTCF binding alterations 
and see if they correlate with differential promoter-distal-element interactions. It would 
also be useful to perform ChIP-seq with members of the Cohesion complex, such as 
RAD21, given that the Cohesin complex is found at most CTCF sites (335). These data 
could then be integrated with our existing ChIP-seq data sets to analyse the interplay of 
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3. In order to determine whether our data is relevant to disease, we will correlate the 
Kasumi-1 interaction profile with that of a t(8;21) AML patient.  We have already 
prepared a Capture HiC library with a t(8;21) AML patient sample, which is now ready for 
analysis. In addition, we could compare the t(8;21) AML interaction profile with other 
AML subtypes, and normal samples of the same maturation stage. This will allow us to 
identify disease specific DNA interactions. The role of these interactions in disease 
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C/EBPαER Kasumi-1 Kasumi-1 
minus E2 plus E2 minus E2 plus E2 siMM  siRE  
(fpkm) (fpkm) (fpkm) (fpkm) (fpkm) (fpkm) 
ATF3 3.38 3.00 3.00 1.88 5.64 2.02 
GUCY1A3 10.89 9.00 12.00 5.64 5.75 1.02 
MYO1B 6.14 5.00 5.00 2.90 5.83 3.27 
IRF1 5.39 5.00 5.00 2.40 5.86 2.99 
TRIM47 2.70 3.00 2.00 1.29 6.15 2.31 
ZNF436 7.43 6.00 5.00 3.35 6.24 3.17 
ETV5 6.74 6.00 5.00 2.42 6.89 2.86 
PLOD2 3.98 3.00 5.00 1.61 7.33 2.68 
PIK3C2B 3.14 3.00 3.00 2.10 7.94 3.31 
CCND1 4.30 3.00 4.00 2.16 8.06 1.44 
SVOPL 3.34 2.00 3.00 1.61 8.93 2.76 
MOV10 7.38 7.00 7.00 4.57 9.25 3.26 
GPRC5C 7.33 8.00 5.00 0.52 9.65 1.68 
FBXW9 3.13 4.00 2.00 1.90 10.01 5.73 
CHAC1 8.38 13.00 7.00 1.91 10.41 5.34 
NCKIPSD 5.40 6.00 4.00 2.28 11.02 6.49 
NAV1 4.08 4.00 3.00 2.33 11.65 3.22 
ZFP36L1 2.86 3.00 2.00 1.20 11.91 3.72 
CA8 6.52 6.00 5.00 2.62 12.98 5.50 
SLMO2-ATP5E 21.94 22.00 17.00 9.77 13.33 5.56 
HDAC7 5.11 5.00 4.00 3.32 13.87 6.15 
STC2 9.00 10.00 6.00 2.66 14.22 7.55 
APOBEC3G 13.62 10.00 15.00 3.14 14.45 3.09 
GATA2 4.88 5.00 4.00 2.57 15.50 3.70 
SLC45A3 5.43 6.00 6.00 3.45 18.05 2.80 
ANGPT1 20.06 20.00 21.00 10.35 20.01 2.04 
DHRS3 20.53 21.00 17.00 7.65 20.21 6.64 
JUN 4.25 5.00 2.00 1.52 21.30 10.39 
DDIT4 29.65 35.00 10.00 2.53 21.55 11.69 
ST18 14.29 13.00 15.00 5.84 21.64 2.36 

























MDFI 11.94 11.00 9.00 4.69 23.50 2.35 
CD96 19.28 17.00 21.00 9.08 24.24 12.84 
ABHD4 4.14 4.00 5.00 1.95 24.78 13.51 
UBE2L6 17.56 17.00 18.00 9.28 27.23 13.74 
ISYNA1 3.95 4.00 3.00 2.78 29.14 12.65 
CD300A 32.26 32.00 22.00 5.12 30.00 16.72 
SLC2A3 27.38 26.00 24.00 9.27 30.92 1.95 
BIN1 17.72 21.00 18.00 10.80 33.99 12.88 
ASNS 81.44 88.00 66.00 16.58 34.97 20.17 
CD52 35.08 31.00 28.00 10.18 41.36 16.17 
RPTOR 15.01 19.00 12.00 8.15 43.29 19.03 
CD69 44.75 43.00 39.00 17.30 43.49 12.57 
IFI16 39.31 33.00 37.00 19.26 46.21 14.53 
TMIGD2 23.83 29.00 22.00 13.80 51.87 28.47 
TRIM8 14.60 15.00 15.00 7.94 53.44 22.55 
TBX1 6.00 6.00 6.00 3.02 57.68 22.60 
DUSP6 74.95 69.00 78.00 33.12 81.98 20.26 
NRN1 61.65 60.00 57.00 22.90 92.06 50.25 
JUP 24.98 32.00 23.00 14.74 100.29 48.22 
FSCN1 21.74 29.00 18.00 15.02 141.91 59.04 
LOC101927497 42.52 37.00 49.00 18.87 152.00 78.68 
CKB 28.24 38.00 23.00 11.52 170.00 44.72 
PTPRCAP 28.74 43.00 26.00 9.24 206.68 112.12 
EGFL7 49.79 83.00 41.00 39.59 223.04 59.09 
CD34 114.50 103.00 120.00 61.58 405.03 99.18 
TBC1D16 2.16 2.86 1.97 1.22 5.23 2.65 
RAB38 2.41 2.61 1.81 0.96 5.43 2.40 
FGF11 2.42 2.47 2.57 0.52 5.60 3.11 
FGF16 2.06 1.82 2.19 0.88 5.87 2.79 
RLTPR 2.47 2.89 2.63 1.09 7.45 3.58 
AK4 3.21 2.98 2.28 0.66 8.65 4.78 
DDN 2.60 2.83 2.27 1.65 8.91 4.13 
VWCE 2.08 3.01 1.87 1.50 9.92 5.25 
MEX3A 2.17 2.02 2.22 1.14 10.09 5.09 
MTSS1 1.97 1.67 2.25 0.99 11.20 0.74 
ZNF467 1.74 2.24 1.69 1.04 13.90 7.60 
SHANK3 1.74 2.37 1.61 0.71 16.89 5.75 
 
